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Summary 
 
arrett’s oesophagus is a common condition in which the normal stratified 
squamous oesophageal epithelium is replaced by metaplastic reflux-
induced glandular (“columnar”) mucosa (Jankowski, Barr, Wang et al. 
2010;Playford 2005).  Over the last three decades, the incidences of oesophageal 
adenocarcinoma (OA) and Barrett’s oesophagus have risen to the point that OA is 
now common in the United Kingdom, with Scotland having one of the highest rates 
in the world (Jankowski, Provenzale, & Moayyedi 2002).  Unfortunately most 
cancers present at an advanced stage with five year survival less than 30% (Holmes 
and Vaughan 2007).  Barrett’s oesophagus is associated with malignant progression 
via a recognised metaplasia-dysplasia-carcinoma sequence (Jankowski, Wright, 
Meltzer et al. 1999).  The premalignant nature of Barrett’s oesophagus has powered 
intense clinical interest in the hope of eventually having an impact on the earlier 
diagnosis and treatment of dysplasia, and ultimately the prognosis of oesophageal 
adenocarcinoma. 
Despite years of research interest, Barrett’s oesophagus remains an enigmatic 
condition.  The exact incidence is unknown, and it is recognised that not all patients 
with Barrett’s oesophagus will progress to adenocarcinoma.  Current strategies aim 
to ascertain the presence of dysplasia, the current gold standard marker of malignant 
progression.  However although Barrett’s mucosa is visible at endoscopy, the 
presence of dysplasia is difficult to diagnose as these areas tend to be focal and 
inconspicuous to the naked eye.  Current systematic biopsy regimes are 
recommended, but can be fraught with sampling errors.  Furthermore, the molecular 
mechanisms underlying Barrett’s metaplasia and progression to dysplasia remain 
unclear.  Molecular risk biomarkers have been sought with modest success, and at 
present dysplasia remains the most reliable clinical marker.  However dysplasia itself 
is not without limitations: focal dysplasia can be difficult to ascertain, with many 
biopsies sometimes necessary to detect it reliably (Abela, Going, Mackenzie et al. 
2008).  Inter-observer variability may cause over or under diagnosis, especially 
regarding LGD (Flejou 2005). Moreover, although patients with HGD are at elevated 
risk of progression to OA, few studies provide reliable data on rates of progression 
B 
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from HGD to OA, with estimates varying between 16-59% at five years (Reid, 
Blount, Feng et al. 2000;Schnell, Sontag, Chejfec et al. 2001;Shaheen and Richter 
2009;Spechler SJ 2011).  There is a real need, therefore, to be able to identify and 
treat those patients at greatest risk of malignant transformation, and reassure those at 
low risk.  Without an improved molecular understanding of Barrett's metaplasia and 
progression to neoplasia, clinically useful prognostic biomarkers (allowing 
appropriate targeting of surveillance and therapy) will be delayed.  
The current challenges associated with Barrett’s oesophagus are 1) to accurately 
determine the rate of malignant progression of Barrett’s oesophagus and identify 
clinical risk factors, 2) to improve the endoscopic detection of dysplasia and early 
neoplasia allowing earlier diagnosis and treatment and, 3) to understand the 
molecular mechanisms involved in the initiation of Barrett’s metaplasia, and the 
pathways involved in disease progression.   
In an attempt to improve the care of patients with Barrett’s oesophagus within the 
West of Scotland, my thesis will address each of the main challenges associated with 
this puzzling condition at clinical, endoscopic and molecular levels.  The hypotheses 
of my thesis are threefold -   
a) Patients with Barrett's oesophagus in the West of Scotland have high rates of 
progression to high grade dysplasia and oesophageal adenocarcinoma. 
b) The WavSTAT optical biopsy system will be able to correctly identify non-
dysplastic and dysplastic Barrett's oesophagus. 
c) The Wnt signalling pathway is upregulated in Barrett's oesophagus and dysplasia. 
 
The aims of my thesis are as follows: 
1) To present a general overview of the Barrett’s literature highlighting current 
clinical challenges 
2) To examine the incidence of dysplasia and oesophageal adenocarcinoma in the 
West of Scotland by analysing a cohort of patients undergoing surveillance 
endoscopy 
3) To review the current endoscopic imaging adjuncts for the diagnosis of Barrett’s 
oesophagus and dysplasia, and assess the role of optical biopsy forceps in 
determining the presence of dysplasia 
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4) To evaluate the role of Wnt signalling in Barrett’s oesophagus, from metaplasia 
to carcinoma in a mouse model, with complementary human studies 
Chapter 1 introduces the reader to Barrett’s oesophagus and highlights current areas 
of clinical challenge and debate.  A universal definition of Barrett’s oesophagus does 
not exist and Chapter 2 explores the need for the presence of intestinal metaplasia in 
the diagnosis of Barrett’s oesophagus.  Chapters 3 and 4 present original data from a 
West of Scotland Barrett’s oesophagus database, specifically analysing rates of 
dysplasia and adenocarcinoma and cause of death.  This study suggests patients with 
Barrett’s oesophagus in the West of Scotland are at high risk of disease progression 
with almost 10% of patients dying from oesophageal adenocarcinoma.  The results 
highlight the importance of a comprehensive surveillance in our “high risk” 
population - an ideal niche for future chemopreventative and molecular studies.  In 
an attempt to improve the diagnosis of dysplasia in our West of Scotland population, 
Chapter 5 reviews current endoscopic imaging adjuncts used in research and clinical 
practice while Chapter 6 presents original data from a pilot study assessing the use of 
innovative optical biopsy forceps in the endoscopic diagnosis of dysplasia.  While 
this technology is in its infancy and further changes in the algorithm are required, the 
optical forceps could be a promising tool for ongoing surveillance in high risk 
Barrett’s patients.  Chapter 7 summarises the role of biomarkers in Barrett’s 
oesophagus, reviewing the literature and highlighting the lack of clinically useful 
markers of disease progression to date.  The Wnt signalling pathway plays an 
important role in normal oesophageal (and intestinal) development, yet when 
aberrantly activated leads to carcinogenesis.  To date, very little is known about the 
role of Wnt signalling in Barrett’s oesophagus.  Chapter 8 presents the results of a 
mouse model of upregulated Wnt signalling and the interesting finding of dysplasia 
within the oesophageal mucosa.  Chapter 9 therefore translates these results to the 
human population by assessing the role of Wnt signalling in Barrett’s metaplasia and 
dysplasia by immunohistochemical analysis of a panel of markers.  The results 
suggest Wnt signalling is upregulated in Barrett’s dysplasia, particularly in high 
grade, and this may have a future role as a biomarker.  Chapter 10 summarises the 
main findings of the thesis, and presents future directions. 
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Chapter 1 
Barrett’s Oesophagus  : A review 
 
arrett’s oesophagus is an acquired condition in which the normal stratified 
squamous lining of the oesophagus is replaced by a glandular 
(“columnar”) epithelium (Jankowski, Barr, Wang, & Delaney 2010).  
Barrett’s “columnar lined” oesophagus is a common condition and is of clinical 
significance due to its predisposition to oesophageal adenocarcinoma.  Over the last 
three decades the incidences of adenocarcinoma and Barrett’s oesophagus have risen 
to the point that oesophageal adenocarcinoma is now one of the commonest cancers 
in the United Kingdom, with Scotland having one of the highest rates in the world 
(Jankowski, Provenzale, & Moayyedi 2002;www.cancerresearchuk.org 2006).  
Unfortunately most cases of adenocarcinoma present at an advanced stage and the 
prognosis is poor with five year survival rates of less than 30% (AUGIS, BSG, & 
NCASP 2010;Holmes & Vaughan 2007).  The premalignant nature of Barrett’s 
oesophagus has powered an intense clinical interest within this field, in the hope of 
eventually having an impact on the earlier diagnosis and treatment of dysplasia and 
ultimately the prognosis of oesophageal adenocarcinoma.  This first chapter provides 
a review of the literature, highlighting current clinical challenges and areas requiring 
further study. 
  
B 
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1.1 The History of Barrett’s Oesophagus 
In 1906, Wilder Tileston a Boston pathologist described three cases of peptic 
ulceration of the oesophagus, noting “the close resemblance of the mucous 
membrane about the ulcer to that normally found in the stomach” (Tileston 1906).  In 
1950, Norman Barrett proposed that clinicians should define the oesophagus as “that 
part of the foregut, distal to the cricopharyngeal sphincter, which is lined by 
squamous epithelium” (Barrett 1950).  He went on to describe a case of peptic 
ulceration within a tubular organ arising from a gastric type epithelium associated 
with an oesophageal stricture.  From his previous observations that the oesophagus 
was lined with squamous epithelium, he concluded that the tubular viscus was a 
segment of stomach that had been tethered within the chest, presumably a 
congenitally short oesophagus.  This paper was one of the first to describe the 
association between oesophagitis, reflux disease and hiatus hernia. 
In 1953 Allison and Johnstone argued that the tubular, columnar lined structure 
described by Barrett was actually “an oesophagus lined with gastric mucous 
membrane” (Allison and Johnstone 1953).  They showed that the tubular structure 
was not covered by peritoneum, and contained submucosal glands as would be found 
in the oesophagus. Perhaps to placate Barrett, the editor of Thorax, they suggested 
that ulceration in the columnar lined oesophagus be termed “Barrett’s ulcers”.  By 
1957, Barrett accepted Allison and Johnstone’s theory and suggested the disease be 
called “lower oesophagus lined by columnar epithelium”.  However, the name 
"Barrett’s oesophagus" has stuck even though the present concept is not as Barrett 
initially described (Barrett 1957).   
Over the following decade, further studies supported the view that “columnar lined 
oesophagus” (CLO) was an acquired sequel of reflux.  Moersch et al reviewed 36 
specimens from patients who had undergone oesophageal resection for oesophagitis, 
concluding that the columnar mucosa of Barrett’s oesophagus was acquired 
following repeated exposure of the distal oesophagus to gastric refluxate (Moersch, 
Ellis, & McDonald 1959).  Bremner and colleagues confirmed the theory in an 
animal model in 1970 and the congenital theory was globally discarded (Bremner, 
Lynch, & Ellis 1970). 
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1.2 The Diagnosis of Barrett’s Oesophagus 
1.2.1 The definition of Barrett’s oesophagus 
Norman Barrett commenced his landmark paper of 1957 with the following words: 
“This paper concerns a condition whose existence is denied by some, misunderstood 
by others, and ignored by the majority of surgeons” (Barrett 1957).  These words still 
apply today as no universally accepted definition of Barrett’s oesophagus currently 
exists.   
The American College of Gastroenterology (ACG) suggest “Barrett’s oesophagus is 
a change in the distal oesophageal epithelium of any length that can be recognized 
as columnar type mucosa at endoscopy and is confirmed to have intestinal 
metaplasia by biopsy of the tubular oesophagus” (Wang and Sampliner 2008).  The 
American Gastroenterological Association (AGA), the American Society of 
Gastrointestinal Endoscopy (ASGE) and the French Society of Digestive Endoscopy 
(FSDE) have similar definitions requiring the presence of intestinal metaplasia on 
biopsy (Boyer, Laugier, Chemali et al. 2007;The AGA Institute Medical Position 
Panel 2011;The Standards of Practice Committee of the American Society for 
Gastrointestinal Endoscopy 2006).  The requirement for identification of intestinal 
metaplasia on biopsy is not demanded by the British Society of Gastroenterology 
(BSG) who define Barrett’s oesophagus as “an endoscopically apparent area above 
the oesophagogastric junction that is suggestive of Barrett’s which is supported by 
the finding of columnar lined oesophagus on histology” (Playford 2005).  The 
Montreal workshop (the Global Evidence Based Consensus Workshop on the 
Definition and Classification of Reflux Disease) recently proposed that the term 
“Barrett’s oesophagus” should be applied if any type of oesophageal columnar 
metaplasia is confirmed histologically, with qualification if an intestinal-type 
metaplasia is present (Vakil, van Zanten, Kahrilas et al. 2006).   
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1.2.2 The endoscopic assessment of Barrett’s oesophagus 
The diagnosis of Barrett’s oesophagus requires two components  
a) the direct visualisation of the oesophagus by endoscopy and  
b) the histological assessment of biopsy samples.   
Under normal conditions the squamocolumnar (SC) junction (the intersection 
between the squamous lining of the oesophagus and the columnar lining of the 
stomach) and gastroesophageal (GO) junction are located at the same level, whereas 
in Barrett’s oesophagus the SC junction migrates proximally.  Endoscopic 
assessment of the normal oesophagus reveals a white or light pink colouring of the 
squamous mucosa, while in Barrett’s oesophagus the salmon pink columnar 
epithelium extends proximally into the oesophagus (Figure 1.1).  Using high 
resolution white light endoscopy the oesophagus should be carefully examined 
paying particular attention to appropriate landmarks, namely the SC junction and GO 
junction.  The length of the Barrett’s segment is noted from the level of the most 
proximal gastric folds on minimal insufflation to the level of the proximally placed 
SC junction, and whether the columnar mucosa is circumferential or projecting as 
tongues of Barrett’s mucosa.  In order to standardise the endoscopic reporting of 
Barrett’s oesophagus, the Prague classification should be used to assess the 
circumferential (C) and maximum (M) extent of the endoscopically visualised 
segment (Figure 1.2) (Sharma, Dent, & Armstrong 2006).   
Figure 1.1 Barrett’s oesophagus at endoscopy 
A
 
B
 
 
 
(A) Endoscopic view of oesophagus noting salmon pink colour of Barrett’s segment.   
(B) Endoscopic view of Barrett’s tongues at oesophagogastric junction. 
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Figure 1.2 The endoscopic assessment of Barrett’s oesophagus  
 
 
 
Endoscopists should start at Box 1 working anticlockwise finishing at Box 6.  This allows 
standardised assessment and reporting of Barrett’s oesophagus.  Taken with permission from 
International Working Group for the Classification of Oesophagitis (www.iwgco.com).  
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The Barrett’s segment should be carefully assessed with image adjunct tools such as 
narrow band imaging for any mucosal nodularity, ulceration or discrete lesions with 
extensive biopsies of these areas as there is evidence these lesions are associated with 
dysplasia and intramucosal cancer (Reid, Blount, Feng, & Levine 2000).  Following 
careful endoscopic inspection, most centres recommend a systematic biopsy 
approach, with four quadrant biopsies taken every two centimetres within the 
Barrett’s segment (Playford 2005;Wang & Sampliner 2008).  Barrett’s oesophagus, 
and in particular dysplasia can be focal and patchy, and a systematic approach has 
been shown to detect more dysplasia and early cancer than a random biopsy 
approach (Abela, Going, Mackenzie, McKernan, O'Mahoney, & Stuart 
2008;Fitzgerald, Saeed, Khoo et al. 2001).   
 
1.2.3 The histological assessment of Barrett’s oesophagus 
The second component in establishing the diagnosis of Barrett’s oesophagus is the 
accurate histological assessment of biopsy material.  Oesophageal biopsies from 
patients with Barrett’s oesophagus are assessed by a specialist upper gastrointestinal 
pathologist ideally with an interest in the condition.  The histological diagnosis of 
Barrett’s oesophagus is made by the identification of an oesophageal columnar 
epithelium on sections stained with haematoxylin and eosin.  It is vital to ensure that 
biopsy specimens are labelled appropriately, defining the exact location of the 
biopsy, as intestinal metaplasia of the cardia is a different entity from intestinal 
metaplasia of the oesophagus.   
The histology of Barrett’s mucosa is complex and heterogenous.  Following Allison 
and Johnstone’s initial description of an oesophagus lined with a columnar 
epithelium, other clinicians have discovered a mosaic of histological types.  In 1976 
Paull and colleagues provided a clear histological description of columnar lined 
oesophagus from a case series of 11 patients with Barrett’s epithelium, concluding 
there were three types of columnar epithelia above the lower oesophageal sphincter: 
1) gastric fundic type with parietal and chief cells, 2) junctional type with cardiac 
mucous glands and 3) a distinctive so called “specialised” type with mucous glands 
and intestinal-like goblet cells (Paull, Trier, Dalton et al. 1976) (Figure 1.3). Goblet 
cells can be identified as barrel-shaped cells containing an acidic mucin which stains 
with Alcian blue pH2.5.  The staining largely depends on the type of 
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mucopolysaccharide within the crypt: sialylated mucins stain blue and sulphated 
mucopolysaccharides a brown-black colour (Figure 1.4).  This special stain can help 
pathologists clearly identify the presence of goblet cells. 
At the time of Barrett’s original description and other early studies, Barrett’s 
oesophagus was an endoscopic diagnosis and its histology of purely academic 
interest.  However events changed in the 1970s when it became apparent an 
association between Barrett’s oesophagus and oesophageal adenocarcinoma existed, 
and the histological findings, particularly of intestinal metaplasia with its neoplastic 
potential, became paramount (Haggitt, Tryselaar, Ellis et al. 1978). 
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Figure 1.3 The histological subtypes of Barrett’s metaplasia 
 
Display of the characteristic histological diversity found within Barrett’s oesophagus.  
A. Cardiac like crypt without goblet cells.  B. Point (*) marks area on mucosal surface where 
cells from crypt in A meet cells from crypt in C.  C Intestinal crypt with numerous goblet cells, 
in keeping with intestinal metaplasia.  Figure taken from (Moyes and Going 2011)  
 
Figure 1.4 Mucosal phenotypic diversity in Barrett’s oesophagus using 
Alcian blue stain 
 
 
A. Alcian blue (pH2.5) staining of goblet cells.  The sialylated mucopolysaccharides stain blue, 
and sulphated stain brownish-black.  This section clearly shows the presence of goblet cells, 
while specimen B demonstrates a cardiac-like phenotype with an absence of immunostaining.  
Figure taken from (Moyes & Going 2011)  
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1.3 Dysplasia 
Barrett’s oesophagus appears to progress in a stepwise manner with cellular changes 
ranging from metaplasia, to low grade dysplasia, to high grade dysplasia and 
ultimately invasive cancer – known as the metaplasia-dysplasia-carcinoma sequence 
(Jankowski, Wright, Meltzer, Triadafilopoulos, Geboes, Casson, Kerr, & Young 
1999).  Dysplasia is one of the most important features of Barrett’s oesophagus as it 
currently remains the gold standard marker of risk for disease progression.  The 
presence of dysplasia also determines the frequency of surveillance endoscopy and 
guides management options.   
Dysplasia may be viewed as “the histological expression of genetic changes which 
favour cell growth and neoplasia” (Noffsinger 2008;Spechler 2001).  Dysplasia is 
diagnosed in the presence of cytological and architectural changes such as nuclear 
enlargement, hyperchromatism, surface maturation, atypical mitosis and loss of 
cytoplasmic maturation (Goldblum 2003).  These changes suggest that the epithelium 
is damaged, after undergoing a series of genetic and epigenetic changes resulting in 
the clonal proliferation of cells with a predisposition to malignancy.  Dysplasia is 
generally categorized as low or high grade depending on the degree of genetic 
damage, the potential for carcinogenesis and is diagnosed according to histological 
changes.  Most pathologists with an interest in Barrett’s oesophagus would classify 
dysplasia according to the Vienna classification system (Table 1.1) (Schlemper, 
Riddell, & Kato 2000).   
Studies have shown that the extent of dysplasia is an important risk factor for disease 
progression.  A recent large scale study from Seattle showed that the extent of low 
grade dysplasia was a significant risk factor for the development of oesophageal 
adenocarcinoma (Srivastava, Hornick, Li et al. 2007).  They also found that although 
high grade dysplasia is associated with a greater risk of neoplasia, the actual extent of 
high grade dysplasia was not an independent risk factor for progression. 
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Table 1.1 Vienna classification of gastrointestinal epithelial neoplasia 
 
Category  Subclassification 
1 Negative for neoplasia/dysplasia  
2 Indefinite for neoplasia/dysplasia  
3 Non-invasive low grade neoplasia  
4 Non-invasive high grade neoplasia 4.1 High grade dysplasia 
4.2 Non-invasive carcinoma (carcinoma in situ)* 
4.3 Suspicion of invasive carcinoma 
5 Invasive neoplasia 5.1 Intramucosal carcinoma 
$ 
5.2 Submucosal carcinoma or beyond 
 
* Non-invasive indicates absence of evident invasion and $ intramucosal indicates invasion into the lamina propria or muscularis mucosae.  (Adapted from original 
manuscript by RJ Schlemper, Gut 2000 (Schlemper, Riddell, & Kato 2000)) 
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1.3.1 The challenges of dysplasia in Barrett’s oesophagus 
The diagnosis of dysplasia itself however can be challenging as it may be difficult 
for pathologists to distinguish between reactive changes associated with reflux 
oesophagitis and low grade dysplasia.  Interobserver agreement between pathologists 
regarding low grade dysplasia can be less than 50%, although the rates of 
concordance are higher with high grade dysplasia (Kerkhof, Kusters, van Dekken et 
al. 2007;Spechler 2001).  The diagnosis of low grade dysplasia is often inaccurate 
when made by pathologists without expertise in Barrett’s oesophagus.  Studies from 
the Netherlands have shown that 85% of low grade dysplasia cases diagnosed by 
general pathologists were downgraded to “no dysplasia” on review by expert 
pathologists (Curvers, ten Kate, Krishnadath et al. 2010).  These findings are in 
keeping with results from Germany and the United States (Alikhan, Rex, Khan et al. 
1999;Vieth 2007). 
 The second difficulty with diagnosing dysplasia is due to sampling error.  Unlike the 
colon where early cancers often take the form of polyps, early dysplasia and 
carcinoma in Barrett’s oesophagus may be difficult to identify as it is flat, patchy and 
relatively inconspicuous (Montgomery, Goldblum, & Greenson 2001).  Endoscopists 
are encouraged to perform extensive four quadrant biopsy to maximize the chance of 
identifying any inconspicuous lesion.  However this technique is not without fault 
and areas of dysplasia or indeed a focus of invasive cancer can be missed.  In a series 
of patients undergoing oesophagectomy for high grade dysplasia, invasive cancer 
was found in 30-40% of cases after pathological examination of the resected 
specimen (Spechler SJ 2011). 
The third challenge which dysplasia presents is the lack of correlation between the 
presence of dysplasia and the clinical outcome.  Even if the diagnosis of dysplasia is 
accurately made, not all patients will progress through the metaplasia-dysplasia-
carcinoma sequence (Coppola, Nasir, & Turner 2010).  Indeed most patients with 
Barrett’s oesophagus will never develop oesophageal cancer.  Furthermore, some 
patients with previously documented evidence of dysplasia, often reveal no dysplasia 
on subsequent endoscopies.  It is unclear if this phenomenon is purely due to 
sampling error, or whether the dysplasia has actually regressed.  Adenocarcinomas 
have been found in patients whose previous endoscopies have never shown any 
dysplasia (Reid, Li, Galipeau et al. 2010).  In this case it is not known if this too is 
due to sampling error, or a result of rapid progression between surveillance 
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endoscopies, or if the cancer has completely bypassed the dysplastic stage 
(Montgomery, Goldblum, & Greenson 2001).  Additional techniques to improve the 
diagnosis of dysplasia are clearly required. 
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1.4 The Epidemiology of Barrett’s Oesophagus 
1.4.1 The incidence and prevalence of oesophageal adenocarcinoma 
and Barrett’s oesophagus 
The incidence of oesophageal adenocarcinoma has risen over the last three decades 
in Western Europe and the United States, with the United Kingdom now having the 
highest incidence of cancer in the world (12-16/100 000 cases) (Jankowski, 
Provenzale, & Moayyedi 2002).  Oesophageal adenocarcinoma is more common in 
males although the reasons for this remain unclear (Bollschweiler, Wolfgarten, 
Gutschow et al. 2001;Derakshan, Liptrot, Paul et al. 2009).  The survival from 
oesophageal adenocarcinoma remains poor as patients often present at an advanced 
stage with overall survival rates of less than 30% at five years (Jamieson, Mathew, 
Ludemann et al. 2004).  Studies have shown that survival is inversely related to 
tumour stage and the presence of lymph node metastases, with T1 stage disease 
carrying five year survival rates of more than 90% (Farrow and Vaughan 1996;Liu, 
Hofstetter, Rashid et al. 2005).  Therefore detection of oesophageal adenocarcinoma 
at an earlier stage may improve the survival among patients. 
Barrett’s oesophagus is a common condition with 10-20% of patients undergoing 
endoscopic examination for reflux symptoms found to have the disease, but the true 
incidence of Barrett’s oesophagus in the general population remains unknown 
(Spechler 2002).  One of the most accurate population studies from Sweden suggests 
that the incidence of Barrett’s oesophagus in 3000 adults sampled was 1.6% 
(Ronkainen J, Aro, Storskrubb et al. 2005).  However these results may be a little 
low as the study group was highly selective, with patients included if they had only 
intestinal metaplasia and the number of biopsies taken was limited.  Nevertheless, 
similar results have been found in Italy and China (Zagari, Fuccio, Wallander et al. 
2008;Zou, He, & Ma 2011).  An American study invited 961 patients undergoing 
colonoscopy to undergo elective gastroscopy to detect Barrett’s oesophagus.  The 
overall prevalence of Barrett’s oesophagus was 6.8% with 5.2% of the asymptomatic 
population having short segment disease, and only 5.7% of those complaining of 
heartburn with short segment disease (Rex, Cummings, & Shaw 2003).  One of the 
challenges associated with unravelling the true incidence of Barrett’s oesophagus 
within the general population is that the condition is often asymptomatic with 46.2% 
of patients reporting no reflux symptoms (Reid, Li, Galipeau, & Vaughan 2010).   
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1.4.2 Risk factors associated with Barrett’s oesophagus 
The development of oesophageal adenocarcinoma is associated with four main risk 
factors – gastroesophageal reflux disease, obesity, smoking and a diet low in fruit 
and vegetables (Reid, Li, Galipeau, & Vaughan 2010).  The conventional risk factors 
for the development of Barrett’s oesophagus include male sex, advancing age, 
history of reflux disease, ethnicity (white) and tobacco use (Shaheen & Richter 
2009).  The symptom severity of gastroesophageal reflux disease does not seem to 
relate to the presence of Barrett’s oesophagus, although symptom frequency and 
chronicity (total years with reflux symptoms) are better predictors of the presence of 
the disease (Conio, Filiberti, & Blanchi 2002).  The use of non-steroidal anti-
inflammatory drugs (NSAIDS) may be associated with a decreased risk of Barrett’s 
oesophagus and disease progression, and the awaited results of the AspECT trial will 
help to evaluate the role of low dose aspirin and proton pump inhibitors as 
chemopreventative agents (Jankowski and Barr 2006;Nguyen, Richardson, & El-
Serag 2010). 
Some reports suggest that a higher proportion of first degree relatives of patients with 
Barrett’s oesophagus have the condition and studies suggest a genetic component to 
oesophageal adenocarcinoma (Reid, Li, Galipeau, & Vaughan 2010).  However 
further research is required to fully understand and identify the “at risk” genes.  An 
increasing body mass index (BMI) is associated with reflux disease, Barrett’s 
oesophagus and oesophageal adenocarcinoma.  A population study reported an 
association between Barrett’s oesophagus and increasing waist-to-hip ratio, 
suggesting that the high risk of Barrett’s was due to central adiposity (Edelstein, 
Farrow, Bronner et al. 2007). 
Unfortunately these risk factors only point to the presence of Barrett’s oesophagus 
and are neither sensitive nor specific enough for identifying individuals at high risk 
of progression to cancer.  Therefore at present, all patients with Barrett’s oesophagus 
are enrolled in an endoscopic surveillance programme.     
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1.4.3 Risk Factors Associated with Disease Progression 
The vast majority of patients with Barrett’s oesophagus will not develop oesophageal 
adenocarcinoma.  Over the last decade many groups have investigated factors which 
may predict progression to dysplasia and adenocarcinoma, with variable success.  
Predictors of progression in Barrett’s oesophagus can be classified into patient 
factors, endoscopic predictors, pathological predictors and biomarkers. 
 
Patient Factors 
Although several groups suggest increasing age is a risk factor for dysplasia and 
adenocarcinoma, there is insufficient data from well conducted studies to support 
this.  It is recognised that a male predominance is associated with adenocarcinoma, 
and this also seems to be a risk factor for progression to dysplasia (Prasad, Bansal, 
Sharma et al. 2010).  The association between smoking and Barrett’s associated 
adenocarcinoma is not as strong as the link between smoking and squamous 
oesophageal cancer, nor is the role of dietary factors. 
 
Endoscopic Factors 
There is evidence that increasing segment length may be associated with an 
increased risk of progression to dysplasia and cancer (Anandasabapathy, Jhamb, & 
Davila 2007).  The presence of nodules or visible abnormalities during endoscopy is 
associated with disease progression (Montgomery, Bronner, & Greenson 2002).  
Patients with Barrett’s oesophagus often have a hiatus hernia, and there is some 
evidence that the length of the hiatus hernia (more than six centimetres) is predictive 
of progression to high grade dysplasia and adenocarcinoma (Weston, Sharma, 
Mathur et al. 2004). 
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Pathological Predictors 
The grade of dysplasia remains the current gold standard for risk stratification in 
patients with Barrett’s oesophagus.  The presence of low grade dysplasia, particularly 
when confirmed by an expert pathologist is now a recognised risk factor for 
progression (Prasad, Bansal, Sharma, & Wang 2010).  Studies have suggested the 
extent of dysplasia, whether focal or diffuse, may predict disease progression 
although assessing the extent of dysplasia is a very labour intensive technique 
preventing its widespread use in clinical practice (Buttar, Wang, & Sebo 
2012;Srivastava, Hornick, Li, Blount, Sanchez, Cowan, Ayub, Maley, Reid, & Odze 
2007).  
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1.5 The Pathogenesis of Barrett’s Oesophagus 
The induction of Barrett’s metaplasia is really rather speculative as there are no 
reliable, physiological animal models.  Allison and Johnstone believed that Barrett’s 
oesophagus developed from gastric columnar cells migrating from the stomach into 
the oesophagus in response to the reflux damaged squamous epithelium (Allison & 
Johnstone 1953).  However more recent work suggests that chronic exposure to 
gastric and duodenal juices results in luminal damage to the squamous lining, 
exposing oesophageal stem cells lying in the basal layers of the epithelium (Dvorak, 
Payne, & Chavarria 2007;Pera and Pera 2002).  The refluxate stimulates abnormal 
differentiation in a genetically susceptible host leading to formation of a more 
“robust” columnar lined oesophagus.  Although the progenitor cell in humans 
remains unknown, metaplastic transformation arises as a consequence of changes in 
cellular gene expression and these changes are induced by gastroesophageal reflux, a 
key pathogenic factor.   
The events resulting in the metaplastic transformation of squamous to columnar 
epithelium are not clear, nor is the source of the columnar cells (Spechler, Fitzgerald, 
Prasad et al. 2010).  It has been proposed that the cardiac mucosa itself is an acquired 
metaplastic mucosa resulting from reflux damage to the squamous epithelium 
(Chandrasoma, Der, & Ma 2000).  pH and manometry studies suggest that the extent 
of cardiac mucosa is increased in those with increased levels of acid reflux and is 
absent in children with no reflux.  Chandrasoma has proposed that the entire 
oesophagus is normally lined by squamous epithelium with an abrupt transition to 
gastric oxyntic mucosa at the gastro-oesophageal junction (Chandrasoma 1997).  
Reflux of acid and bile damages the squamous lining and transforms it to the 
glandular columnar epithelium.  Cardiac mucosa can develop above the anastomosis 
of a gastric pull-up in patients who have undergone oesophagectomy, supporting the 
view this may be an acquired condition (Lord, Wickramasinghe, & Johansson 2004). 
Reflux of acid, pepsin and bile has little or no effect on gastric fundic mucosa.  
However it has two effects on squamous epithelium – oesophagitis and metaplastic 
transformation from squamous into cardiac type glandular mucosa (Chandrasoma 
1997).  Glandular metaplasia of the squamous epithelium first produces the simplest 
type of columnar mucosa which contains only mucous cells (ie cardiac mucosa) 
(Chandrasoma 1997).  Other types of glandular mucosa evolve from this mucosa by 
developing specialised cells such as parietal cells and goblet cells.  Studies have 
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shown severity of reflux is associated with length of the columnar lined segment 
(Clark, Ireland, & Chandrasoma 1994).  Incomplete intestinal metaplasia is 
associated with gastric adenocarcinoma (Correa, Piazuelo, & Wilson 2010).  It may 
be that the intestinal metaplasia of the oesophagus is premalignant, but there are few 
original studies showing that this is indeed the case (Haggitt, Tryselaar, Ellis, & 
Colcher 1978).  
1.5.1 Stem cells 
Jankowski and many other experts believe Barrett’s metaplasia arises from stem cells 
within the native oesophagus or adjacent oesophageal glandular tissue (Jankowski, 
Harrison, Perry et al. 2000).  However the origins of the stem cells are unclear 
although three theories have been put forward.  The de novo metaplasia theory 
suggests that stem cells in the inflamed oesophageal squamous mucosa are exposed 
and damaged by reflux, producing metaplastic changes within the stem cells.  These 
cells undergo phenotypic changes resulting in Barrett’s stem cells capable of 
surviving in a hostile reflux environment.  This is a similar process to metaplasia of 
the vagina (Sodhani, Gupta, Prakash et al. 1999).  The second theory is the 
transitional zone theory.  Cells from the gastro-oesophageal junction, the transitional 
zone, or the gastric cardia colonise the distal oesophagus in response to noxious 
luminal agents in an attempt to re-epithelialize the damaged mucosa.  These cells 
express a columnar phenotype and may be the progenitors for the Barrett’s cell 
population.  This theory is supported by metaplasia seen in other transitional zones in 
the body such as the cervix and the prostate gland (Jankowski, Harrison, Perry, 
Balkwill, & Tselepsis 2000;Wallner, Syvan, Stenling et al. 2000).  An interesting 
paper studying p63 null mice embryos suggested, upon programmed damage to the 
squamous epithelium, mice developed an intestinal metaplasia with gene expression 
profiles similar to Barrett’s oesophagus (Wang, Ouyang, Yamamoto et al. 2011).  
The last theory, the duct-cell metaplasia theory, is that stem cells in the oesophageal 
ducts selectively colonise the oesophagus in response to reflux induced damage.  
Other studies suggest the progenitor cells may be circulating stem cells from bone 
marrow (Spechler, Fitzgerald, Prasad, & Wang 2010).     
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1.5.2 Local environment 
Stem cells are essential in the metaplastic transformation of the native squamous 
oesophageal mucosa, but the extrinsic forces resulting in the changes in stem cells 
remain unknown.  It is generally accepted that a clear association exists between host 
susceptibility (genetic and epigenetic abnormalities) and the intraluminal 
environment (mucosal inflammation and acid/bile acid reflux).   
Recent studies have shown that molecular events within the squamous epithelium, 
triggered by reflux disease, may cause Barrett’s oesophagus.  In cell culture, acid and 
bile induce the expression of caudal homeobox genes, CDX1 and CDX2 which are 
responsible for intestinal development during embryogenesis (Souza, Krishnan, & 
Spechler 2008).  Gastroesophageal reflux may therefore induce aberrant expression 
of Cdx genes as a first stage in the metaplastic process.  It is well recognised that 
acid and bile reflux leads to oxidative stress within oesophageal cells causing DNA 
damage and free radical formation which can initiate the process of apoptosis, 
cellular senescence or carcinogenesis (Dvorak, Payne, & Chavarria 2007). 
Inflammation in the oesophagus in response to gastroesophageal reflux disease, was 
first linked to cancer in 1863 and is now considered to be one of the hallmarks of 
cancer (Colotta, Allavena, Sica et al. 2009;Lao-Sirieix and Fitzgerald 2010).  An 
inflammatory infiltrate is often seen in the oesophageal mucosa in response to reflux, 
and even when gastroduodenal reflux disease is corrected by acid suppressing 
medication, a mild chronic inflammatory infiltrate persists.  Inflammation can 
generate free radicals and this may lead to increased expression of various cytokines 
and upregulation of genes, propagating the metaplastic transformation (Reid, Li, 
Galipeau, & Vaughan 2010).   
 
1.5.3 Molecular abnormalities in Barrett’s oesophagus 
Unlike colon cancer, Barrett’s oesophagus and oesophageal adenocarcinoma are 
genetically heterogenous conditions, in which there are many abnormalities 
involving tumour suppressor genes and key pathways.  Chapter 7 reviews the 
literature concerning biomarkers and Barrett’s oesophagus. 
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1.6 Endoscopic Surveillance Programmes 
Barrett’s oesophagus is a complex condition in which the pathophysiology of the 
disease remains enigmatic.  The malignant potential of Barrett’s epithelium is 
important and the future management of patients with Barrett’s oesophagus should 
concentrate on improving risk stratification of patients and initiating early 
appropriate treatments.  This will allow targeted surveillance and treatment of those 
at higher risk of progression to dysplasia and cancer, and reassurance and avoidance 
of regular unnecessary endoscopies for those at no/low risk of progression.   
Most centres advocate endoscopic surveillance of Barrett’s oesophagus, aiming to 
identify cancer at an early stage when it is curable, and detect dysplasia in order that 
endoscopic treatments may be offered.  However there continues to be debate 
surrounding the usefulness and cost effectiveness of endoscopic surveillance 
programmes as the yield is often low.  Barrett’s mucosa is often heterogenous 
containing various epithelia, and areas of dysplasia found alongside areas of 
metaplasia.  This leads to one of the main problems in carrying out endoscopic 
surveillance as small neoplastic lesions may be missed as they are often not visible.  
Despite these concerns, Barrett’s oesophagus is a disease which is amenable to 
surveillance as it is a common condition, is associated with the development of 
oesophageal adenocarcinoma and tends to have a stepwise progression from 
metaplasia to dysplasia and carcinoma (Spechler S.J 2011).  Survival from 
oesophageal adenocarcinoma is dependent on the depth of invasion and the presence 
of lymph node metastases.  Patients with T1 stage have survival rates of more than 
90% at five years, whilst patients with T4 disease or lymph node metastases have 
rates of less than 25% (Kim, Grobmyer, Smith et al. 2011).  Observational studies 
suggest that patients with surveillance detected cancers have a better prognosis as 
they are diagnosed at an early stage compared with those who present with 
symptoms (Corley, Levin, & Habel 2002;Spechler S.J 2011).  Endoscopic 
surveillance is therefore recommended to detect dysplasia and early cancer. 
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1.6.1 Entry Criteria To Surveillance Programme 
Patients with a clear diagnosis of Barrett’s oesophagus should be invited to 
participate in endoscopic surveillance programmes.  As discussed the general 
consensus definition of Barrett’s oesophagus is a condition in which the normal 
squamous lining of the oesophagus is replaced by a columnar metaplasia at risk of 
malignant progression.  However the diagnostic criteria required to make such a 
diagnosis vary among gastroenterological and surgical societies.   
Patients should be counselled regarding the risks and benefits of endoscopic 
surveillance, and the limitations associated with such a programme.  Other important 
criteria may depend upon patient age (perhaps surveillance in those over 80 is not 
appropriate), other comorbidities and life expectancy (likelihood of survival over the 
next few years) and the ability to undergo repeated endoscopic procedures or other 
treatment options.  Barrett’s oesophagus is a common condition with population 
estimates suggesting a disease prevalence of 2-7%.  Endoscopic surveillance 
therefore is a time and resource consuming process with significant cost 
implications. 
1.6.2 Surveillance Protocols 
The aim of endoscopic surveillance in patients with Barrett’s oesophagus is to detect 
and treat dysplasia and cancer at an early stage.  Most centres advocate the use of 
high resolution white light endoscopy with the use of image adjuncts such as narrow 
band imaging if available. 
Endoscopic assessment 
At endoscopy, the oesophagus is inspected and the presence of important landmarks 
noted, namely the oesophagogastric junction (the level of the proximal gastric folds 
on minimal insufflation) and the squamocolumnar junction.  The presence of a 
columnar lining of the oesophagus is noted (salmon pink colour compared to normal 
white/pink of squamous epithelium) and any subtle mucosal abnormalities.  The 
Barrett’s segment should be described using the Prague C&M classification system, 
where C describes the circumferential extent of the columnar lining, and M applies to 
the whole segment of metaplasia, including any tongues or islands of Barrett’s 
mucosa (Sharma, Dent, & Armstrong 2006).  Most guidelines suggest obtaining four 
quadrant biopsies at two centimetre intervals along the Barrett’s segment (Playford 
2005;Wang & Sampliner 2008).  Any mucosal lesion such as nodules, ulcers, 
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erosions or mucosal irregularity should be separately biopsied as there is evidence 
that these lesions are linked to the presence of dysplasia or cancer (Reid, Blount, 
Feng, & Levine 2000).  The rationale for a comprehensive biopsy protocol arises 
from the focal nature of dysplasia and often the lack of associated mucosal 
abnormalities (Abela, Going, Mackenzie, McKernan, O'Mahoney, & Stuart 2008).  
There has been debate whether the use of jumbo forceps improves endoscopic 
sampling by providing the pathologist with larger pieces of tissue (Gonzalez, Yu, 
Smith et al. 2010).  However there is no persuading evidence to suggest these are 
necessary for routine endoscopic surveillance.    
There is some evidence that the Seattle protocol, using a smaller interval of one 
centimetre in addition to biopsy of visible lesions, was more effective at detecting 
adenocarcinoma in patients with high grade dysplasia (Reid, Blount, Feng, & Levine 
2000).  However the increasing use of endomucosal resection for patients with 
dysplasia or visible lesions has resulted in very few centres now adhering to the 
Seattle protocol.  Indeed a study of patients undergoing oesophagectomy for high 
grade dysplasia showed no difference in undiagnosed cancer incidence between 
those undergoing traditional quadrantic biopsies every two centimetres compared 
with those using the Seattle protocol (Kariv, Plesec, & Goldblum 2009). 
Histological Assessment 
Biopsies taken from each two centimetre level within the Barrett’s segment, and any 
focal abnormality should be placed in individual specimen pots and clearly labelled.  
It is important that the pathologist is aware of the location of the biopsy as metaplasia 
of the distal oesophagus can mimic changes seen in the cardia of the stomach.  
Biopsy specimens should ideally be assessed by a gastrointestinal pathologist with 
expertise in Barrett’s oesophagus.  Each biopsy is cut and stained with haematoxylin 
and eosin to allow initial assessment of the tissue and classification according to the 
Vienna classification system, see Table 1.1 (Schlemper, Riddell, & Kato 2000).  The 
columnar lining is assessed for the presence of intestinal metaplasia, junctional type 
mucosa or fundic type mucosa.  The pathological assessment of Barrett’s biopsy 
samples is vitally important, as it is the presence (or absence) of dysplasia which 
determines further surveillance intervals and/or the need for treatment. 
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1.6.3 Surveillance Intervals 
The time interval between surveillance procedures is based on the presence or 
absence of dysplasia, and our limited understanding of the biology of Barrett’s 
oesophagus.  The recommendations from each gastrointestinal society are not based 
on results from randomised clinical trials and it seems that the societies do not agree 
on surveillance intervals (Boyer, Laugier, Chemali, Arpurt, Boustiere, Canard, 
Dalbies, Gay, Escourrou, Napoleon, Palazzo, Ponchon, Richard-Mollard, Sautereau, 
Tucat, & Vedrenne 2007;Hirota W, Zuckerman, Adler et al. 2006;Playford 
2005;Wang & Sampliner 2008;Wang, Wongkeesong, & Buttar 2005).  Table 1.2 
summarises the important points within each guideline. 
The general principles of the surveillance programme advise patients without 
metaplasia to undergo regular endoscopic assessment every 2-3 years.  The French 
Society of Digestive Endoscopy is the only body to suggest surveillance intervals 
should depend on the length of Barrett’s segment as shown in Table 1.2 (Boyer, 
Laugier, Chemali, Arpurt, Boustiere, Canard, Dalbies, Gay, Escourrou, Napoleon, 
Palazzo, Ponchon, Richard-Mollard, Sautereau, Tucat, & Vedrenne 2007).  In the 
presence of dysplasia the surveillance interval is shortened.  It is recommended that 
patients with low grade dysplasia are treated with eight weeks of high dose PPI 
therapy to reduce inflammation which is often associated with dysplasia.  If the 
repeat biopsy continues to suggest the presence of low grade dysplasia after review 
by an expert pathologist, the surveillance interval is reduced to six months.  In the 
absence of low grade changes on two successive endoscopies, the surveillance period 
is lengthened to an annual endoscopy initially then every two years. 
In the presence of high grade dysplasia, most institutions would recommend 
treatment with high dose PPI therapy and repeat endoscopy with further biopsy or 
endomucosal resection of any abnormal area.  Should high grade dysplasia be 
confirmed on repeat biopsy, the patient should be referred to a clinician with 
expertise in Barrett’s oesophagus and treatment offered.  Other imaging modalities 
may be required (EUS, CT, PET) to stage the disease as high grade dysplasia is often 
associated with the presence of intramucosal cancer. 
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Table 1.2 Summary of Surveillance Guidelines for Barrett’s Oesophagus 
Organisation Diagnostic 
Criteria 
Metaplasia Low Grade Dysplasia High Grade Dysplasia 
BSG (2005) Columnar 
metaplasia 
Every 2 years Acid suppression, repeat OGD 
If LGD persists, 6 monthly 
If LGD absent, 2 negative OGDs and repeat 
2 years 
OGD every 6 months or refer 
for treatment 
ACG (2008) Intestinal 
metaplasia 
2 OGDs in first year 
If negative for dysplasia, every 3 years 
Repeat OGD 6 months 
If LGD absent, annual until no dysplasia for 
2 years 
Repeat OGD 3 months 
If HGD persists, refer for 
intervention 
AGA (2005)  Intestinal 
metaplasia 
2 OGDs in first year 
If negative for dysplasia, every 5 years 
Repeat OGD 1 year 
If LGD present, annual OGD 
Repeat OGD 3 monthly 
 
ASGE (2006) Intestinal 
metaplasia 
2 OGDs in first year 
If negative for dysplasia, every 3 years 
Repeat OGD 6 months 
If LGD persists, repeat 6 months then annual 
endoscopy 
Repeat OGD 3 monthly 
If HGD absent after 2 OGD, 
lengthen interval to 1 year 
FSDE (2007) Intestinal 
metaplasia 
Short segment (<3cm) 5 years 
Long segment (3-6cm), 3 years 
Long segment (>6cm), 2 years 
Repeat OGD 2 months 
If LGD persists, repeat 6 months then annual 
endoscopy 
Repeat OGD 
If HGD persists, refer for 
intervention 
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1.6.4 Limitations of Barrett’s Oesophagus Surveillance 
The current endoscopic surveillance programme carries limitations.  The endoscopic 
procedure can be uncomfortable for patients, and time consuming especially in those 
with long segment disease in whom many biopsies should be performed.  Many 
dysplastic or early neoplastic lesions are not visible to the naked eye, resulting in 
missed lesions on biopsy.  The vast majority of patients with Barrett’s oesophagus 
will not develop cancer (0.5% annual cancer risk), but continue to undergo the 
anxiety often associated with repeated endoscopies. 
The interpretation of dysplasia, particularly low grade dysplasia is often difficult, and 
many specimens when reviewed by expert pathologists are often downgraded.  
Patients and clinicians are also fairly poor at rigid adherence to the surveillance 
protocols and this may have an impact on the diagnosis of dysplasia (Waxman 2011).  
Lastly, some oesophageal adenocarcinomas may arise as de novo cancers without 
any evidence of previous dysplasia, or present as interval cancers. 
 
1.6.5 Improving the Surveillance Programme 
The endoscopic surveillance programme could be improved.  Firstly, a larger area 
could be sampled by using more aggressive biopsy protocols, or other techniques 
such as brush or sponge cytology.  Targeting areas of dysplasia may allow more 
rigorous sampling within areas of interest.  In order to perform this, new technologies 
need to be applied, such as confocal microscopy or autofluorescence.  Perhaps the 
most promising improvement would be risk stratification of patients using a variety 
of markers, such as clinical risk factors and biomarkers.  In the meantime we await 
with interest the results of a randomised clinical trial assessing the role of endoscopic 
surveillance (versus no surveillance) for the prevention of early mortality in patients 
with Barrett’s oesophagus (Jankowski & Barr 2006). 
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1.7 Aims of thesis 
In an attempt to improve the care of patients with Barrett’s oesophagus within the 
West of Scotland and understand the molecular mechanisms underlying the disease, 
my thesis will address the main challenges associated with this enigmatic condition 
at clinical, endoscopic and molecular levels.  The aims of my thesis are as follows: 
1) To present a general overview of the Barrett’s literature highlighting current 
clinical challenges and discuss the role of intestinal metaplasia in the diagnosis of 
Barrett’s oesophagus 
2) To examine the incidence of dysplasia and oesophageal adenocarcinoma in the 
West of Scotland by analysing a cohort of patients undergoing surveillance 
endoscopy and study the effects of deprivation on disease progression 
3) To review the current endoscopic imaging adjuncts for the diagnosis of Barrett’s 
oesophagus and dysplasia, and assess the role of optical biopsy forceps in 
determining the presence of dysplasia 
4) To evaluate the role of Wnt signalling in Barrett’s oesophagus, from metaplasia 
to carcinoma in a mouse model, with complementary human studies 
 
  
41 
 
Chapter 2 
Intestinal metaplasia –  the only cancer precursor? 
t is generally accepted that the cancer risk in Barrett’s oesophagus is conferred 
by intestinal metaplasia, characterised by the presence of goblet cells.  This 
belief is difficult to test, as it is often impossible to prove an absence of goblet 
cells in a particular oesophagus.  Furthermore, little is known about the distribution 
and temporal drift of the intestinal phenotype.  However studies suggest genetic and 
epigenetic abnormalities are present within the non-intestinal mucosa making it 
difficult to believe the intestinal phenotype alone confers malignant risk.  In order to 
determine patient-specific cancer risk, a consensus definition is required and an 
understanding of the metaplastic nature of the columnar mucosa and the evolution of 
dysplasia is needed.  It is unlikely malignant risk can be limited to whether intestinal 
metaplasia is present or absent. 
 
Publication 
Moyes LH, Going JJ.  Goblet cells in Barrett’s oesophagus: cancer precursor, risk 
marker or irrelevance.  Diagnostic Histopathology 2012; 18 (12): 503-510.  
I 
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2.1 Background  
It is widely considered that metaplasia to a mucosa with goblet cells is associated 
with premalignant dysplasia and risk of progression to oesophageal adenocarcinoma.  
Intestinal metaplasia (IM) is regarded as a prerequisite for the diagnosis of Barrett’s 
oesophagus and enrolment into endoscopic surveillance programmes in the USA and 
Germany.  On the other hand, the British Society of Gastroenterologists and the 
Japan Esophageal Society do not require IM for the diagnosis which can be made 
when columnar mucosa of cardiac, oxyntic or intestinal types are found in a mucosal 
biopsy of oesophageal origin.   
Studies over the recent decades have shown that Barrett’s dysplasia and 
adenocarcinoma develop in the presence of, and perhaps even from IM.  However, 
there is molecular evidence to suggest Barrett’s “columnar lined” oesophagus, even 
without IM may have malignant potential (Riddell and Odze 2009).   
The original evidence for a specific role of IM as the usual precursor of oesophageal 
adenocarcinoma was reviewed, along with whether its presence or absence is really 
an appropriate precondition for a diagnosis of Barrett’s oesophagus.   
2.2 Literature search 
A literature search was performed using PubMed, Embase and Ovid databases 
searching for English literature available since 1900.  The search was performed with 
MESH terms “Barrett”, “Barrett’s esophagus/oesophagus”, “columnar lined 
esophagus/oesophagus”, “oesophageal adenocarcinoma”, “intestinal metaplasia”, 
“metaplasia” and “goblet cells”.  All related reference articles were examined and 
included in the analysis if relevant.  In this chapter, the terms “Barrett’s oesophagus” 
and “columnar lined oesophagus” are synonymous. 
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2.3 Barrett’s associated adenocarcinoma – the original studies 
By the 1970s when the association between gastro-oesophageal reflux, hiatus hernia 
and columnar lined oesophagus (CLO) had been accepted (DeMeester and 
DeMeester 2000), surgeons and pathologists recognised the link between CLO and 
oesophageal adenocarcinoma motivating research and justifying endoscopic 
surveillance programmes (Reid and Weinstein 1987). 
The first recorded case of oesophageal adenocarcinoma in an aberrant gastric type 
mucosa was described by Morson and Belcher in 1952 (Morson and Belcher 1952).  
Since then numerous studies of patients with resected adenocarcinomas arising in 
Barrett’s oesophagus have been published, although most are limited by small patient 
numbers with few detailed descriptions of the pathology and histology (Adler 
1963;Armstrong, Blalock, & Carrera 1959;Berenson, Riddell, & Skinner 
1978;Haggitt, Tryselaar, Ellis, & Colcher 1978;Hamilton and Smith 1987;Hawe, 
Payne, Weiland et al. 1973;Lortat-Jacob, Maillard, Richard et al. 1968;Maas, Katz, 
& Pascale 1974;McCorkle and Blades 1955;Murray, Watson, Johnston et al. 
2003;Naef, Savary, & Ozzello 1975;Nilsson, Skobe, Johansson et al. 2000;Paraf, 
Flejou, Pignon et al. 1995;Rosenberg, Budev, Edwards et al. 1985;Ruol, Parenti, 
Zaninotto et al. 2000;Skinner, Walther, Riddell et al. 1983;Smith, Hamilton, Boitnott 
et al. 1984;Spechler SJ, Robbins, Rubins et al. 1984).   
Haggitt originally suggested that if atrophic gastritis with intestinal metaplasia 
predisposed to gastric carcinoma, the columnar epithelium of the oesophagus with its 
intestinal metaplasia may signify a similar predisposition in the oesophagus (Haggitt, 
Tryselaar, Ellis, & Colcher 1978).  Dr Haggitt’s study of 14 patients with 
oesophageal adenocarcinoma showed that 12 cancers arose within an epithelium 
resembling gastric cardiac mucosa with mucous glands but no parietal cells.  Earlier 
studies identified adenocarcinoma in the presence of only a glandular mucosa and it 
was not until Paull’s histological description of the columnar lined oesophagus that 
most studies identified intestinal metaplasia as the predominant mucosa associated 
with dysplasia and cancer.   
The original reports and studies which suggest a link between Barrett’s oesophagus 
and adenocarcinoma are summarised in Table 2.1.  Many of these describe few 
patients and varied inclusion/exclusion criteria make interpretation difficult.  Early 
reports often exclude lesions near the cardia and short segments of columnar lined 
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oesophagus, allowing a diagnosis of Barrett’s oesophagus only if the columnar lining 
is more than 3cm above the gastroesophageal junction.  Another difficulty with 
earlier studies was determining the exact cellular origin of the tumour, most 
presenting at an advanced stage.  However despite these diagnostic difficulties, most 
studies concluded that adenocarcinomas developed within an area of columnar lined 
oesophagus, often in association with intestinal metaplasia.   
Sjogren’s review of the literature (121 cases of adenocarcinoma associated with 
Barrett’s oesophagus) found many reports did not describe the adjacent epithelial 
type (Sjogren and Johnson 1983).  However, by the 1990s "specialised" intestinal 
metaplasia was widely recognised as the most common epithelium associated with 
Barrett’s oesophagus and by inference, conferred its malignant potential (Haggitt 
1994).  The annual cancer risk was quoted around 0.8% in patients with 
endoscopically obvious disease.  Later a metaplasia-dysplasia-adenocarcinoma 
sequence was proposed and endoscopic surveillance programmes for patients with 
Barrett’s oesophagus commenced to identify dysplasia and allow earlier recognition 
and treatment of cancers (Reid, Blount, Rubin et al. 1992).   
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Table 2.1 Summary of original studies describing carcinoma in the presence of columnar lined oesophagus  
Reference Patients Sex Location Histology Intestinal metaplasia Comments 
Morson BC (1952) 1 M Mid 
oesophagus 
Glandular 
Distal limit – cardiac type 
Intestinal type including goblet 
cells 
Yes  
McCorkle RC (1955) 1 M Mid Glandular No comment  
Armstrong RA (1959) 1 M Mid Glandular No comment  
Adler RH (1963) 1 M Cardia Glandular No comment  
Lortat-Jacob JL 
(1968) 
16     3 cases – arising in oesophageal/cardiac glands 
2 cases – derive from glandular components 
6 cases – in association with peptic ulceration 
Hawe A (1973) 5 4M 1F Mid/lower Glandular No comment  
Maas LC (1974) 1 M Mid Columnar epithelium without 
parietal cells 
  
Naef AP (1975) 12 Unknown Mid/lower Columnar epithelium No comment  
Berenson MM (1978) 2 2M N/A Gastric and intestinal type Yes  
Haggitt (1978) 12 8M 4F Mid/lower Cardiac type (12/12)  100% 
Intestinal type (9/12)  75% 
Fundic type (2/12)      17% 
Dysplasia (10/12)       80% 
Present 
Proximal location 
“Specialised intestinal type similar to atrophic 
gastritis which is associated with gastric 
cancer, so perhaps intestinal type may signify a 
similar predisposition”.  In this cohort, most 
common type was cardiac mucosa. 
Smith RR (1984) 21 23M 3F Mid/lower Specialised type (21/21) 100% 
Dysplasia (26/26)            100% 
 
Present  
Rosenberg JC (1985) 9 8M 1F N/A Specialised type (9/9) 100% 
Dysplasia (9/9)            100% 
Present  
Hamilton SR (1987) 14 N/A Mid/lower Dysplasia occurred in Present Intestinal metaplasia most commonly 
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 Specialised type (93%) 
 Cardiac type (21%) 
 
associated with dysplasia and cancer 
Skinner DB (1983) 20 18M 2F Mid/lower Intestinal type alone (60%) 
Cardiac type alone    (40%) 
Fundic type alone     (10%)  
Intestinal and cardiac (30%) 
Intestinal all cases (100%) 
Present Intestinal metaplasia present in all cancer cases 
(100%) whereas only present in 74% benign 
cases. IM most common type to undergo 
malignant change, although dysplasia seen in 
all epithelial types.  
Spechler SJ (1984) 8 N/A N/A Intestinal type (8/8)        100% Present 67% patients displayed IM and all 8 cancers in 
this cohort.  33% did not have IM with no 
cancers in this cohort. 
Paraf F (1995) 67 61M 6F  Intestinal type (32/67)     48% 
Cardiac type (25/67)        38% 
Fundic type (2/67)           3% 
All types (7/67)                11% 
Dysplasia (50/67)             76% 
Dysplasia and intestinal    98% 
Dysplasia and cardiac        2% 
Present Intestinal metaplasia most commonly 
associated with dysplasia. 
Nilsson J (2000) 5 4M 1F Mid/lower Specialised type (5/5)      100% Present All cancers arose on a background of long 
segment IM. 
“The risk of missing small areas of SCM 
within columnar mucosa when obtaining 
specimens is far from negligible”. 
Ruol A (2000) 26 25M 1F Mid/lower Intestinal type 25/26          (96%) 
Dysplasia present 22/26     (85%) 
Present  
Murray L (2003) 29 22M 7F N/A Intestinal type 26/29          (90%) 
Cardiac type    1/29            (3%) 
Unknown         3/29            (6%) 
Present “Risk of cancer almost exclusively in patients 
with SIM” 
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2.4 Are goblet cells really necessary for progression to cancer? 
The association between CLO and adenocarcinoma has been recognised for many 
years, with an acceptance that the mucosal type surrounding the malignancy tends to 
be intestinal, and often dysplastic.  However, patients without intestinal metaplasia 
on index endoscopy, may progress to intestinal metaplasia and subsequent 
adenocarcinoma.  The first paper to suggest that goblet cells, a histological marker 
for intestinal metaplasia, were not always detected in patients with CLO suggested 
that 20% of patients did not exhibit intestinal metaplasia on two endoscopic 
examinations (Kim, Waring, Spechler et al. 1994).  These results have been 
corroborated by Harrison who found that even if 15 or 16 biopsies were performed, 
there was still no guaranteed detection of goblet cells within a columnar segment 
(Harrison, Perry, Haddadin et al. 2007).   
Several factors influence the identified prevalence of intestinal metaplasia - age, 
number of endoscopies, number of biopsies, length of reflux symptoms and length of 
the columnar lined segment (Csendes, Smok, & Burdiles 2003;Harrison, Perry, 
Haddadin, McDonald, Bryan, Abrams, Sampliner, Talley, Moayyedi, & Jankowski 
2007;Oberg, Johannson, & Wenner 2001;Oberg, Peters, & DeMeester 
2000;Qualman, Murray, McClung et al. 1990).  A large prospective study analysed 
3568 biopsies from 1751 patients with non-dysplastic CLO, demonstrating intestinal 
metaplasia in 65.8% of cases (Gatenby, Ramus, Caygill et al. 2008).  Increased 
prevalence of intestinal metaplasia detection was correlated with male sex, increasing 
age and number of biopsies and longer segment lengths, in keeping with previous 
studies.  At the start of the study 12.7% of patients displayed intestinal metaplasia on 
initial biopsies, with 72% at 5 years, and 90.8% at 10 years.  This study had 322 
patients with CLO (negative for goblet cells) and 612 patients with CLO (positive for 
goblet cells).  Whilst the results were not statistically significant, there was a trend 
towards a higher risk of progression to dysplasia and adenocarcinoma in the group 
with intestinal metaplasia.  Of the 322 patients without intestinal metaplasia, ten 
patients developed adenocarcinoma and two patients, high grade dysplasia.  These 
patients would have been excluded from surveillance programmes according to the 
American College Guidelines.  The authors do not deny that detection of intestinal 
metaplasia is associated with increased malignancy, but point out that failure to 
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detect intestinal metaplasia does not mean it is not present or is associated with 
malignant potential.   
If malignant risk is specifically conferred by intestinal metaplasia, patients with a 
columnar “glandular” mucosa alone (i.e. no intestinal metaplasia) on biopsy should 
be less likely to develop adenocarcinoma.  Kelty and colleagues classified 688 
patients into three groups – no glandular metaplasia, glandular metaplasia without 
intestinal metaplasia and glandular metaplasia with intestinal metaplasia (Kelty, 
Gough, van Wyk et al. 2007).  On index endoscopy, 379 patients (55.1%) had 
intestinal metaplasia and 309 patients (44.9%) only glandular with each group having 
equal numbers of biopsies (average 4, range 2-15).  28 patients developed cancer in 
the follow up period, 17 in the intestinal metaplasia group and 11 in the glandular 
only group (p=NS).  The overall cancer risk was 0.34% per year with no significant 
difference between groups with intestinal metaplasia and those with glandular 
mucosa alone.  This study adds weight to the argument that patients with glandular 
mucosa, without identifiable goblet cells, also carry a malignant risk, should be 
diagnosed as Barrett’s oesophagus and invited to participate in endoscopic 
surveillance programmes.   
Takubo reviewed 141 endomucosal resection specimens (German patients) 
specifying the background mucosa as squamous, cardiac, fundic and intestinal with 
goblet cells (Takubo, Aida, Naomoto et al. 2009).  Cardiac mucosa was seen in the 
presence of adenocarcinoma: it was claimed 75% of cases had a mucosal background 
without goblet cells.  Approximately one third of these small tumours were 
completely surrounded by CLO; one third had non-neoplastic CLO on one aspect 
with dysplastic/neoplastic CLO on the other; and one third non-neoplastic CLO on 
one side and squamous on the other.  Cardio-oxyntic mucosa was more common than 
intestinal type than oxyntic alone (70.9% vs 22% vs 3.5%).  It is unclear the extent to 
which this lack of peritumoral goblet cells could be a consequence of tumour 
overgrowth, due to sampling errors or whether the disease in Japan is a different 
entity to CLO of the western world.   
However, a recent study by Chandrasoma and colleagues assessing the role of a 
systematic biopsy protocol in patients with Barrett’s oesophagus and the prevalence 
of intestinal metaplasia disagrees with the above studies (Chandrasoma, Wijetunge, 
DeMeester et al. 2012).  At index endoscopy, 187 of 214 patients presented with 
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intestinal metaplasia with 55 patients progressing to dysplasia or cancer.  In the 
group with no intestinal metaplasia on systemic biopsy, no patient progressed.  They 
conclude that systematic biopsy is necessary to adequately assess patients with 
Barrett’s oesophagus and those patients without intestinal metaplasia carry an 
insignificant cancer risk and should be discharged from further endoscopic follow 
up.  However, the total number of patients in this biopsy study was moderated with 
only 27 non-IM cases. 
Most pathologists and clinicians accept the view that IM is associated with the 
development of oesophageal adenocarcinoma.  Dysplasia invariably arises within 
areas of IM, and Barrett’s adenocarcinoma is nearly always preceded and 
accompanied by dysplasia.  However, there are some cases in which a “non-goblet” 
epithelium carries risk of malignant progression.  Neoplasia is unlikely to arise 
directly from the goblet cells as these are terminally differentiated cells.  Goblet cell 
density varies.  Is risk proportional to density? It appears even areas of low density 
carry some malignant risk, and therefore it is unlikely a non-goblet mucosa would be 
risk-free. 
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2.5 Non-goblet columnar epithelium – at risk of progression? 
Several research groups have looked for evidence that a non-goblet epithelium may 
also carry malignant potential.  Metaplastic oesophageal columnar epithelium 
without goblet cells shows similar chromosomal and DNA content abnormalities to 
those with goblet cells (Kelty, Gough, van Wyk, Stephenson, & Ackroyd 
2007;Takubo, Aida, Naomoto, Sawabe, Arai, Shiraishi, Matsuura, Ell, May, Pech, 
Stolte, & Vieth 2009).  Patients with CLO without goblet cells have a similar risk of 
neoplastic progression compared with those patients in whom goblet cells are 
present.  However there are clearly other factors besides genetics involved in the 
development of Barrett’s oesophagus and the local milieu plays an important role. 
Hahn assessed the expression of CDX2 and other markers of intestinal differentiation 
in non-goblet epithelium (Hahn, Blount, Ayub et al. 2009). Patients without goblet 
cells had a lower percentage of CDX2 staining (43%) compared with those 
expressing goblet cells (98%) but did show phenotypic evidence of intestinal 
differentiation (immunohistochemical positivity of markers such as Das-1, villin and 
MUC-2).  It has been suggested that squamous epithelium converts initially to a non-
goblet columnar epithelium before goblet cell metaplasia.  It may appear the unstable 
metaplastic epithelium is associated with malignant transformation. 
There is a proportion of patients with columnar lined oesophagus who do not show 
goblet cells on biopsies regardless of the site and number of biopsies performed 
(Riddell & Odze 2009).  This could be due to sampling errors but there is now 
evidence to suggest a non-goblet cell mucosa, such as cardiac type, also carries DNA 
and chromosomal abnormalities and is associated with malignant transformation and 
neoplastic progression (Liu, Hahn, Odze et al. 2009).  However the actual risk of this 
“non-goblet” epithelium is currently unknown.  There are two retrospective follow 
up studies suggesting both types of epithelium carry a risk of malignant 
transformation but due to their retrospective nature it is difficult to quantify such risk 
(Gatenby, Ramus, Caygill, Shepherd, & Watson 2008;Kelty, Gough, van Wyk, 
Stephenson, & Ackroyd 2007).   
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2.6 Conclusion 
In conclusion, the phrase “no goblet cells implies no cancer risk” needs to be 
challenged.  Studies suggest that patients without goblet cells are at risk of cancer 
and should not be excluded from surveillance programmes.  This is in line with 
current British guidelines and clinical practice within the UK.  On a more practical 
note, it seems that the issue of whether goblet cells are present or not may become 
less important if the non-goblet epithelium is also at risk of malignant transformation 
(Riddell & Odze 2009). It is still unclear how the squamous epithelium undergoes its 
initial metaplastic transformation to a columnar mucosa, and whether cardiac type 
mucosa is indeed a precursor to intestinal metaplasia.  Metaplastic transformation 
appears to be the key event leading to an unstable epithelium which is capable of 
neoplastic progression.  In order to improve patient care, the key focus should be risk 
stratification based on clinical (duration, length of symptoms), phenotypic 
composition and molecular markers.  It is unlikely the presence (or absence) of 
goblet cells will be sufficient for effective risk management. 
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Chapter 3 
High Risk of Dysplasia and Adenocarcinoma: The  Glasgow Experience 
ecent meta-analyses suggest the rates of malignant progression in patients 
with Barrett’s oesophagus are lower than originally reported.  However 
Scotland has one of the highest rates of oesophageal adenocarcinoma in 
the world, and the incidence of Barrett’s oesophagus has risen in parallel.  The West 
of Scotland population appears to be a high risk population and there is a concern 
that the low rates of malignant progression in lower risk populations may lull 
physicians, health economists and politicians into complacency concerning this 
potentially lethal condition.  Barrett’s oesophagus, and particularly dysplasia can be 
treated with endoscopic intervention (endoscopic resection and radiofrequency 
ablation) and specialist centres now have access to excellent endoscopic facilities 
allowing appropriate and timely intervention.  A clear understanding of the natural 
history of Barrett’s oesophagus is required to allow surveillance of “at risk” patients, 
and improve resource management.  The aim of this study was to assess the 
incidence of progression to dysplasia and/or adenocarcinoma in a cohort of patients 
with Barrett’s oesophagus undergoing surveillance endoscopy in a Glasgow hospital. 
 
 
  
R 
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3.1 Introduction 
Oesophageal adenocarcinoma is the fifth most common cause of cancer death in 
Scotland.  The incidence of oesophageal adenocarcinoma (OA) has continued to rise 
over the last two decades, currently 16.9/100 000 person years follow up (Jankowski, 
Provenzale, & Moayyedi 2002;NHS National Services Scotland 2012).  Although 
survival rates have improved with more accurate staging and better perioperative 
support, survival remains low with only one in four patients surviving five years 
(Clinical Resource and Audit Group (CRAG) 2005).   
Barrett’s oesophagus is a recognised precursor of oesophageal adenocarcinoma.  
About 12% of people undergoing endoscopy for reflux symptoms have Barrett’s 
oesophagus although the true incidence of Barrett’s oesophagus in the general 
population remains unknown (Spechler 2002).  One of the most accurate population 
studies from Sweden suggests the incidence of Barrett’s oesophagus in 3000 adults 
sampled was 1.6% (Ronkainen J, Aro, Storskrubb, Johansson, Lind, Bolling-
Sternevald, Vieth, Stolte, Talley, & Agreus 2005).  Similar results were found in an 
endoscopic study from Italy (Zagari, Fuccio, Wallander, Johansson, Fiocca, 
Casanova, Farahmand, Winchester, Roda, & Bazzoli 2008).  One of the challenges 
associated with unravelling the true incidence of Barrett’s oesophagus is that the 
condition is often asymptomatic with 46.2% of patients reporting no reflux 
symptoms (Reid, Li, Galipeau, & Vaughan 2010).  Furthermore the vast majority of 
oesophageal adenocarcinomas arise in patients with no prior diagnosis of Barrett’s 
oesophagus (Dulai, Guha, Khan et al. 2002).   
Dysplasia is one of the most important features of Barrett’s oesophagus and it 
currently remains the clinical gold standard marker of disease progression.  The 
presence of high grade dysplasia is associated with the highest risk of malignant 
progression with cancer rates of 16-59%, although it is well recognised that not all 
patients progress to dysplasia (Reid, Blount, Feng, & Levine 2000;Schnell, Sontag, 
Chejfec, Aranha, Metz, O'Connell, Seidel, & Sonnerberg 2001;Spechler SJ 2011).  
With an improvement in the endoscopic therapies available for patients with 
dysplasia, it is necessary to know the incidence rates of dysplasia and 
adenocarcinoma to allow earlier and appropriate treatment for patients.  Ultimately 
the hope is this would have an impact on the incidence and outcome of oesophageal 
adenocarcinoma. 
54 
 
Recent studies from Europe and the US have suggested that malignant progression in 
Barrett’s oesophagus is sufficiently uncommon to call into question cost-
effectiveness of endoscopic surveillance and even dysplasia treatment (de Jonge, van 
Blankenstein, Looman et al. 2010;Hur, Choi, Rubenstein et al. 2012;Sikkema, de 
Jonge, & Steyerberg 2010).  However there are questions about ascertainment of true 
Barrett’s oesophagus and segment length in these studies.  There are still not enough 
good studies of rates of incidence and progression to dysplasia and adenocarcinoma 
in well characterised Barrett’s oesophagus.   
3.2 Study Aims 
The West of Scotland has one of the highest incidences of Barrett’s oesophagus in 
the United Kingdom but little is known about the rates of progression to dysplasia 
and adenocarcinoma within this population (Caygill, Watson, Reed et al. 2003).  
Therefore, the aims of this cohort study were: 
1) to determine the incidence and progression of dysplasia in a well-defined cohort of 
patients undergoing surveillance of Barrett’s oesophagus in the West of Scotland. 
2) to assess the effect of segment length on malignant progression in Barrett’s 
oesophagus. 
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3.3 Methods 
Database 
Patients with endoscopically visible and histologically proven Barrett’s oesophagus 
identified between January 1994 and December 2009, and undergoing endoscopic 
and biopsy surveillance at Glasgow Royal Infirmary (GRI) or Stobhill Hospital were 
reviewed and added to a computer database (Microsoft Access). All patients were 
resident within the catchment area of GRI, an inner city teaching hospital covered a 
deprived population of 560 000 in NE Glasgow.  Any tertiary referrals of patients 
non-resident within the catchment area of GRI were excluded from the database.   
Definition of Barrett’s oesophagus 
Patients were diagnosed with Barrett’s oesophagus in the presence of an 
endoscopically visible columnar lined oesophagus above the gastroesophageal 
junction, located by the most proximal margin of the gastric folds AND oesophageal 
columnar (glandular) epithelium on histology.  In keeping with British Society of 
Gastroenterology guidelines, the presence of goblet cells (intestinal metaplasia) was 
not a prerequisite, although goblet cells were present in the majority of patients 
diagnosed with Barrett’s oesophagus.   
Patients 
All patients with Barrett’s oesophagus were added to the database (n=1057).  Patients 
in whom further endoscopy was considered inappropriate due to age and 
comorbidities were excluded as were those who decline further surveillance or were 
lost to follow up.  Following the initial exclusions, 880 patients were left, of whom a 
further 143 with oesophageal adenocarcinoma or high grade dysplasia at presentation 
or within one year of their index endoscopy were excluded.  Fifteen patients initially 
classified “indefinite for dysplasia” were also excluded as not assignable to either 
group (low grade dysplasia or no dysplasia).  Seven hundred and twenty two patients 
were included in the final analysis (Figure 3.1).   
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Figure 3.1 Flow diagram of patient selection 
 
 
1057 patients 
880 patients 
Exclusion of 
HGD/OAC at 
presentation or in 1st 
year  n=143 
Exclusion of indefinite 
for dysplasia n=15 
722 patients 
No dysplasia n=664 LGD n=58 
177 cases excluded 
Further surveillance 
inappropriate n=66
  
Declined further 
surveillance n=63 
Transfer of care n=17 
Lost to follow up n=15 
No histological 
evidence of BE n=16 
57 
 
Patients with short (≤ 3cm) and long (> 3cm) Barrett’s segment were included.  
Patients underwent surveillance endoscopy with or without intended implementation 
of the Seattle protocol (quadrantic biopsies every 2cm throughout the length of the 
Barrett’s segment) (Reid, Blount, Feng, & Levine 2000).  In the absence of 
dysplasia, patients were offered surveillance endoscopy every two years, and the 
surveillance interval decreased to 3-6 months in those with low grade dysplasia.  All 
patients with high grade dysplasia or invasive adenocarcinoma were discussed at a 
multidisciplinary oesophagogastric oncology meeting.  Patients with high grade 
dysplasia were offered surgery (if medically fit) or endoscopic treatment, including 
argon coagulation or photodynamic therapy, moving towards endoscopic mucosal 
resection (EMR) and radiofrequency ablation (RFA) of the residual segment from 
2008.  All patients continued acid suppression with prescribed proton pump 
inhibitors throughout surveillance. 
Histology 
Oesophageal biopsy specimens were interpreted and reported by staff at the 
pathology laboratory (GRI) with supervision by three GI specialist histopathologists, 
one with a research interest in Barrett’s oesophagus (Dr James J Going).  Two of the 
pathologists were in post over the entire recruitment period.  Dysplasia was classified 
according to the Vienna classification and any difficult cases discussed among 
consultant pathologists for consensus opinion (Odze 2006).  Persistent dysplasia was 
defined as dysplasia present at two or more endoscopies at least one year apart while 
non-persistent dysplasia was identified at one surveillance endoscopy and not 
subsequently after a minimum follow up of one year.  In this series, Barrett’s high 
grade dysplasia and oesophageal adenocarcinoma were only diagnosed in patients 
with a previous endoscopic and histological diagnosis of Barrett’s oesophagus.   
Histology 
Deaths were identified between 1994 and 2010 inclusive, and the cause of death 
obtained from the regional Registrar’s Office using patient name and date of birth.  
Only the primary cause of death was considered.  Person years follow up were 
calculated for each patient from the date of entry into the database (1994-2009) until 
the date of death or 31
st
 December 2012, whichever was earlier. 
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Statistical analysis 
Data are presented as median (range).  Variables were partitioned using standard 
thresholds: age <65, 65-74, >75; male, female; segment length ≤3cm, >3cm.  Groups 
were compared using Chi square or Fisher’s exact test, with a p value of <0.05 
deemed significant.  Student t-test analysed continuous variables.  Kaplan-Meier 
survival analysis was used to assess the effect of risk factors such as segment length 
on the development of dysplasia and cancer.  Multivariate regression analysis was 
used to examine the effects of variables on progression to HGD or adenocarcinoma 
with adjustment for confounders such as age and sex.  The analysis was performed 
using SPSS software (SPSS for Windows v18.0, SPSS Inc, Chicago, IL, USA). 
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3.4 Results 
Patient demographics 
A total of 880 patients with Barrett’s oesophagus were identified by endoscopy with 
biopsy confirmation between January 1994 and December 2009 (summarised in 
Table 3.1).  There were 562 males (median age 62 years ± 13, range 17-96 years) and 
318 females (median age 69 years ± 12, range 31-97 years).  The median length of 
Barrett’s segment was 6.6 ± 3.7 (range 1-22cm).   
Patients with oesophageal adenocarcinoma (n=95) or high grade dysplasia (n=48) 
either at index endoscopy or within one year of the initial diagnosis of Barrett’s 
oesophagus were excluded from further analysis (Figure 3.1).  Fifteen patients 
labelled as “indefinite for dysplasia” were also excluded. The remaining cohort of 
722 patients, with no dysplasia or low grade dysplasia at presentation, was analysed.  
This group underwent a total of 6249 years follow up (median 8.6 years). 
Biopsy protocol 
Of the 664 patients with no dysplasia on index endoscopy, adherence to the Seattle 
biopsy protocol (352 patients, 53%) yielded substantially greater individual biopsy 
numbers (median number of sites biopsied 54 v 17, p<0.001).  Implementation of the 
biopsy protocol was higher among the four surgeons than the eight physicians (78% 
vs 22%, p<0.05) and was associated with higher numbers of biopsies with dysplasia 
(surgeons 103/141 patients with dysplasia (73%) vs physicians 38/141 patients with 
dysplasia (27%), p<0.01) as previously described (Abela, Going, Mackenzie, 
McKernan, O'Mahoney, & Stuart 2008).  Six hundred and four patients (91%) had 
histological evidence of goblet cells (intestinal metaplasia).  
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Table 3.1 Summary of patient characteristics (n=880) 
Characteristic Category n  
Sex Male 
Female 
562 
318 
64% 
36% 
Age (years) Male 
Female 
62 
69 
Range 17-96 
Range 31-97 
Length of segment (cm) Metaplasia 
LGD 
HGD 
Cancer 
6.5 
6.8 
7.9 
8.3 
Range 1-17 
Range 1-22 
Range 3-22 
Range 1-22 
Carstairs deprivation index Deprived (5-7) 
Moderate (3&4) 
Affluent (1&2) 
576 
172 
132 
66% 
19% 
15% 
Pathology at index endoscopy Metaplasia 
Indefinite for dysplasia 
Low grade dysplasia 
High grade dysplasia 
Adenocarcinoma 
664 
15 
58 
48 
95 
75.4% 
1.7% 
6.6% 
5.5% 
10.8% 
Carstairs deprivation index is an area-based measure (derived from 2001 census data) and uses 
postcode of residence at diagnosis to assign patients to one of seven categories which are 
amalgamated into affluent (categories 1&2), intermediate (categories 3&4) and deprived (categories 
5-7).  The role of deprivation and Barrett’s oesophagus will be discussed in Chapter 4. 
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Patient mortality 
During the study period 223 (n=223/722, 31%) patients died: 126 (57%) men and 97 
(43%) women.  The mean age at death was 74 years with men dying younger than 
women (70 years vs 77 years, t=3.9 95% CI 3.5-9.2, p<0.001 Student t-test).  Twenty 
four deaths (11%) were directly related to Barrett’s associated oesophageal 
adenocarcinoma and 93 deaths (42%) from myocardial infarction (MI) or other 
cardiovascular event (Table 3.2).  Deaths from oesophageal adenocarcinoma were 
more common in those with LGD rather than glandular metaplasia at presentation 
(16 patients with LGD (67%) vs 8 patients with metaplasia alone (33%), p=0.01).  
 
Table 3.2 Cause of death in patients with Barrett’s oesophagus (n=223) 
Death  Number % 
Cancer related Oesophageal cancer 24 11 
 Urological (bladder, kidney, prostate) 
GI (stomach, colon, HCC, pancreas) 
Gynaecological (uterus) 
Lung 
ENT (including lymphoma)
 
5 
19 
3 
11 
5 
2 
9 
1 
5 
2 
Non cancer Cardiac event (inc MI) 
Respiratory (pneumonia, PE) 
93 
41 
42 
18 
 Sepsis 
 
12 5 
 Alcohol related  10 5 
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Risk of progression to high grade dysplasia and cancer 
Within the 722-patient cohort, the median age of patients developing HGD or OA 
was 69 years compared to non-progressors (64 years, p<0.05).  At diagnosis of 
HGD/OA, male patients were younger than females (65 years vs 75 years, p<0.01). 
The annual risks of HGD, OA and combined HGD/OA were 0.17%, 0.36% and 
0.53% respectively (Table 3.3).  These risks were substantially higher in patients 
with LGD at baseline endoscopy (2.0%, 2.7% and 4.7%, p<0.001).  Figure 3.2 
illustrates the proportion of patients developing either HGD or OA according to the 
presence or absence of LGD at baseline endoscopy.  Within 2, 5 and 10 years from 
initial diagnosis of Barrett’s oesophagus, either HGD or OA was diagnosed in 1%, 
2% and 6% patients without baseline LGD dysplasia, compared with 5%, 10% and 
40% patients with LGD at presentation (p<0.001).  On regression analysis, male sex 
(p<0.05), the presence of LGD at baseline endoscopy (p<0.001) and being older 
(p<0.01) were associated with an increased risk of malignant progression. 
Figure 3.2 The progression of patients with Barrett’s oesophagus to 
HGD/OA according to the presence or absence of baseline LGD 
 
Survival plot illustrating the proportion of patients progressing to HGD or adenocarcinoma over time.  
Patients with low grade dysplasia (LGD) at baseline endoscopy carry higher rates of disease 
progression compared with patients with columnar metaplasia alone at baseline (p<0.001) 
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Table 3.3 Annual incidence rates of HGD, OA, and combined HGD/OA in patients with Barrett’s oesophagus (n=722) 
 Follow up 
(years) 
HGD 
cases (n) 
OA cases 
(n) 
Combined 
HGD/OA (n) 
Annual risk HGD 
(%) 
Annual risk OA 
(%) 
Combined HGD/OA 
(%) 
All cases 6249 19 33 52 0.30 (0.18-0.46) 0.53 (0.42-0.61) 0.83 (0.73-0.93) 
Male 
Female 
3813 
2436 
15 
4 
20 
13 
35 
17 
0.39 (0.22-0.58) 
0.16 (0.09-0.24) 
0.52 (0.48-0.56) 
0.82 (0.77-0.90) 
0.91 (0.79-1.02) 
0.98 (0.82-1.22) 
No dysplasia at baseline 5802 10 21 31 0.17 (0.08-0.28) 0.36 (0.22-0.44) 0.53 (0.41-0.66) 
Male 
Female 
3495 
2307 
7 
3 
13 
8 
20 
11 
0.20 (0.13-0.30) 
0.13 (0.07-0.20) 
0.37 (0.23-0.46) 
0.35 (0.25-0.45) 
0.57 (0.50-0.62) 
0.48 (0.41-0.55) 
LGD at baseline 447 9 12 21 2.01 (1.08-3.15) 2.68 (2.00-3.10) 4.69 (3.55-5.55) 
Male 
Female 
318 
129 
8 
1 
7 
5 
15 
6 
2.52 (1.80-3.20) 
0.78 (0.14-1.20) 
2.20 (1.72-2.72) 
3.88 (2.10-4.86) 
4.72 (3.70-5.70) 
4.66 (2.80-6.68) 
 
HGD (high grade dysplasia), OA (oesophageal adenocarcinoma), n (number of patients) 
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Outcomes for patients with columnar metaplasia but no baseline dysplasia  
Of the 664 patients with columnar metaplasia only on baseline endoscopy, 85 (13%) 
subsequently progressed to LGD, HGD or invasive adenocarcinoma with a male 
preponderance (52 men, 33 women).  
Of these, 54 of 664 patients (8%; 32 men, 22 women) developed LGD during follow 
up, with an incidence rate of 0.93% per year.  Median time to development of LGD 
was 36 months (range 12-96).  Ten patients (1.5%, 7 men, 3 women) developed 
HGD during the study period, with an incidence rate of 0.17% per year.  Twenty one 
patients (3.2%, 13 men, 8 women) developed oesophageal adenocarcinoma, an 
overall incidence rate of 0.36% per year. 
 
Outcomes for patients with prevalent low grade dysplasia  
Fifty eight patients presented with LGD at baseline endoscopy (40 men, 18 women; 
median age 67 years, range 49-96).  Of these, 21 (36%) progressed to HGD or OA 
(HGD n=9, OA n=12) with annual incidence rates of HGD and OA of 2.0% and 
2.7% respectively.  Patients with low grade dysplasia on index endoscopy were older 
than those without (67 years vs 64 years, p<0.05) and more likely to be male 
(p<0.02).   
 
Segment length and progression to high grade dysplasia or 
adenocarcinoma 
The length of the Barrett’s segment was collected for all 85 patients who progressed 
to dysplasia and adenocarcinoma.  Patients with long segment Barrett’s oesophagus 
(>3cm) had higher rates of progression to dysplasia and adenocarcinoma than 
patients with short segments (long segment, n=73 (87%); short segment, n=12 
(13%), 95% CI short 174-190 vs long 180-193, p=0.04, Figure 3.3). 
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Figure 3.3 Time to high grade dysplasia and/or adenocarcinoma according 
to segment length 
 
Survival plot displaying the progression to dysplasia and/or adenocarcinoma according to segment 
length (short vs long).  Patients with long segment disease tended to progress to dysplasia or 
adenocarcinoma more quickly than those with short segment disease (p=0.04).   
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3.5 Discussion 
The cohort study of patients with Barrett’s oesophagus in the West of Scotland has 
shown patients with LGD at baseline endoscopy are at increased risk of progression 
to dysplasia and oesophageal adenocarcinoma.  Older age (>75 years) and male sex 
were independent risk factors for disease progression. 
The risk of adenocarcinoma in Barrett’s oesophagus has been long debated.  Early 
studies suggested high incidence rates with annual rates of malignant progression of 
1.9% per year in the 1980s (Hammeeteman, Tytgat, & Houthoff 1989).  Over time, 
larger studies suggested lower risks with systematic reviews estimating annual risk of 
progression to adenocarcinoma to vary between 0.5% and 0.63% per year 
(Hammeeteman, Tytgat, & Houthoff 1989;Shaheen, Crosby, & Bozymski 
2000;Sikkema, de Jonge, & Steyerberg 2010).  Several recent studies have suggested 
that Barrett’s oesophagus is still less hazardous with annual risk of progression 
around 0.15-0.2% (de Jonge, van Blankenstein, Looman, Casparie, Meijer, & 
Kuipers 2010).  One concern when interpreting studies is the potential lack of a clear 
definition of Barrett’s oesophagus which may lead to overdiagnosis and subsequent 
dilution of the dysplasia/ adenocarcinoma progression rate.  Therefore for inclusion 
in our study, all patients required a prospective endoscopic and histological diagnosis 
of Barrett’s oesophagus rather than relying solely on retrospective endoscopic or 
pathological records, ensuring a well-defined Barrett’s cohort. 
There is significant variation in the reported rates of dysplasia and adenocarcinoma 
in patients with Barrett’s oesophagus but the UK appears to have a higher burden of 
oesophageal adenocarcinoma compared with the US (12-16 per 100 000 in UK 
compared with 3-5 per 100 000 in US) (www.cancerresearchuk.org 2006).  
Furthermore, there has been a rise in the incidence of Barrett’s associated 
adenocarcinoma in the UK over the last three decades, increasing by more than 5% 
per year, with Scotland now having the highest rates (Jankowski, Provenzale, & 
Moayyedi 2002;McKinney, Sharp, Macfarlane et al. 1995).  Presumably this trend is 
related to the increased prevalence of Barrett’s oesophagus within the UK (Prach, 
MacDonald, Hopwood et al. 1997).   
The rates of progression to HGD and adenocarcinoma in our study are comparable 
with recent systematic reviews.  A recent US multicentre cohort of patients with 
Barrett’s oesophagus reported similar results to our study although the rate of 
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progression to adenocarcinoma was lower (LGD 3.6% per year; HGD 0.48% per 
year and 0.27% per year adenocarcinoma) (Wani, Falk, Hall et al. 2011).  A 
population study (the Danish Pathology Registry) from Denmark reported lower 
annual incidence rates of high grade dysplasia and adenocarcinoma than previously 
described (HGD 0.19% and adenocarcinoma 0.12%) (Hvid-Jensen, Pedersen, 
Drewes et al. 2011).  A large-scale Dutch population study of pathology records from 
16325 patients reported an annual cancer risk of 0.4%, and incidence rates of 4.3 per 
1000 person years for OA and 5.8 per 1000 person years for combined HGD and 
adenocarcinoma (de Jonge, van Blankenstein, Looman, Casparie, Meijer, & Kuipers 
2010).  
Our study describes the presence of LGD at baseline endoscopy as an independent 
risk factor for disease progression, with 40% of patients developing HGD or 
adenocarcinoma within 10 years.  This has been confirmed by a recent risk 
assessment study from a Northern Ireland population where LGD was the strongest 
predictor of progression (Bird-Leiberman, Dunn, Coleman et al. 2012).  
At 22 per 100,000 per annum Scotland has one of the highest rates of oesophageal 
adenocarcinoma in the world, compared with Denmark and The Netherlands (17 per 
100,000 and 12 per 100,000) (Anon 2008).  The reasons for our higher mortality 
rates are difficult to define at present.  Although deprivation and obesity may play a 
part, other environmental factors (such as diet, vitamin D and nitrate levels) and 
epi/genetic factors may be involved.  Several genes and biomarkers have been 
studied in the development and progression of Barrett’s oesophagus but further 
research using gene sequencing is required (Moyes & Going 2011).  Of course, our 
higher rates could be linked to “the Glasgow effect”.  There has been considerable 
amount of attention recently in relation to this epidemiological phenomenon – the 
high levels of mortality in Scotland (and Glasgow)  compared to other UK cites 
which cannot be solely explained by differences in socioeconomic status (Hanlon, 
Lawder, Buchanan et al. 2005).   
  
68 
 
Study limitations 
There are limitations within this study.  The analysis was retrospective within a local 
cohort.  However our unit is currently establishing a prospective database of all 
patients with Barrett’s oesophagus throughout the 1.2 million population within the 
West of Scotland to determine which risk factors (clinical and molecular) may play a 
role in malignant progression.  This will provide an excellent opportunity to assess 
the effects of deprivation and Barrett’s epithelium and to understand the molecular 
and pathophysiological abnormalities associated with this unstable oesophageal 
mucosa.  In the future combined staging of Barrett’s oesophagus with clinical and 
pathological markers may aid in appropriate risk stratification of patients, targeting 
surveillance endoscopy and therapeutic interventions in those at high risk.   
3.6 Conclusion 
Patients with Barrett’s population in the West of Scotland have high rates of 
malignant progression confirming the need for careful endoscopic surveillance.  Low 
grade dysplasia is a significant risk factor for progression to HGD or 
adenocarcinoma, with 40% of patients with LGD at presentation progressing within 
10 years.  This is a high risk group of patients and an interesting cohort on which to 
focus further research.  Additional work is required to assess the reasons why 
patients have a tendency towards dysplasia and understand the molecular and 
physiological abnormalities associated with this unstable oesophageal mucosa.  In 
the future, we would anticipate other factors (clinical and molecular) will aid in 
appropriate risk stratification of patients, targeting surveillance endoscopy and 
therapeutic interventions in those at high risk.  For the present time, we have a “high 
risk” Barrett’s population in the West of Scotland providing an ideal niche for 
molecular and chemopreventative studies. 
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Chapter 4 
Deprivation and Barrett’s oesophagus: an observational study  
he West of Scotland, and in particular the city of Glasgow, is renowned for 
its high mortality rates from ischaemic heart disease and cancer.  The 
incidence of oesophageal adenocarcinoma has risen in Scotland over the 
last thirty years, increases not wholly explained by changes in diagnostic or reporting 
practices (Brewster, Fraser, McKinney et al. 2000).  An observational study of 
patients with Barrett’s oesophagus within the catchment area of Glasgow Royal 
Infirmary was performed to assess any relationship between Barrett’s oesophagus, 
dysplasia and adenocarcinoma and deprivation.  The results show a clear association 
between deprivation and higher rates of disease progression and cancer related death, 
with patients in deprived areas at greater risk than those in affluent areas.  Although 
the reasons for this remains unclear, further research assessing environmental 
(smoking, alcohol, diet) and genetic factors within this “at risk” population is 
required. 
T 
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4.1 Introduction 
For many years, Glasgow has been renowned for its high mortality rates, specifically 
from ischaemic heart disease and cancer, compared with the rest of the world.  In 
2010, the media described this as the “Glasgow Effect”.  A recent study by Professor 
Walsh and his colleagues assessing mortality in three UK cities (Glasgow, Liverpool 
and Manchester) found that although the deprivation profiles were almost identical, 
premature deaths in Glasgow were more than 30% higher and all deaths 
approximately 15% higher (Walsh, Bendel, Jones et al. 2010).  The relationship 
between deprivation and poor outcomes has been recognised for many years.  In 
1985, Hume acknowledged that Greater Glasgow Health Board mortality rates varied 
between different communities, with greater mortality in areas of socioeconomic 
deprivation (Hume and Womersley 1985).   
The association between poor health, cancer outcomes and deprivation in the West of 
Scotland has been previously described.  Coleman and colleagues reported a 5% 
difference in survival between patients from the most deprived areas compared with 
the most affluent areas within the UK (Coleman, Babb, Damiecki et al. 1999).  More 
recently, Hole and McArdle confirmed that cancer specific survival rates following 
colorectal cancer were lower in deprived patients residing in the West of Scotland 
(Hole and McArdle 2002).  As the West of Scotland has a spectrum of 
socioeconomic groups, residing in close proximity to one another, and a high 
incidence of Barrett’s oesophagus and adenocarcinoma, it appears to be an ideal 
setting to examine the effects of deprivation on these conditions. 
There is no single universally agreed definition of deprivation.  Material deprivation 
reflects the accessibility of material goods and resources to people and is a useful 
marker of deprivation in clinical studies.  Material deprivation is measured by the 
Carstairs and Morris index, originally developed in the 1980s using the 1981 census 
data (Carstairs and Morris 1991).  It is a scale composed of four variables which 
when combined creates a composite score.   
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The variables are: 
1) Overcrowding – persons in private households living at a density of more 
than one person per room as a proportion of all persons in private households 
2) Male unemployment – proportion of economically active males who are 
seeking work 
3) Social class 4 or 5 – proportion of all persons in private households with head 
of household in social class 4 or 5 
4) No car – proportion of all persons in private households with no car 
Deprivation is often associated with smoking, increased alcohol consumption, poor 
nutrition with diets lacking in fruit and vegetables and perhaps family history. 
The Carstairs deprivation score is divided into seven categories ranging from very 
high deprivation (category 7) to very low (category 1) deprivation.  Figure 4.1 
summarises the proportions of people in Scotland living in postcode sectors assigned 
to deprivation categories according to health board.  It clearly shows Greater 
Glasgow has the largest number of people living in deprivation categories 6 and 7.  
Furthermore of all those living in deprivation category 7 areas, 80% reside in 
Glasgow.  The Carstairs deprivation index has been utilised in cancer patients and is 
particularly appropriate for use in our population (Hole & McArdle 2002).  
4.2 Study Aims  
The aim of this study was to assess any relationship between the presence of 
Barrett’s oesophagus, in particular dysplasia and adenocarcinoma, and deprivation 
using the postcode sector of residence.  A secondary aim was to examine the number 
of deaths in our cohort according to postcode sector. 
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Figure 4.1 Deprivation at health board level 
 
Distribution of health board populations by Carstairs deprivation category (1991 census).  Reproduced from 
www.show.scot.nhs.uk/publications/isd/deprivation_and_health/images 
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4.3 Methods 
Database 
The previously described database of all patients diagnosed with Barrett’s 
oesophagus from January 1994 to December 2009 (Chapter 3) was used for this 
study.  All patients with histologically proven Barrett’s oesophagus resided within 
the catchment area of Glasgow Royal Infirmary, an inner-city teaching hospital in the 
north east of the city, covering a population of 560,000.  Tertiary referrals of patients 
non-resident within the catchment area were excluded. 
Postcode 
The postcode of residence at the time of diagnosis was obtained and the Carstairs 
deprivation index used to categorise each postcode into one of seven groups.  For 
illustrative purposes the seven categories were amalgamated into three groups: 
affluent (categories 1 and 2), intermediate (categories 3 and 4) and deprived 
(categories 5-7).  The postal town associated with each postcode was also noted.  
Table 4.1 lists each postal town and postcode within the Glasgow Royal Infirmary 
catchment area. 
Outcome measures 
The two main outcome measures were 1) cause of death and 2) number of cases of 
high grade dysplasia and/or oesophageal adenocarcinoma. 
1) Cause of death  
Deaths were identified between 1994 and 2011 inclusive, and the cause of death 
obtained from the regional Registrar’s Office for Deaths and Births using patient 
name and date of birth.  For the purposes of the study, only the primary cause of 
death was considered.  Deaths were categorised into four groups:  
(1) Barrett’s related oesophageal adenocarcinoma,  
(2) myocardial infarction (or ischaemic related event), 
(3) other cancer death (colon, lung, pancreatic, prostate) 
(4) other non-cancer related death (pneumonia, alcohol related death, renal 
failure, sepsis or pulmonary embolism) 
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2) Diagnosis of dysplasia/adenocarcinoma 
All cases diagnosed with high grade dysplasia and Barrett’s related oesophageal 
adenocarcinoma were included (as previously described in Chapter 3).  
Statistical analysis 
Data are presented as mean values ± standard deviation.  Comparison between 
groups was performed using Chi square or Fisher’s exact test, with a p value of 
<0.05 deemed significant.  The analysis was performed using SPSS for Windows 
v18.0, SPSS Inc, Chicago, IL, USA. 
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Table 4.1 List of postcodes and postal towns of Barrett’s patients 
Postcode 
G 
Postal town Postcode Postal town 
1 City centre PA1 Paisley (central) 
G12 Dowanhill PA13 Kilmalcolm 
G15 Drumchapel PA14 Port Glasgow 
G2 City centre (south east) PA15 Greenock 
G20  Maryhill PA16 Greenock 
G21 Springburn PA19 Gourock 
G3 Finnieston PA2 Paisley (south) 
G31 Dennistoun PA20 Isle of Bute 
G32 Shettleston PA23 Dunoon 
G33 Stepps PA28 Campbeltown 
G34 Garthamlock PA29 Tarbert 
G4 City centre (north) PA3 Paisley (north) 
G40 Rutherglen PA34 Oban 
G41 Bellahouston PA38 Appin 
G42 Queen’s Park PA4 Renfrew 
G43 Thornliebank PA42 Isle of Islay 
G44 Cathcart PA5 Johnstone 
G45 Carmunnock PA78 Isle of Coll 
G46 Giffnock PA8 Erskine 
G5 City centre (south) ML1 Newarthil 
G51 Shieldhall ML10 Strathaven 
G52 Renfrew ML12 Douglas 
G53 Nitshill ML4 Bellshill 
G60 Old Kilpatrick ML5 Coatbridge 
G61 Bearsden ML6 Caldercruix 
G62 Milngavie ML7 Shotts 
G63 Balfron ML8 Carluke 
G64 Torrance ML9 
Ston 
Stonehouse 
G65 Kilsyth KA1 Hurlford 
G66 Lennoxtown KA10 Troon 
G67 Cumbernauld KA12 Dreghorn 
G68 Croy KA13 Kilwinning 
G69 Muirhead KA15 Beith 
G71 Uddingston KA18 Cumnock 
G72 Cambuslang KA2 Dundonald 
G73 Rutherglen (south) KA22 Ardrossan 
G74 Stewartfield KA25 Kilbirnie 
G76 Eaglesham KA26 Girvan 
G77 Newton Mearns KA30 Largs 
G78 Neilston KA4 Galston 
G81 Clydebank KA5 Mauchline 
G83 Inverbeg KA6 Dalmellington 
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4.4 Results 
Patient demographics 
A total of 880 patients underwent endoscopic surveillance for Barrett’s oesophagus 
between January 1994 and December 2009 (summarised in Table 3.1).  Of these, 91 
patients (10%) resided out with the local catchment area of Glasgow Royal Infirmary 
being referred from the Isles, Lanarkshire, Stirling or Dumfries for further 
endoscopic assessment and/or treatment.  50 postcode sectors constitute the “G” 
(Glasgow) postcode area, and 39 (78%) of these sectors were represented in this 
cohort of Barrett’s patients. 
In the study population, the proportion of Barrett’s oesophagus appeared to be higher 
in deprived areas compared to affluent areas with 65% of patients living in deprived 
areas (Figure 4.2).  The majority of patients with Barrett’s oesophagus lived in the 
postal towns of Springburn, Shettleston, Stepps, Dennistoun and the Gallowgate.  
Although there was a male preponderance across all categories, the majority of 
patients within the cohort were deprived males. 
Figure 4.2 Cases of Barrett’s oesophagus by deprivation category and sex 
Bar chart displaying number of cases of Barrett’s oesophagus (n=880) according to sex and Carstairs 
deprivation category codes.  There was a preponderance of male patients and a higher number of 
patients with Barrett’s oesophagus residing in deprived areas (categories 5-7).  
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Deprivation and segment length 
The mean segment length in the Barrett’s cohort was 6.6cm (range 2-22cm).  
Although the ratio of short: long segment disease was comparable across all 
deprivation categories, there was a greater proportion of patients with long segment 
disease living in deprived areas, than those in affluent areas (Figure 4.3).  Patients 
with Barrett’s segments >15cm tended to live in deprived areas (categories 5-7) 
whereas there were no patients with >15cm segment residing in an affluent area 
(categories 1&2, p=0.07). 
Figure 4.3 Barrett’s oesophagus and deprivation and segment length  
 
Bar chart displaying percentage of all patients with Barrett’s oesophagus (n=880) according to 
Carstairs deprivation category and length of Barrett’s segment.   
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Deprivation and cause of death 
There were 308 deaths with 74% patients living in deprived inner city areas, with the 
highest number of deaths occurring in Stepps, Shettleston and Dennistoun (p<0.001).  
Figure 4.4 illustrates the spectrum of postcode sectors found within the Barrett’s 
cohort, and highlights the areas with highest number of deaths (purple and black 
stars).   
Of the 308 deaths, there were 81 deaths from oesophageal adenocarcinoma (27%), 
61 deaths from ischaemic heart disease (22%), 50 deaths from other cancers (16%) 
and 109 deaths from other causes (35%).  Figure 4.5 is a histogram displaying the 
cause of death grouped by deprivation.  The majority of deaths (all cause) were 
found in patients who resided in deprived areas.  Deprivation category 7 had twice 
the number of deaths compared with all other areas: and the greatest proportion of 
OA related deaths.  Moreover 20% of the deaths within this area were from other 
non-cancer causes such as alcohol (liver disease), suicide or pneumonia and 15% 
from ischaemic heart disease.  Deaths from oesophageal adenocarcinoma occurred in 
32% of those living within category 7 compared with only 7% in those in affluent 
categories 1 and 2 (p<0.001).   
The distribution of deaths from oesophageal adenocarcinoma and ischaemic heart 
disease was similar to the distribution of all-cause deaths (Figure 4.6 and 4.7).  There 
was a clear association between deprivation and higher oesophageal cancer-specific 
and ischaemic-related deaths (OA p<0.001 and IHD p<0.05) (Table 4.2).   
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Figure 4.5 Cause of death in Barrett’s patients by deprivation category 
 
 
Bar chart displaying cause of death in patients with Barrett’s oesophagus (n=308) according to 
Carstairs deprivation category.  All cause and oesophageal adenocarcinoma mortality rates were 
higher in those patients residing in deprived areas (deprivation category 5-7, p<0.001). 
 
Legends to Figures overleaf 
Figure 4.4 Illustrative map of Greater Glasgow showing distribution of deaths (all-
cause) within the Barrett’s cohort (n=308).  Black and purple stars related to highest 
number of deaths. 
Figure 4.6 Illustrative map of Greater Glasgow displaying number of oesophageal 
adenocarcinoma related deaths according to postal towns (n=81) 
Figure 4.7 Illustrative map of Greater Glasgow displaying number of deaths from 
ischaemic heart disease according to postal town of residence (n=61).  
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Figure 4.4 Number of all-cause deaths within population with Barrett’s oesophagus according to postal town 
 
81 
 
Figure 4.6 Number of deaths from oesophageal adenocarcinoma within Barrett’s cohort according to postal town  
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Figure 4.7 Number of deaths from ischaemic heart disease within population with Barrett’s oesophagus according to postal town  
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High grade dysplasia and adenocarcinoma by postal sector  
Malignant change, defined as the presence or development of HGD, OA or combined 
HGD/OA, was present in 197 cases (22%).  Deprivation was associated with higher 
rates of progression to HGD and OA (p<0.001).  Patients living in deprived areas 
were more likely to present with initial dysplasia (48% deprived vs 7% affluent 
areas, p<0.05) and develop dysplasia during follow up (57% deprived vs 9% affluent 
areas, p<0.01).   
Figure 4.8 Progression to HGD/OA by deprivation category and presence 
of low grade dysplasia at initial presentation (n=197) 
 
Bar chart displaying the number of cases of HGD and oesophageal adenocarcinoma (n=197) 
according to Carstairs deprivation category and the presence (green) or absence (blue) of low grade 
dysplasia at presentation. 
 
Of 197 patients progressing to HGD and OA, the majority of patients lived in 
Shettleston, Dennistoun, Muirheard and Stepps – the most “at risk” and deprived 
areas within this Glasgow cohort. 
  
84 
 
4.5 Discussion 
This observational study has shown a clear relationship between socioeconomic 
deprivation and an increase in the number of cases of Barrett’s oesophagus, with 
higher numbers of deprived patients progressing to HGD and oesophageal cancer and 
cancer related death.   
 
The National Records of Scotland reported higher death rates in Glasgow, compared 
with the rest of Scotland with the main cause of death due to circulatory disease, 
followed by cancer (ISD Scotland 2012).  Higher mortality rates are associated with 
lower socioeconomic status, poor diet and deprivation.  This study has shown that the 
“at risk” areas within the catchment of the Royal Infirmary are those with the highest 
deprivation index, namely Shettleston, Dennistoun and Stepps.  This is true for all-
cause mortality, oesophageal cancer death and ischaemic heart mortality.  These 
areas also carried the highest rates of malignant progression.  This is one of the first 
studies to show a clear association between deprivation and Barrett’s 
adenocarcinoma. 
 
It is generally believed that Barrett’s oesophagus and its associated adenocarcinoma 
are more common in white Caucasian males of higher socioeconomic status although 
there are limited studies to support this.  In 2005, Ford and colleagues studied a large 
population (20,412 patients) with Barrett’s oesophagus in England.  They suggested 
white race and higher socioeconomic status were risk factors for the development of 
oesophagitis and Barrett’s oesophagus (Ford, Forman, Reynolds et al. 2005).  Other 
studies have assessed the relationship between deprivation and oesophageal 
adenocarcinoma, but the results are variable.  A study in Scotland, using national 
data suggested that in contrast to the association between squamous oesophageal 
cancer and deprivation, there was no clear association between deprivation and 
oesophageal adenocarcinoma (Brewster, Fraser, McKinney, & Black 2000).  
However, a case control study from the US, with level of education as a marker for 
socioeconomic status, showed those with higher education were at lower risk of 
developing Barrett’s oesophagus (Kubo, Levin, Block et al. 2009).  This was 
corroborated by a large population study in Sweden (HUNT study) which suggested 
the risk of reflux increased with decreasing socioeconomic status, based on 
occupation, education and material deprivation (Jansson, Nordenstedt, Johansson et 
al. 2007).   
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The dramatic increase in incidence of oesophageal adenocarcinoma, particularly in 
Caucasian males appears to be in response to environmental and lifestyle factors.  
Factors such as alcohol intake (volume and type of alcohol), smoking, diet and 
exercise may play a role (Kubo, Levin, Block, Rumore, Quesenberry, Buffler, & 
Corley 2009).  Our high risk areas of Shettleston, Stepps and Dennistoun have 
patients with alcohol and smoking addictions.  Although the relationship between 
smoking and squamous carcinoma of the oesophagus is clearly demonstrated, and 
has recently been linked with Barrett’s oesophagus, an association with oesophageal 
adenocarcinoma has not been well-defined (Cook, Shaheen, Anderson et al. 2012).  
Deprivation is associated with smoking, higher alcohol intake and a diet poor in fruit 
and vegetables (Hanlon, Lawder, Buchanan, Redpath, Walsh, Wood, Bain, Brewster, 
& Chalmers 2005).  These effects of deprivation may play a part on the development 
of Barrett’s oesophagus and progression to adenocarcinoma although further work is 
required. 
 
Although studies assessing relationships between deprivation and oesophageal 
adenocarcinoma are limited, there are numerous studies reporting a link between 
socioeconomic status and cancers such as breast, colon and lung cancer.  A review 
studying the effect of deprivation and cancer outcome leaves little doubt that 
socioeconomic status is an important factor, although the underlying explanations are 
not so well documented (Woods, Rachet, & Coleman 2006).  One reason may be the 
stage of presentation of disease with patients from higher social classes being more 
aware of symptoms and presenting earlier.  However a systematic review did not find 
convincing evidence for patient delay among deprived women with breast cancer 
(Ramirez, Westcombe, & Burgess 1999).  Tumour biology may play a role with 
lifestyle factors, such as alcohol and diet influencing the biology of the tumour.  
However this needs further research.  Patient factors such as comorbidity and 
psychosocial factors (marital status and level of social support) are known to 
influence survival from cancer (Macleod, Ross, Fallowfield et al. 2004).  In a study 
of patients with bowel cancer, comorbidity increased the risk of cancer death, 
although it did not vary with socioeconomic status (Munro and Bentley 2004).  The 
role of nutrition and obesity is an interesting factor and although little work has been 
performed in this area, obesity and poor nutritional state is more common among 
deprived women (Woods, Rachet, & Coleman 2006).   
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Study limitations 
The study does carry some limitations.  It is an observational study looking at 
patients within the catchment area of Glasgow Royal Infirmary, a tertiary referral 
centre for cases of Barrett’s oesophagus, particularly for specialist investigation and 
endoscopic treatments, and is the regional oesophagogastric unit.  However in an 
attempt to remove potential bias, only patients with Barrett’s oesophagus attending 
the Royal Infirmary as the “local” hospital, were included in the analysis, removing 
the bias associated with an increased number of malignant cases from other centres.  
The number of persons residing within catchment areas of the different deprivation 
categories would be key to understanding the true prevalence of Barrett’s oesophagus 
and cancer death within the West of Scotland population.  Furthermore, there are 
three other hospitals covering the southern and western areas of Glasgow and these 
patients have not been included in the analysis and these should be included in future 
work to provide “true” population data.  Additional work is currently underway to 
develop a prospective database which will include all patients with Barrett’s 
oesophagus within Greater Glasgow, allowing further studies to accurately identify 
the prevalence of the disease, and incidence of malignant progression.  Evaluation of 
other factors such as BMI, smoking status, alcohol intake and detailed nutritional 
assessment, besides socioeconomic status and deprivation, will be performed. 
 
In conclusion, this observational study of patients with Barrett’s oesophagus in 
Glasgow has shown a clear association between deprivation and Barrett’s 
oesophagus and adenocarcinoma.  The underlying factors are unclear but our “at 
risk” population is an ideal niche for further studies.  
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Chapter 5 
Image adjuncts for the assessment of Barrett’s oesophagus  
here has been a vast improvement in the quality of endoscopic systems 
over the last decade.  The current standard high resolution white light 
endoscope provides the endoscopist with high definition and a clear picture 
of the oesophageal epithelium, improving visualisation of the Barrett’s segment.  As 
a result, small cancers and areas of abnormality are more readily visualised at 
endoscopy, yet the diagnosis of dysplasia and early malignant transformation still 
remains difficult.  The role of the “expert” endoscopist in improving diagnostic yield 
of dysplasia and early neoplasia appears well defined (Curvers, Singh, Song et al. 
2008).  To maximise the endoscopic diagnosis of dysplasia and early cancer several 
image adjuncts have been developed.  This chapter summarises the literature 
regarding current endoscopic imaging techniques used in the diagnosis of Barrett’s 
oesophagus and highlights areas for improvement and further research. 
T 
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5.1 Introduction 
In the United Kingdom, Barrett’s oesophagus is diagnosed at endoscopy by the 
presence of columnar epithelium lining the oesophagus above the proximal gastric 
folds and by histological confirmation of a metaplastic columnar epithelium 
(Playford 2005).  Barrett’s mucosa is often heterogenous with areas of fundic, gastric 
and intestinal epithelia found alongside areas of dysplasia.  Dysplasia is often 
difficult to identify at endoscopy as lesions are often flat and inconspicuous, leading 
to one of the main problems in carrying out endoscopic surveillance of patients with 
Barrett’s oesophagus, as small neoplastic lesions may be missed (Montgomery, 
Goldblum, & Greenson 2001). 
Current surveillance programmes advocate rigorous biopsy sampling of areas where 
there are no visible lesions, and targeted biopsy of any abnormal mucosa using white 
light endoscopy (Playford 2005).  Most clinicians dealing with patients with Barrett’s 
oesophagus take four quadrant biopsies for every two cm along the length of the 
Barrett’s segment (Fitzgerald, Saeed, Khoo, Farthing, & Burnham 2001;Wang & 
Sampliner 2008).  This procedure can be labour intensive, tedious and uncomfortable 
for patients particularly in those with long segment disease, and may be associated 
with sampling error.  Studies have suggested poorer compliance with increasing 
segment lengths, and indeed even in the best circumstances only 4-6% of the 
Barrett’s epithelium is actually sampled (Sharma, Hawes, Bansal et al. 2013).  
  
89 
 
5.2 High resolution magnification endoscopy 
Standard endoscopes were designed to view the mucosa from a focus distance of 1-
2cm and the combination of low pixel density and low resolution monitors often 
compromised the quality of the image when the tip of the scope was advanced to an 
area of interest.  More recently, new endoscopic systems have been developed to 
improve the focus and image quality of the visualised mucosa.  High resolution 
endoscopes (HRE) are equipped with high quality charge-coupled device chips with 
moveable lenses that allow the endoscopist to focus in on an area of interest without 
blurring the image compared with standard video endoscopes (Wolfsen 2009).  
Magnification endoscopy (HRME) provides the endoscopist with a zoom function 
which is excellent in detecting minute abnormalities in mucosal and vascular 
structures within the area of interest.  When combined with narrow band imaging, 
HRME is a very useful tool for assessing specific lesions (Figure 5.1).  
Figure 5.1 High resolution magnification image of Barrett’s nodule 
  
(A) Low magnification NBI HRE view of BE with 
focal HGD.  Note raised area with irregular pattern 
(B) High magnification NBI HRE view of focal 
HGD.  Note abnormal vascular and mucosal pattern 
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5.3 Chromoendoscopy 
In order to overcome some of the constraints associated with standard endoscopy, 
high resolution endoscopy was combined with chromoendoscopy using various dyes 
in an attempt to improve detection of mucosal abnormalities.  Chromoendoscopy 
agents can be classified into three broad groups based on their mechanism of action: 
absorptive (Lugol’s iodine, methylene blue), reactive (congo red) and contrast (acetic 
acid, indigo carmine).  The two essential steps of chromoendoscopy are firstly to 
remove any surface mucus (N-acetylcysteine or water are successful mucolytics) 
followed by the application of the dye either directly flushing it through the working 
channel or using a spray catheter (Singh, Mei, & Sethi 2011).  Table 5.1 summarises 
the mode of action, uses and limitations of the most common agents used in clinical 
practice. 
The first chromoendoscopy agent within the oesophagus was Lugol’s iodine.  
Lugol’s iodine binds to glycogen within the normal squamous epithelium of the 
oesophagus and stains it brown.  Absence of staining from glycogen depletion is 
indicative of inflammation, squamous high grade dysplasia and carcinoma.  A study 
from the Linxian region of China, known for its high rates of squamous cell 
carcinoma, showed Lugol’s iodine was sensitive and specific for high grade 
squamous dysplasia and carcinoma (96% and 63% respectively) (Wei, Abnet, Lu et 
al. 2005).  Barrett’s epithelium does not stain with Lugol’s iodine, and currently its 
most useful clinical role is the assessment of residual squamous tissue after mucosal 
ablation therapy. 
Studies using methylene blue, acetic acid or indigo carmine dyes with magnification 
endoscopy have identified mucosal glandular patterns aiding the diagnosis of 
intestinal metaplasia, rather than simple colour changes within the mucosa (Canto 
2005;Sharma, Weston, Topalovski et al. 2003).  Methylene blue is the most studied, 
and perhaps controversial, adjunct in detecting Barrett’s epithelium.  It is selectively 
taken up by goblet cells within the intestinalised mucosa, and not absorbed by gastric 
or squamous epithelia.  Initial studies suggested methylene blue targeted biopsies 
resulted in a higher yield of Barrett’s epithelium and dysplasia compared with 
random standard biopsies (Canto, Setrakian, Willis et al. 2000).  However these 
results have not been reproducible and follow up studies have shown mixed results.  
The main issues seem to be absence of staining in dysplastic tissue and different 
staining patterns between long and short segment disease.  These discrepancies may 
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be due to differences in application technique, operator skill and interpretation of 
results (Horwhat, Maydonovitch, & Ramos 2008).  There are also concerns that the 
combination of methylene blue and white light may lead to DNA damage (Olliver, 
Wild, Sahay et al. 2003).  A recent meta-analysis of 450 patients showed no benefit 
of methylene blue chromoendoscopy compared with random biopsy in detecting 
intestinal metaplasia, dysplasia or oesophageal carcinoma (Ngamruengphong, 
Sharma, & Das 2009).  In the light of these results and limitations, methylene blue 
may only be of historical interest. 
Acetic acid is not a chromoendoscopy agent per se as it has no specific colour, yet it 
has been used in the diagnosis of squamous dysplasia of the cervix for some time 
(Sauvaget, Fayette, Muwonge et al. 2011).  Acetic acid whitens the squamous 
epithelium of the oesophagus and gives Barrett’s epithelium a reddish hue.  Acetic 
acid acts by breaking the bonds of surface glycoproteins resulting in a transient 
disruption of the cell barrier leading to swelling and reddening of the mucosa, 
enhancing pit patterns (Lambert, Rey, & Sankaranarayanan 2003).  The mucosal pit 
patterns can be assessed using magnification endoscopy – round patterns typifying 
gastric epithelia, whereas villous and ridged patterns represent Barrett’s epithelium.  
A large UK series of 190 patients with Barrett’s oesophagus undergoing acetic acid 
chromoendoscopy (2.5% dye spray) show the acid assisted evaluation detected 
higher rates of dysplasia compared with white light endoscopy alone and excellent 
correlation with histology (Longcroft-Wheaton, Duku, Mead et al. 2010).  The use of 
acetic acid is inexpensive, easy to perform/interpret and can be useful in the 
assessment of Barrett’s epithelium. 
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Table 5.1 Common chromoendoscopy agents 
Agent Mode of action Tissue stain Limitations 
Lugol’s iodine 
  
Absorptive agent – absorbed into 
cellular glycogen 
 
Lugol’s iodine stains to glycogen of 
normal squamous epithelium 
(black/green) 
Lack of staining with glycogen found 
in inflammation/dysplasia/neoplasia  
Not specific to Barrett’s oesophagus 
Unable to differentiate metaplasia from 
dysplasia 
Methylene blue Absorptive agent – absorbed by 
goblet cells within the intestinal 
epithelium 
Intestinal type epithelium blue 
Normal squamous absent stain 
Mucolytic before application 
Vigorous washing of dye 
No universal application method 
No universal interpretation of results 
Acetic acid Contrast agent - cellular barrier 
breakdown to enhance borders and 
surface architecture of mucosa 
Normal squamous stains white 
Barrett’s epithelium has reddish hue 
Short stain life and needs repeated 
applications 
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5.4 Narrow band imaging 
Narrow band imaging (NBI) is a method of optical chromoendoscopy developed in 
Japan in 1999, allowing enhanced visualisation of mucosal abnormalities without the 
messy and time consuming problems associated with dye chromoendoscopy (Gono, 
Obi, Yamaguchi et al. 2004).  NBI is based on the principle that the depth of light 
penetration depends on its wavelength – the longer the wavelength, the deeper the 
penetration.   
The first prototype NBI system (Olympus, Tokyo, Japan) used a light source with 
sequential red-green-blue (RGB) illumination.  This allowed standard white light 
images to be passed through red, green and blue band pass filters, illuminating the 
mucosa.  In NBI mode, all bandwidths are narrowed resulting in a relative increase in 
the intensity of blue light which improves visualisation of the superficial mucosa.  
Mucosal blood vessels in particular are enhanced because blue light excitation is 
highly absorbed by haemoglobin.  A metaplastic epithelium is associated with 
regular mucosa and vascular patterns, while dysplasia can be identified by irregular 
patterns and the presence of abnormal blood vessels (Kara, Ennahachi, Fockens et al. 
2006).   
NBI has several advantages compared with chromoendoscopy.  No staining agents 
are required, it is less messy and more user friendly, and it allows inspection of the 
whole endoscopic field.  It also allows the endoscopist to easily switch between 
standard and NBI modes as required during a procedure. 
Various groups have proposed classification systems for the use of NBI in the 
assessment of Barrett’s mucosa (Herrero, Weusten, & Bergmann 2010).  Raganuth 
and colleagues recently described a grading system which was simple to use, 
accurate at predicting the presence of metaplasia and high grade dysplasia, and was 
associated with good interobserver agreement (Singh, Anagnostopoulos, Yao et al. 
2008).  The four categories of pit/microvasculature patterns were recognised as 
illustrated in Figure 5.2.  A recent meta-analysis of eight studies (446 patients with 
2194 lesions) suggested that NBI was useful for the detection of Barrett’s mucosa 
(sensitivity 95%, specificity 65%) and high grade dysplasia (sensitivity 96%, 
specificity 94%) (Mannath, Subramanian, Hawkey et al. 2010).  However the 
majority of these studies were conducted in high volume units by expert endoscopists 
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and further work may be required to standardise the classification of 
mucosal/vascular patterns to allow its incorporation in routine clinical practice. 
Figure 5.2 Mucosal patterns within Barrett’s oesophagus as identified on 
NBI-zoom 
  
  
(A) Round/oval pits with regular microvasculature.  (B) Villous/ridge pits with regular 
microvasculature as found in metaplasia while (C) and (D) demonstrate irregular vasculature and pits 
associated with high grade dysplasia. Images reproduced with permission from Professor Raganuth 
(personal communication). 
 
 
 
A 
D C 
B 
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Several studies have compared high resolution endoscopy (HRE) alone, or combined 
with dye chromoendoscopy, versus HRE-NBI in identifying areas of dysplasia or 
early cancer.  Early studies concluded that NBI is an excellent tool for detailed 
inspection of suspicious areas within a Barrett’s segment (Canto 2005).  Kara and 
colleagues compared NBI and chromoendoscopy for the detection of HGD and early 
adenocarcinoma.  The results showed no difference in the detection achieved by both 
techniques, although only 28 patients were included in the study (Kara, Peters, 
Rosmolen et al. 2005).  More recently, an international randomised controlled trial 
compared the use of HRE and NBI in relation to the diagnosis of IM, the number of 
biopsies required, and the detection of dysplasia (Sharma, Hawes, Bansal, Gupta, 
Curvers, Rastogi, Singh, Hall, Mathur, Wani, Hoffman, Gaddam, Fockens, & 
Bergmann 2013).  The results confirmed no difference in the detection of IM using 
either NBI or HRE, although NBI required significantly fewer biopsies (mean 3.6 vs 
7.6, p<0.0001).  All cases of HGD or adenocarcinoma were correctly identified by 
NBI having irregular mucosal/vascular patterns.  Furthermore, no area with a normal 
pattern by NBI had dysplasia.  However the accuracy of low grade dysplasia was 
limited. 
These results are very encouraging and NBI clearly has a role in the assessment of 
Barrett’s oesophagus and the diagnosis of HGD and early neoplasia.  However these 
results are from tertiary referral centres and may not be reproduced in general 
hospitals.  There remains a lack of consensus regarding the interpretation of 
mucosal/vascular patterns and intense training would be required in an attempt to 
reduce interobserver variability.   
Despite these challenges, there are now several commercially available electronic 
chromoendoscopy systems – NBI (Olympus, Southend-on-Sea, UK), Fujinon 
Intelligent ChromoEndoscopy (Fujinon Inc, Saitama, Japan) and Pentax I-Scan 
(Pentax Inc, Tokyo, Japan).  NBI (Olympus endoscopic system) is now more widely 
available throughout endoscopy units in the UK, and should be used as an adjunct for 
the routine assessment of patients with Barrett’s oesophagus. 
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5.5 Autofluorescence 
Fluorescence endoscopy may become a useful adjunct in the diagnosis of Barrett’s 
dysplasia although the literature is still in its infancy.  Fluorescence imaging 
differentiates tissue types based on differences in their fluorescence emissions.  
Tissues are exposed to short wavelength light, either ultraviolet or blue light, which 
leads to excitation of endogenous biological molecules (fluorophores) that emit 
fluorescent light of longer wavelengths.  As these signals are generated within the 
tissue itself, this phenomenon is known as autofluorescence (AF) (Haringsma and 
Tytgat 1999).   
The fluorophores responsible for tissue autofluorescence include connective tissue 
matrix (collagen, elastin), cellular metabolic coenzymes (NADH, FAD), aromatic 
amino acids (tryptophan, tyrosine, phenylalanine), byproducts of the heme pathway 
(porphyrins) and lipopigments (lipofuscin) (DaCosta, Wilson, & Marcon 2007).  
Each group of fluorophores is characterised by individual excitation and emission 
wavelengths.  Normal and neoplastic tissues have different autofluorescent 
characteristics because of differences in the concentration and distributions of 
fluorophores and chromophores.  The incident and fluorescent light can also be 
absorbed by other tissues, haemoglobin being the main chromophore in 
gastrointestinal tissues. 
Although each fluorophore has its individual fluorescence spectrum, most tissues 
contain a mixture of different fluorophores which are found in various concentrations 
and depths.  Therefore identifying individual fluorophores is problematic.  
Furthermore, the use of autofluorescence in the detection of dysplasia or early 
neoplasia is dependent on changes within the normal oesophageal mucosa (DaCosta, 
Wilson, & Marcon 2007).   
Autofluorescence imaging (AFI) is an endoscopic system which detects differences 
in the natural endogenous fluorescence of normal, dysplastic and neoplastic tissues 
using blue light illumination, which is detected through a charge coupled device 
(CCD).  The image processor incorporates the CCD signals into a real time image of 
normal mucosa (green) and dysplasia or neoplasia (varying tones of blue/purple) 
(Kara, Peters, ten Kate et al. 2005) (Figure 5.3). 
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Figure 5.3 Autofluorescence in Barrett’s oesophagus  
 
Autofluorescence image of Barrett’s oesophagus (B) with corresponding white light image (A).  
Dysplasia at 3’o’clock position appears purple.  Reproduced from (Herrero, Weusten, & Bergmann 
2010) 
 
Initial studies of AFI added little to the diagnosis of dysplasia as first generation AF 
systems did not have clear contrast between dysplastic and non-dysplastic tissue as 
the fibreoptic endoscopes provided relatively poor white light.  However the 
development of newer prototypes and white light HRE has produced excellent 
images which can guide the clinician.  In a study from Amsterdam the addition of 
AFI increased the detection of high grade dysplasia by 10% in addition to detecting a 
substantial number of other lesions not identified by white light (Kara, Peters, ten 
Kate, van Deventer, Fockens, & Bergmanm 2005).  However there were high false 
positive rates with AFI (PPV 49%) as some of the suspicious areas did not have 
dysplasia on histological assessment.   
AFI does increase the targeted detection of HGD/early neoplasia and may be of use 
in tertiary referral centres to aid location of lesions for further therapy (Figure 5.4).  
However compared with standard Seattle protocol, it does not result in higher 
dysplasia detection rates.  AFI alone has not clinically been as useful as NBI due to 
the poorer detection of dysplasia/early neoplasia and the high false positive rates. 
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Figure 5.4 Autofluorescence image of nodule in Barrett’s oesophagus  
 
High magnification autofluorescence view of high grade nodule with early neoplasia.  Note 
surrounding normal tissue (green) with dysplastic nodule and surrounding raised edges in keeping 
with HGD/early cancer. 
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5.6 Trimodal imaging endoscopy 
A further improvement in endoscopic imaging began with the introduction of 
endoscopic trimodal imaging (ETMI), combining the use of white light HRE, AFI 
and NBI.  This system enhances and improves the combined accuracy of the three 
modalities allowing better detection of mucosal abnormalities.  The results from a 
large multicentre study in Europe and the United States assessing the trimodal 
imaging system were encouraging (Curvers, Singh, Song, Wolfsen, Ragunath, Wang, 
Wallace, Fockens, & Bergmanm 2008).  At endoscopy, HRE was used to examine 
and describe the Barrett’s segment, AFI was used to identify areas suspicious of 
dysplasia and NBI was then used to examine the mucosal and vascular pattern of 
suspicious lesions before obtaining random and image-targeted biopsies.  The 
addition of AFI increased the number of patients with high grade dysplasia from 53% 
to 90%, and the use of NBI reduced the false positive rate of AFI from 81% to 26%.  
These results are indeed promising but the majority of new endoscopic imaging 
systems are prototypes and not widely available outwith study centres.  The systems 
are used in specialised centres which tend to have a high risk patient population and 
experienced endoscopists with an interest in Barrett’s oesophagus.   
More recently, a similar study was performed in the community, comparing 
endoscopic trimodal imaging (ETMI) versus standard video endoscopy (Curvers, van 
Vilsteren, Baak et al. 2011).  There was no significant difference in the overall 
histological yield between ETMI and standard endoscopy.  They concluded that 
ETMI performed in the community setting did not improve detection of dysplasia.   
5.7 Optical coherence tomography 
Optical coherence tomography (OCT) is a novel non-invasive technique that uses 
infrared light to excite oesophageal tissue, with reflected light being subsequently 
analysed according to the delay and intensity of reflection, producing black/white 
cross-sectional images of the microanatomy (Li, Boppart, van Dam et al. 2000).  
Real time images are obtained by a miniprobe which can be placed through the 
working channel of the endoscope.  The images strongly resemble those obtained by 
histological microscopy with an image depth of 1-3mm and high resolution (1-
10μm).  The potential advantage of OCT is an “optical biopsy” – an in situ image 
which may obviate the need for tissue sampling and improve the detection of 
malignancy.  Recent studies have assessed the efficacy of OCT in the diagnosis of 
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dysplasia in Barrett’s oesophagus.  While OCT is able to detect dysplasia (78% 
diagnostic yield), there were limitations with sensitivity rates of only 68% and high 
interobserver variability (Isenberg, Sivak, Chak et al. 2005).  With the emergence of 
ablative therapies to treat high grade dysplasia and intramucosal cancer, there is a 
concern that current endoscopy is unable to identify subsquamous Barrett’s 
epithelium.  An elegant ex vivo study by Cobb and colleagues has shown OCT is a 
promising tool for the recognition and surveillance of intestinal metaplasia 
(subsquamous and surface) in patients who have undergone ablative therapies (Cobb, 
Hwang, Upton et al. 2010).   
One of the main concerns is that OCT remains a bench technique and cannot be 
applied to clinical practice at the present time.  Despite technological advances, 
image resolution is still insufficient to compete with standard histological images.  
Technical challenges include movement artefacts due to breathing and peristalsis, 
and the compressibility of the tissues can distort optical images.  There are also 
concerns that OCT cannot adequately differentiate metaplasia and dysplasia 
(Bergmann and Tytgat 2005).   
While OCT is an exciting concept, further work will be required before it has a role 
in the clinical assessment of patients with Barrett’s oesophagus.  The ability to 
survey a wider area of mucosa would be beneficial for endoscopic surveillance and 
improvements in resolution may aid diagnosis of occult malignancy. 
5.8 Conclusion 
There have been significant advances in the endoscopic assessment of Barrett’s 
oesophagus with improved video systems and particularly the development of NBI.  
NBI is an exciting new development and an excellent adjunct in the diagnosis of 
HGD/early neoplasia but further research is required to translate this adjunct into 
daily clinical practice.  Trimodal imaging carries the greatest potential for use in 
clinics, as the combined advantages of the three modalities outweigh the use of each 
modality on its own.   
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Chapter 6 
Endoscopic detection of dysplasia in Barrett’s oesophagus : a novel 
technique 
arrett’s oesophagus can be visualised at endoscopy, but the diagnosis must 
be confirmed by the histological findings of a metaplastic columnar 
epithelium and/or dysplasia.  Dysplasia can be difficult to identify at 
endoscopy as lesions are often flat, inconspicuous and easily missed during 
surveillance endoscopy.  Laser induced tissue fluorescence has been used to 
differentiate normal and malignant tissue with varying degrees of success.  However 
the recent improvement in high definition endoscopy systems and other image 
adjuncts has led to a renewed interest in the use of laser autofluorescence in Barrett’s 
oesophagus.  The aim of this study was to assess the use of “optical” biopsy forceps 
to identify the presence of metaplasia and dysplasia in patients with Barrett’s 
oesophagus. 
  
B 
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6.1 Introduction 
The West of Scotland has the highest rates of oesophageal cancer and the incidence 
has risen over the last thirty years (NHS National Services Scotland 2012). Early 
accurate detection and treatment of precancerous Barrett's epithelium may reduce the 
incidence of oesophageal cancer over time. As the diagnosis of dysplasia has such a 
crucial impact on disease management and subsequent patient outcomes, a system 
that could aid identification of dysplasia by the endoscopist in real time would have 
great clinical utility.  Due to the heterogeneity of Barrett’s mucosa and the small 
endoscopic biopsy size only a small area of the oesophageal mucosa is generally 
sampled.  Dysplastic areas therefore may be missed with current biopsy techniques. 
White light endoscopy (WLE) and narrow band imaging (NBI) are currently used for 
imaging Barrett’s mucosa.  Recent advances in light sources, detectors and fibre 
optics have encouraged development of optical systems to visualise and evaluate 
epithelia in vivo (Wang and van Dam 2004).  An “optical biopsy” uses point 
measurements from an optical probe allowing in vivo assessment of mucosa without 
the need for tissue removal, or targeted biopsies in areas likely to contain dysplasia.  
This could reduce the number of “normal/non-dysplastic” biopsies taken during 
surveillance endoscopy and focus on areas of interest.  All methods of optical 
imaging collect backscattered photons from the mucosa after initial stimulation with 
light.  Optical techniques which have been used to date in gastrointestinal epithelia 
include light induced fluorescence, Raman spectroscopy and elastic scattering 
spectroscopy (Lovat, Johnson, Mackenzie et al. 2006;Panjehpour, Overholt, Vo-Dinh 
et al. 1996).  Each technique has its own features and specific applications, but all 
depend on architectural and biochemical changes within the mucosa. 
All tissues display endogenous fluorescence when exposed to light of certain 
wavelength.  Different excitation wavelengths activate different fluorophores within 
tissues.  Examples of fluorophores within oesophageal tissue are collagen, 
nicotinamide adenine dinucleotide (NAD), flavins and porphyrins.  When these 
biomolecules absorb light, electrons elevate to higher energy states.  Subsequent 
relaxation leads to emission of fluorescence (DaCosta, Wilson, & Marcon 2007).  
The wavelength of the emitted signal is longer than the wavelength of the excitation 
light, allowing the difference in excitation/emission wavelengths to be measured.  
Pattern recognition analysis is used to develop algorithms aided by computer 
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software which can classify tissue as non-dysplastic, dysplastic or neoplastic 
(Panjehpour, Overholt, Vo-Dinh, Haggitt, Edwards, & Buckley 1996).   
The first Laser-Induced Fluorescence Spectroscopy (LIFS) study in gastrointestinal 
tissue was performed by Kapadia and colleagues (Kapadia, Cutruzzola, O'Brien et al. 
1990).  In an ex vivo study, sixteen colonic adenomas were differentiated from 
hyperplastic polyps with a sensitivity and specificity of 100% and 94% respectively.  
Cothren performed the first in vivo study during colonoscopy, showing adenomas 
could be distinguished from normal colonic tissue in 97% cases (Cothren, Richards-
Kortum, Sivak et al. 1990).  Panjehpour and colleagues performed the first LIFS 
study in 32 patients with oesophageal adenocarcinoma (Panjehpour, Overholt, 
Schmidhammer et al. 1995).  They classified tissue into normal or malignant with 
sensitivity and specificity of 100% and 98% respectively.  A follow up study of 36 
patients with Barrett’s oesophagus accurately identified high grade dysplasia, but not 
low grade dysplasia (Panjehpour, Overholt, Vo-Dinh, Haggitt, Edwards, & Buckley 
1996). 
The WavSTAT® Optical Biopsy System is based on the principles of laser induced 
fluorescence and was approved by the FDA in November 2000 as safe and effective 
for adjunctive use during endoscopy of the colon to improve the endoscopist’s 
clinical sensitivity to identify adenomatous polyps.  
6.2 Study Aim 
The aim of this pilot study was to assess the feasibility of the WavSTAT® Optical 
Biopsy System to identify dysplasia or neoplasia within Barrett’s oesophagus.   
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6.3 Methods 
6.3.1 Patients 
Patients with Barrett’s oesophagus were invited to participate in the study if they 
were scheduled for endoscopy for the following reasons: (1) upper gastrointestinal 
symptoms suggestive of reflux disease, (2) regular surveillance for Barrett’s 
metaplasia or low grade dysplasia, and (3) follow up after endoscopic therapy for 
high grade dysplasia or early cancer.  The patients were enrolled on a first-come 
first-enrolled system.  The study protocol was approved by the South East Scotland 
Research Ethics Committee.  Information packs were delivered to all patients and a 
telephone discussion available on request. Written informed consent was obtained 
before the procedure.   
 
6.3.2 Endoscopic system 
The standard endoscopy system used during the study consisted of a high resolution 
white light endoscope with optical zoom (GIF-H180, Olympus Inc, Tokyo, Japan), a 
light source with two filters, one for white light imaging and one for NBI (CLV-180, 
Olympus Inc, Tokyo, Japan) and a processor (CV-180, Olympus Inc, Tokyo, Japan). 
 
6.3.3 Optical biopsy system 
The WavSTAT
®
 Optical Biopsy System (SpectraScience Inc, San Diego, USA) was 
gifted to the endoscopy unit of Glasgow Royal Infirmary, to allow a pilot study to be 
performed among patients with Barrett’s oesophagus, residing in the West of 
Scotland.  The WavSTAT
®
 Optical Biopsy System consists of a laser light source 
console with optical fibre embedded biopsy forceps, statistical tissue recognition 
algorithm software, activation foot pedal and a touch screen user-interface console 
(Figure 6.1).  The device contains an internal flash memory to store data.  The 
WavSTAT
®
 system uses modified standard biopsy forceps containing an optical 
fibre to send light (337 nanometre wavelength pulsed nitrogen laser) to the tissue, 
scanning the area in question.  The tissue reacts to the light, emitting a fluorescence 
signal (autofluorescence) which on returning via the optical fibre is analysed by the 
computer’s statistical software algorithm.  Non-dysplastic tissue generates a different 
fluorescence signal to dysplastic or cancerous tissue.  The algorithm determines in 
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real time whether the tissue in question is non-dysplastic, dysplastic or cancerous.  
The user-interface console then displays the classification in green “non-dysplastic” 
or red “dysplastic”.   
The optical biopsy is performed by first touching the oesophageal tissue with the tip 
of the WavSTAT
®
 optical biopsy forceps.  The foot pedal is pressed, triggering firing 
of the laser down the optical fibre.  The proper placement of the probe against the 
tissue is verified on the WavSTAT
®
 monitor, and a warning issued if the probe 
placement  is not suitable.  The fluorescent signal was returned by the same probe 
and analysed by the software programme.  The process takes 1-2 seconds for each 
optical biopsy.   
Figure 6.1 The WavSTAT system 
 
 
Image of new generation WavSTAT monitor and optical biopsy forceps.  The forceps are single use 
and able to take an optical and physical biopsy sample. 
 
6.3.4 Methodology 
Participants were prepared for the endoscopic examination using routine outpatient 
protocols, namely fasting from midnight and cessation of any oral anticoagulants.  
Patients underwent upper endoscopy either under conscious sedation with 
intravenous midazolam, or application of topical anaesthetic (lidocaine spray). 
The oesophagus was initially examined using the standard endoscopy system as 
previously described.  The presence and length of the Barrett’s segment was noted 
and recorded according to the Prague C&M classification (Sharma, Dent, & 
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Armstrong 2006).  The presence of oesophagitis, hiatus hernia and any visible 
abnormalities suspicious of dysplasia or early neoplasia were noted.  The location of 
any suspicious lesions (distance from the incisors and endoscopic quadrant) was 
recorded.   
After initial assessment of the Barrett’s segment, an optical biopsy was performed, 
followed by a physical biopsy (taken from the same piece of tissue as the optical 
biopsy).  The whole Barrett’s segment was sampled in this manner according to the 
Seattle protocol – four quadrant biopsies (optical followed by physical) taken every 
two centimetres.  Any suspicious areas were also individually targeted.  Biopsies of 
normal stomach and normal squamous oesophagus were taken as control tissue.  The 
results from the optical biopsy (red-dysplastic, green-non dysplastic) were noted on 
pre-printed endoscopy proformas.   
 
6.3.5 Tissue Handling and Analysis 
Each physical biopsy was placed alone in standard labelled specimen pots containing 
10% buffered formalin and sent to histology.  All pots were numbered, 
corresponding to the optical biopsy identification number on the endoscopic 
proforma, thus ensuring a direct correlation would be made between the physical and 
optical biopsy (1:1 correlation). 
The physical biopsies were processed, stained with haematoxylin and eosin, and 
assessed by an expert GI histopathologist with an interest in Barrett’s oesophagus 
(Dr James Going, Royal Infirmary, Glasgow).  All slides were read by the site 
pathologist and the presence of dysplasia or carcinoma recorded on standardised 
pathology forms, based on the Vienna classification of GI neoplasia – specifically, 
non-dysplastic Barrett’s oesophagus, indefinite for dysplasia, low grade dysplasia, 
high grade dysplasia or invasive cancer (Schlemper, Riddell, & Kato 2000).  All 
pathology reports were reviewed independently by a second pathologist (Dr ten Kate, 
Amsterdam Medical Centre, Amsterdam), blinded to the first pathologist’s findings.  
On rare occasions, any discrepancies were sent to a third pathologist for another 
independent review.  There was good agreement between the pathologists from two 
sites (Glasgow and Amsterdam) in the interpretation of all biopsy samples (kappa 
value=0.95).  The results of the physical biopsies were then married to the optical 
fluorescence results. 
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6.3.6 Follow up 
Each patient was informed of their physical biopsy results and any further 
surveillance or treatment carried out in their local hospital.  Patient involvement in 
the study ended at this point.  All clinicians involved in the care of the patients were 
alerted to the results and outcomes. 
 
  
108 
 
6.4 Results 
Patient demographics 
One hundred patients consented to participate in the study over a twelve month 
period.  Between March 2010 and May 2010, 31 patients underwent surveillance 
endoscopy with WavSTAT
®
 optical and standard biopsy of the Barrett’s oesophagus 
segment.  There were 20 males and 11 females with a mean age of 67 years (range 
46-80 years).  All patients had a previous diagnosis of Barrett’s oesophagus, were 
participants of the endoscopic surveillance programme and were prescribed regular 
proton pump inhibitor therapy.  Although there was no past history of oesophageal 
adenocarcinoma, 11 patients (35%) had a previous diagnosis of low grade dysplasia.   
The mean segment length was 5.4cm (range 4-15cm) and mean number of 
biopsies/patient was 15 (range 6-33 biopsies).  A visible nodule was identified in one 
case but all other oesophageal sites biopsied appeared endoscopically to be normal 
columnar mucosa.   
Histology 
A total of 384 matched optical and histological biopsies were taken.  Eighty seven 
biopsies were excluded due to histology; squamous epithelium (n=51) or gastric 
mucosa (n=36); data was incomplete for 15 biopsies and 20 biopsies were excluded 
due to acquisition errors during optical biopsy.  Two hundred and sixty two biopsy 
sites were included in the final analysis.  Table 6.1 summarises the histology of all 
biopsy samples.   
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Table 6.1 Histology of oesophageal biopsy sites  
 Number of biopsies 
Vienna 5 (Cancer) 4 
Vienna 4 (HGD) 0 
Vienna 3 (LGD) 20 
Vienna 2 (Indefinite for dysplasia) 5 
Vienna 1 (No dysplasia) 233 
Total 262 
Vienna classification of dysplasia was used to classify oesophageal biopsy specimens (Schlemper, 
Riddell, & Kato 2000).  Total number analysed (n=262) by two experienced pathologists.   
LGD=low grade dysplasia, HGD=high grade dysplasia 
 
Correlation between optical and physical biopsies 
The number of biopsies taken from each patient, and the results from the optical and 
physical biopsies are presented in Table 6.2.  Results from patients 23, 27, 29 and 30 
were excluded due to problems with acquisition of the optical biopsy results.  The 
preliminary results demonstrate no clear correlation between the optical biopsy result 
and the histological assessment of the physical biopsy (r=0.103, Pearson correlation 
coefficient, p=0.95).   
  
110 
 
Table 6.2 Results of optical and physical biopsy (n=262) 
 
 
 OPTICAL BIOPSY RESULTS    PHYSICAL BIOPSY RESULTS 
Patient Number of 
biopsies (n=) 
Green (not 
suspect) 
Red 
(suspect) 
No dysplasia Dysplasia 
1 2 2 0 2 0 
2 10 3 7 10 0 
3 3 1 2 3 0 
4 9 4 5 9 0 
5 14 0 14 9 5 
6 8 0 8 8 0 
7 8 4 4 8 0 
8 15 10 5 15 0 
9 5 2 3 3 2 
10 13 3 10 7 6 
11 2 2 0 1 1 
12 17 11 6 16 1 
13 12 0 12 12 0 
14 22 5 17 21 1 
15 7 2 5 7 0 
16 17 5 12 15 2 
17 12 9 3 12 0 
18 7 5 2 7 0 
19 12 2 10 12 0 
20 2 0 2 1 1 
21 12 5 7 8 4 
22 12 9 3 10 2 
24 20 4 16 20 0 
25 3 3 0 0 3 
26 12 1 11 12 0 
28 2 2 0 2 0 
31 6 4 2 3 3 
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6.5 Discussion 
Current endoscopic programmes often yield large numbers of normal “non-
dysplastic” biopsies in low risk patients (Lovat, Johnson, Mackenzie, Clark, Novelli, 
Davies, O'Donovan, Selvasekar, Thorpe, Pickard, Fitzgerald, Fearn, Bigio, & Bown 
2006).  The presence of dysplasia remains the current gold standard marker of 
disease progression, yet some patients may develop adenocarcinoma without a 
previous diagnosis of dysplasia (Montgomery, Goldblum, & Greenson 2001).  In 
these cases, it is thought dysplasia was present at previous endoscopy but not 
adequately detected.  Furthermore, there is often interobserver variability among 
pathologists particularly in the diagnosis of low grade dysplasia and in the presence 
of reactive atypia and inflammation (Goldblum 2010).  Standard endoscopy and 
biopsy is time consuming, uncomfortable for the patient, and places significant time 
and financial burdens on endoscopy and histopathology services.  These challenges 
have led to development of new optical technologies. 
The WavSTAT
®
 Optical Biopsy system is a laser induced fluorescence system based 
on the principles of light induced fluorescence, which is simple to use and allows real 
time histological assessment of Barrett’s mucosa.  Disappointingly, this pilot study 
failed to show any correlation between the WavSTAT
®
 optical biopsy and the 
physical biopsy in Barrett’s oesophagus.  The system failed to differentiate non 
dysplastic Barrett’s epithelium from dysplastic or early neoplastic tissue.  
The WavSTAT
®
 Optical Biopsy system has several potential advantages.  It is 
relatively cheap, easy to use and provides the endoscopist with instant results, rather 
than a delay of days for histology results from physical biopsy.  The optical biopsy 
forceps do not need to be removed from the endoscope unless a physical biopsy is 
required, allowing the endoscopist to survey long segments of Barrett’s mucosa in a 
shorter time compared with the standard Settle protocol (Lovat, Johnson, Mackenzie, 
Clark, Novelli, Davies, O'Donovan, Selvasekar, Thorpe, Pickard, Fitzgerald, Fearn, 
Bigio, & Bown 2006).  Typically 6 or 7 optical biopsies can be performed in the time 
taken to perform one physical biopsy (Panjehpour, Overholt, Vo-Dinh, Haggitt, 
Edwards, & Buckley 1996).  The non-invasive nature of the optical biopsy reduces 
bleeding which often interferes with visual assessment of the mucosa during 
surveillance endoscopy.  In time the WavSTAT
®
 Optical Biopsy system could 
reduce the number of physical biopsies taken, reducing the number of low risk 
biopsy specimens sent for pathology review (Panjehpour, Overholt, Vo-Dinh et al. 
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2012).  Finally, the technique has the potential to reduce variability in histological 
interpretation of standard biopsy samples.   
LIFS has been used for detection of premalignant lesions within the gastrointestinal 
tract (colonic polyps and oesophageal adenocarcinoma) for two decades with 
promising results.  However despite encouraging preliminary results, optical 
techniques remain at an investigational stage and further work is required before they 
can be used in clinical practice.  These are summarised in Table 6.3. 
The presence of reactive atypia and inflammation within Barrett’s biopsies produces 
diagnostic challenges for the pathologist, particularly in differentiating non-
dysplastic Barrett’s mucosa from low grade dysplasia (Odze 2006).  This is also a 
concern for optical technology – would the presence of atypia and inflammation 
produce false positive results during optical biopsy.  A recent study from Panjehpour 
and colleagues showed no difference in sensitivity between oesophageal biopsies 
with and without inflammation (162/175 biopsies with inflammation, sensitivity 
92.6% vs 118/128 biopsies without inflammation, sensitivity 92.2%) (Panjehpour, 
Overholt, Vo-Dinh, & Coppola 2012).  These results are very encouraging but from a 
high volume, experienced centre and clinical studies in other units are necessary to 
corroborate these results. 
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Table 6.3 Summary of Light-induced Fluorescence Studies 
Study Excitation wavelength Tissue analysed Results 
(Kapadia et al 
1990) 
325nm Colon 
Normal/hyperplastic polyps vs 
adenomas 
Correct diagnosis of 34 normal mucosa/hyperplastic polyp 
specimens and 16 adenomatous polyps. 
(Cothren et al 
1990)  
370nm Colon 
Normal vs adenomas 
Adenomas distinguished from nonadenomatous tissue 97% 
cases 
(Panjehpour et 
al 1995) 
410nm Oesophagus 
Normal vs adenocarcinoma 
Sensitivity 100% and specificity 98% 
(Panjehpour et 
al 1996) 
410nm Oesophagus 
Normal vs LGD vs HGD 
96% no dysplasia classified as benign 
All LGD samples classified as benign 
90% HGD samples classified as premalignant 
28% LGD with focal HGD classified premalignant 
(Vo-Dinh, 
Panjepour, 
Overholt et al. 
1995)  
410nm Oesophagus 
Normal vs adenocarcinoma 
DNF (differential normalised fluorescence) signal 
Sensitivity 96% no dysplasia,  90% HGD 
Low specificity for focal HGD and unable to detect LGD 
(Georgakoudi, 
Jacobson, van 
Dam et al. 
2001) 
Several excitation 
337nm-620nm 
Oesophagus 
Non dysplastic vs LGD/HGD 
HGD vs LGD and no dysplasia: sensitivity 100% and 
specificity 97% 
LGD and HGD vs no dysplasia: sensitivity 79% and 
specificity 88% 
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Study limitations 
The main limitation with this study was the lack of correlation between the optical 
and physical biopsies.  The small number of biopsies with dysplasia and cancer 
reduced the amount of data suitable for analysis.  Within this cohort of patients, there 
were no cases of high grade dysplasia.  The volume of tissue sampled just beneath 
the optical probe is small (1-3mm
3
).  Although multiple readings can be taken very 
quickly, the technique is still prone to sampling error as it does depend on the 
endoscopist identifying visible lesions.  This inherently reduces the sensitivity and 
clinical utility of the technique.   
The current wavelength spectrum using 337nm excitation failed to discriminate 
between dysplastic and non-dysplastic oesophageal tissue.  It is unlikely the failure  
resulted from issues with histological interpretation of the physical biopsies as there 
was strong interobserver agreement among the pathologists (Glasgow and expert 
pathologists in Amsterdam).  It would appear the excitation wavelength of 337nm is 
not capable of assessing the qualities of dysplastic and non-dysplastic tissue in the 
oesophagus and alternative excitation wavelengths, such as 405nm could be studied 
in future studies.   
Future improvements 
Optical biopsy sampling has the potential to provide real-time diagnosis of 
premalignant and early neoplastic tissue in Barrett’s oesophagus.  Unfortunately the 
WavSTAT
®
 Optical Biopsy system in its current state does not meet the necessary 
criteria.  However further work is in progress and once the optimum excitation 
wavelength has been identified, the results may be more favourable.  The principle of 
targeted oesophageal biopsies is good.  Techniques to enhance the oesophageal 
mucosa may aid detection of dysplasia and neoplasia, such as mucosal enhancement 
using chromoendoscopy dyes or tumour markers.  A study by von Holstein used low 
dose Photofrin (fluorescent tumour marker composed of porphyrins) to enhance laser 
induced fluorescence in detection of adenocarcinoma in Barrett’s oesophagus.  They 
found Photofrin related signals in malignant tissue did not significantly differ from 
normal tissue, and the difference between malignant and normal tissue was due to the 
presence of endogenous fluorophores (von Holstein, Nilsson, Andersson-Engels et 
al. 1996).   
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More recently, visually tagged probe molecules which selectively bind neoplastic 
cells have been used with success.  Lu and colleagues developed a peptide that binds 
specifically to high grade dysplasia and adenocarcinoma of the oesophagus (Lu and 
Wang 2008).  The peptide was labelled using a fluorescin-tagged antibody and 
delivered topically.  The oesophagus was then washed to remove any unbound 
antibody and imaging techniques used to visual the mucosa.  Confocal 
endomicroscopy found a 3.8-fold greater fluorescence signal in neoplastic tissue 
compared with non-dysplastic Barrett’s oesophagus with sensitivity and specificity 
rates of 75% and 97% respectively (Strum, Joshi, Lu et al. 2013).  Bird-Leiberman 
and colleagues have shown cell-surface glycan alteration in progression of Barrett’s 
oesophagus to adenocarcinoma leading to changes in lectin binding.  Selective 
binding of lectin (wheat germ agglutin) improved visualisation of high grade 
dysplasia in ex vivo oesophageal tissue (Bird-Leiberman, Neves, Lao-Sirieix et al. 
2012).  Targeted imaging agents have potential to aid optical biopsy imaging 
techniques, but further work to identify novel targets and improving sensitivity and 
specificity is required before implementation in clinical practice. 
6.5 Conclusion 
The role of future endoscopic biopsy technology may lie in the use of the “optical 
biopsy”, offering real time in situ histological diagnosis allowing targeted tissue 
removal.  Although laser induced spectroscopy (and point spectroscopy) is still in its 
infancy, it has the potential to be an excellent imaging adjunct.  Further studies 
developing fluorescence endoscopy may render the optical biopsy system an 
excellent method for the detection of dysplasia and early neoplasia. 
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Chapter 7 
Predictive biomarkers in Barrett’s oesophagus  
arrett's oesophagus is important as a precursor of oesophageal 
adenocarcinoma via a metaplasia-dysplasia-carcinoma sequence. In the 
absence of glandular dysplasia the risk of progression to cancer is low but 
ascertainment of dysplasia is not always straightforward. Sparse mucosal sampling 
may miss dysplasia, or reactive changes may be over-interpreted due to inter and 
intraobserver variation. Low and even high grade dysplasia do not necessarily 
progress, provided prevalent cancer has been rigorously excluded. This 
indeterminacy motivates an ongoing search for clinically useful predictive 
biomarkers. Although many genetic and epigenetic abnormalities have been 
associated with neoplastic progression in Barrett's mucosa no molecular tests have as 
yet been accepted into routine pathology practice. Challenges of assay definition 
remain and many marker studies lack statistical power or have other methodological 
flaws. Even where strong evidence of clinically relevant predictive value does exist 
(in the case of ploidy analysis by flow or image cytometry) adoption into clinical 
practice has been minimal, likely reflecting technological and possible 
reimbursement obstacles. Well-designed multi-centre studies are likely to be required 
to translate improved knowledge of Barrett's carcinogenesis into clinically significant 
progress on predictive testing, and will require a degree of cooperation not so far 
widely seen in the field.  
Publication 
Moyes LH, Going JJ.  Still waiting for predictive biomarkers in Barrett’s 
oesophagus.  Journal of Clinical Pathology 2011; 64:742-750. 
    
B 
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7.1 The Potential for Biomarkers 
It has already been established that Barrett’s oesophagus is an acquired precursor of 
oesophageal adenocarcinoma.  Characteristically, the squamous epithelium of the 
lower oesophagus is replaced by a metaplastic glandular mucosa.  It appears that 
reflux of gastric and/or duodenal contents leads to mucosal injury, cellular 
proliferation and healing resulting in columnar/glandular metaplasia of the normal 
squamous mucosal lining, although the details are not fully elucidated (Manjunath 
and Jankowski 2000).  A metaplasia-dysplasia-carcinoma sequence is characteristic 
of progression to Barrett’s adenocarcinoma.  Current guidelines on both sides of the 
Atlantic suggest that patients with Barrett’s oesophagus should undergo periodic 
surveillance endoscopy and biopsy in the hope of detecting dysplasia and cancer at 
an early stage.  However as most patients with Barrett’s oesophagus never develop 
adenocarcinoma, most patients undergoing surveillance derive no benefit and the 
added psychological concern regarding cancer development may have a significant 
effect on quality of life (Kyrgidis, Kountouras, Zavos et al. 2005;Wright, Gray, & 
Morris 1996).  In addition the massive health economic issues related to surveillance 
programmes make the identification and targeting of selected Barrett’s cases a health 
care priority. 
In this context, a clinical or laboratory marker which did actually predict progression 
to dysplasia (itself a marker of cancer risk), or to cancer in the case of patients with 
dysplasia already, would be extremely valuable, allowing targeting of screening to 
those most at risk. Currently, high grade dysplasia is the most reliable indicator of 
increased risk of progression to malignancy, and indeed it is often already associated 
with invasive cancer when detected (Collard 2002;Spechler SJ 2005). 
However, estimates of the incidence of progression from dysplasia to carcinoma are 
variable, and the diagnosis of dysplasia, particularly low grade dysplasia, can be 
difficult owing to sampling errors, disagreement between observers, and the 
difficulty of discriminating inflammatory and reactive changes from true dysplasia 
(Spechler SJ 2005).  Despite a substantial literature on genetic and molecular 
changes in Barrett's oesophagus and Barrett's adenocarcinoma, practically nothing 
has translated so far into clinical practice.  This chapter shall discuss the current roles 
of candidate molecular and other biomarkers in Barrett's oesophagus, and prospects 
for progress.   
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7.2 Methods 
A search of the English language literature since 1975 was performed using PubMed, 
Embase and Cochrane databases with MESH terms "Barrett's oesophagus/ 
epithelium/ metaplasia", "oesophageal cancer/ adenocarcinoma", "biomarkers", 
"disease progression" and "dysplasia".  Abstracts were examined and relevant 
articles from reference lists of other papers retrieved. 
7.3 Biomarkers 
A biomarker is defined as “a characteristic that is objectively measured and 
evaluated as an indicator of normal biological processes, pathogenic processes or 
pharmacological responses to a therapeutic intervention”. 
Biomarkers should detect a state already established, predict a future state, or both. 
Few achieve either. Good biomarkers require high sensitivity and specificity for the 
state or event they purport to detect: cardiac troponins, for example, are excellent 
markers of myocardial injury but are not highly specific for myocardial infarction. In 
Barrett's oesophagus we might wish for markers of the diagnosis per se; but 
especially useful would be predictors of premalignant or malignant progression. A 
priori such markers are likely to be concerned with key pathways in the development 
of oesophageal adenocarcinoma, and would distinguish clearly between people with 
low and high cancer risk. Ideally a test would be minimally invasive, cost effective, 
and could be used on its own or in conjunction with other techniques (Preston and 
Jankowski 2006). 
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A formal model of phased biomarker development has been proposed, analogous to 
the process in therapeutic drug studies (Pepe, Etzioni, & Feng 2001).  There are five 
phases of development, summarised as follows -  
I. Preclinical exploratory studies to identify potential markers.  
II. Clinical assay development to determine sensitivity and specificity of 
markers in subjects with the disease, compared to normal control subjects.  
III. Retrospective studies on specimens from subjects prior to their diagnosis, to 
test capacity of the marker to detect preclinical disease. 
IV. Prospective screening studies. 
V. Cancer control studies to address whether screening with biomarkers reduces 
the population burden of cancer. 
Biomarkers never studied beyond phases one or two vastly outnumber those taken to 
phases three and four, and there are few established, clinically useful predictive 
biomarkers in Barrett's oesophagus, other than histomorphology. Even so, there are 
markers for which evidence of predictive power does exist, but which are used only 
in a few centres, in particular ploidy, assessed by flow or image cytometry. In ploidy 
studies relatively complex technology and reimbursement issues may have impeded 
wider adoption. 
Some believe panels of biomarkers may eventually provide more useful clinical 
information than any single marker, but the validation challenges for marker 
combinations will be at least as great as for single markers.  To evaluate the 
prospects for new biomarkers, we need first to understand and define morphological 
molecular and genetic abnormalities associated with Barrett's oesophagus. 
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7.4 Morphological Features of Barrett’s Oesophagus  
7.4.1 Intestinal metaplasia 
Intestinal metaplasia per se is not a useful marker of cancer risk, being present in 
most cases if not every case of Barrett's oesophagus, but the belief that oesophageal 
glandular dysplasia and adenocarcinoma usually develop on a background of 
intestinal metaplasia (IM) has led to a perception that without IM cancer risk may be 
low. Recent data suggests this is an over-simplification (Takubo, Aida, Naomoto, 
Sawabe, Arai, Shiraishi, Matsuura, Ell, May, Pech, Stolte, & Vieth 2009).   Studies 
suggest that a columnar metaplasia of the oesophagus carries the same malignant risk 
whether an intestinal phenotype is present or not, and therefore the original 
association of intestinal metaplasia carrying malignant risk has been brought under 
scrutiny (Dent 2011;Kelty, Gough, van Wyk, Stephenson, & Ackroyd 2007).  Also, 
even in the absence of detectable goblet cells, Barrett's mucosa still expresses 
markers and has ultrastructural features of intestinal differentiation.  As previously 
discussed in Chapter 2, the perception that an absence of goblet cells negates a 
diagnosis of Barrett's oesophagus may therefore not survive and will not be 
considered further here (Riddell & Odze 2009). 
7.4.2 Dysplasia 
As in other situations dysplasia is a marker of cancer risk in Barrett's oesophagus. In 
the gastrointestinal tract it is synonymous with intraepithelial neoplasia, and implies 
architectural and cytological changes commonly associated with carcinomas, and 
from which the latter are presumed, at least sometimes, to have evolved (Figure 7.1). 
As a marker of risk, however, dysplasia is far from perfect. There is significant intra 
and interobserver variation in assessing Barrett’s oesophagus (Spechler SJ 2005).  
Pathologists are not good at agreeing on the presence of mild and moderate (low 
grade) dysplasia, although agreement on severe (high grade) dysplasia is better 
(Goldblum 2003;Goldblum 2010).  Dysplasia may be patchy, and many biopsies may 
be necessary to detect it reliably, creating a burden for patient, endoscopist, and 
pathologist (Abela, Going, Mackenzie, McKernan, O'Mahoney, & Stuart 2008).  Not 
all dysplasia will progress to a higher grade or invasive adenocarcinoma; in some 
cases it may regress. 
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Even high grade dysplasia, provided invasive adenocarcinoma is not already present, 
may persist for years before progression to invasion. All of these considerations 
emphasize the limitations of dysplasia as a risk biomarker. That no better biomarker 
has yet emerged is only to restate the challenge. It is likely that dysplasia will remain 
a mainstay of risk assessment in Barrett's oesophagus for some time, with newer 
technologies complementing it initially, not least because morphology may usefully 
allow targeting of marker studies such as ploidy assessment by image cytometry, 
immunohistochemistry, or FISH (fluorescent in situ hybridisation). Different patterns 
of dysplasia are also coming to be recognised and in time may prove to have 
different behaviours (Brown, Whiteman, & Lauwers 2010;Rucker-Schmidt, Sanchez, 
Blount et al. 2009).  Until then, dysplasia agreed on by more than one experienced 
gastrointestinal pathologist may be more robust than an uncorroborated diagnosis. 
Where three pathologists agree on a diagnosis of low grade dysplasia, an elevated 
risk of progression exists perhaps because dysplasia on which any three GI 
pathologists can agree is close to being high grade (Skacel, Petras, Gramlich et al. 
2000). 
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Figure 7.1 Examples of dysplasia associated with Barrett’s epithelium 
  
 
(A) Heterogenous Barrett’s mucosa with no 
dysplasia at *, but low grade dysplasia at **, 
represented by cellular stratification and 
proliferation at the mucosal surface 
(B) Rounded nuclei with chromatin clearing and 
easily visible nucleoli point to high grade 
dysplasia 
(C) Well differentiated Barrett’s adenocarcinoma 
(typical example) 
  
A 
C 
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7.5 Molecular Abnormalities of Barrett’s Oesophagus 
Mutations accumulating in premalignant tissue lead to evolution of cellular clones 
with increasing genomic instability and abnormal cell behaviour until clones of cells 
emerge with invasive and metastatic potential (Barrett, Sanchez, Prevo et al. 
1999;Nowell 1976).  Epigenetic events and aspects of the host environment such as 
inflammation are also important, and cancer can be promoted by factors not known 
to be genotoxic. 
Genomic instability is a fundamental property of neoplastic progression, developing 
before the onset of cancer and characterised by chromosomal instability 
(aneuploidy), epigenetic instability, loss of heterozygosity (LOH) affecting tumour 
suppressor genes and microsatellite instability. The targets of genomic instability are 
usually seen to include proto-oncogenes, tumour suppressor genes, DNA mismatch 
repair genes and mitotic checkpoint genes (Koppert, Wijnhoven, van Dekken et al. 
2005).  Hanahan and Weinberg's popular taxonomy of properties required by cancer 
cells - namely, growth and self-sufficiency, insensitivity to growth inhibitory signals, 
avoidance of apoptosis, replication without limit, sustained angiogenesis, invasion 
and metastasis and more recently inflammation, provides a convenient framework for 
an examination of potential biomarkers (Hanahan and Weinberg 2011;Morales, 
Souza, & Spechler 2002).  However over the last decade the cancer stem cell 
hypothesis has caused a shift in thinking about the key events of carcinogenesis.  
Stem cells and cancer cells share several important properties and there is now 
evidence to suggest dysregulation of the self renewal process of stem cells may be 
the key event in early carcinogenesis rather than random mutation.  This hypothesis, 
if adopted, carries significant implications for diagnosis and therapeutic options in 
cancer (Wicha, Liu, & Dontu 2006). 
7.5.1 Growth Self-Sufficiency 
The cell cycle is an ordered series of events, resulting in cell growth and division into 
two daughter cells.  Normal cells require exogenous growth signals to move from G0 
(quiescence) into the cell cycle (Figure 7.2). A key mechanism controlled by the 
retinoblastoma protein p185 Rb, late in G1, restricts progression into S phase and 
DNA synthesis to cells without DNA damage, which may trigger cell cycle arrest 
and DNA repair, or if the damage cannot be repaired, apoptosis and cell death 
(Souza, Morales, & Spechler 2001). 
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Figure 7.2 The key regulators of the cell cycle 
 
Key to figure: (M) mitosis, (G1) growth phase 1, (S) DNA synthesis, (G2) growth phase 2.  
Retinoblastoma (Rb) is the molecular switch controlling the G1 R point.  The cdk-cyclin complex 
phosphorylates Rb, inactivating it and allowing the cell to progress into S phase.  However in the 
presence of p53 (a tumour suppressor gene), the cyclin-cdk complex is inhibited and Rb remains 
unphosphorylated preventing onward progression.  This holds the cell in G1 preventing replication of 
cells containing damaged DNA. 
 
Progression through the cell cycle is controlled by cyclins and cyclin dependent 
kinases (cdks). Different cdks and cyclins are required at various stages of the cell 
cycle.  There are two main structurally related groups of cdk inhibitors. The Ink4 
family (inhibitors of cdk4) consists of proteins (p15, p16, p18, p19) that inhibit 
cyclin D-cdk 4/6 complexes. Mutations, deletions or silencing through DNA 
methylation of p15 and p16 have been reported in various human malignancies. The 
other group is the Cip/Kip family including p21, p27 and p57 which preferentially 
target Cdk2. p21 (also known as Cip1 or Waf1) is regulated by p53, and although 
there are many mutations in p53, no molecular alterations of p21 have yet been 
reported. 
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Cyclin D 
Cyclin D1 is a proto-oncogene that controls the G1-S transition by activating Cdks 4 
and 6, which phosphorylate p185 Rb (thereby inactivating it) and stimulate 
progression through the cell cycle. A single base polymorphism in a variant known 
as cyclin D1b has been implicated in overexpression and neoplastic transformation, 
and immunohistochemistry shows cyclin D1 overexpression in Barrett's oesophagus 
and oesophageal adenocarcinoma (Casson, Zheng, Evans et al. 2005).  It has been 
claimed that patients with Barrett's metaplasia and cyclin D1 overexpression are 6-7 
times more likely to develop adenocarcinoma although other studies do not support 
this (Bani-Hani, Martin, Hardie et al. 2000;Murray, Sedo, Scott et al. 2006).  
Increased expression of cyclin D1 is an early event in carcinogenesis and may of 
itself predispose to malignant transformation (Zagorowicz and Jankowski 2007).  At 
present abnormalities of cyclin expression cannot be confirmed as markers of 
progression risk. 
Cyclin A 
Cyclin A is also a proto-oncogene expressed in the proliferative compartment in 
normal gastrointestinal mucosae. Cyclin A immunohistochemistry from oesophageal 
brushings in Barrett's patients showed similar localization in the proliferative 
compartment in 76% of samples. However with increasing grades of dysplasia, the 
expression of cyclin A shifted toward the upper crypts and surface epithelium. In 
non-dysplastic tissue, only 24% of patients express cyclin A at the mucosal surface 
compared with 59% of low grade dysplasia patients, 87% of high grade dysplasia 
patients and 100% of adenocarcinoma patients (Lao-Sirieix, Lovat, & Fitzgerald 
2007). 
Cyclin/CDK Inhibitors 
The tumour suppressor p27 inhibits cyclin E/cdk2 complexes, blocking cell cycle 
progression into S phase. p27 knockout mice have increased risk of oesophageal 
cancer compared to wild type mice and low levels or absence of p27 are associated 
with a worse prognosis in human colon, stomach, lung and prostate cancers (Ellis 
and Loda 2004;Ellis, Xu, & Kulke 2001;Singerland and Pagano 2000).  In Barrett's 
oesophagus and oesophageal adenocarcinoma lack of p27 expression is associated 
with malignant transformation and a poorer prognosis (Ellis & Loda 2004).  In non-
dysplastic Barrett's mucosa p27 expression is nuclear but in dysplastic mucosa, 
staining is often cytoplasmic. Low levels of p27 expression correlate with higher 
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histological grade, depth of invasion and lymph node metastasis in patients with 
oesophageal adenocarcinoma (Singh, Lipman, Goldman et al. 1998).  Nuclear 
localization of p27 is essential for its growth-inhibiting function, and loss of 
expression or altered localization in adenocarcinoma are associated with tumour 
progression and adverse prognosis, suggesting that p27 has a role in preventing 
progression of Barrett's epithelium to adenocarcinoma. 
7.5.2 Insensitivity to Anti-growth Signals 
Normal cell growth is restrained by inhibitory signals which block proliferation by 
inducing quiescence or permanent growth arrest (cellular senescence). Most anti-
growth signals are controlled by the retinoblastoma gene protein (p185 Rb) at the G1 
checkpoint. However, tumour cells can overcome this inhibition by inactivating 
tumour suppressor genes via mutation, allelic deletion (loss of heterozygosity) or 
promoter hypermethylation. Loss of the retinoblastoma gene itself seems to be rare in 
Barrett's metaplasia, but abnormalities in genes such as CDKN2A (encoding p16) and 
TP53, which normally block Rb phosphorylation and its activation, are relatively 
frequent. 
p16, tumour suppressor gene 
p16 (INK4 or CDKN2A) is a tumour suppressor gene on chromosome 9p21. p16 
protein binds to and inhibits cdk4/6, resulting in reduced phosphorylation of the 
retinoblastoma protein and inhibition of cell cycle progression through G1. Many 
studies have analysed p16 in cancers but fewer have examined premalignant lesions. 
Paulson and colleagues suggest that inflammation caused by exposure of 
oesophageal mucosa to acid and bile is a potential source of oxidative damage 
(Paulson, Galipeau, Xu et al. 2008). Reactive oxygen and nitric oxide species may 
mediate mutations, including inactivation of p16, with subsequent uncontrolled 
cellular proliferation and disease progression (Kerkhof, Kusters, van Dekken, 
Kuipers, & Siersema 2007).  Early loss of heterozygosity appears to be a common 
mechanism of p16 inactivation associated with subsequent clonal expansion along 
the Barrett segment, favouring further mutations and facilitating disease progression  
(Kerkhof, Kusters, van Dekken, Kuipers, & Siersema 2007;Maley, Galipeau, & Li 
2004).  Other genetic and epigenetic events leading to loss of p16 include 
hypermethylation of CpG islands or allelic deletions. Immunohistochemistry has 
shown abnormalities of p16 expression in all grades of dysplasia. In Barrett's mucosa 
without dysplasia, p16 staining is nuclear. As dysplasia progresses, nuclear staining 
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wanes while cytoplasmic positivity increases - an early signal and a potential 
mechanism of further genetic changes (Shi, Bhagwandeen, & Leong 2008).  A 
prospective study has shown that 9pLOH, 17pLOH and aneuploidy together predict 
progression to adenocarcinoma, but further studies are needed (Galipeau, Li, Blount 
et al. 2007). 
7.5.3 Avoidance of Apoptosis 
TP53, tumour suppressor gene 
Neoplastic cells must avoid apoptosis to expand their numbers. Loss of p53 allows 
cells to bypass apoptosis and proliferate. TP53 is a tumour suppressor gene which 
encodes the protein (p53) involved in regulation of cell cycle progression, DNA 
repair, cellular senescence and apoptosis. It induces expression of p21 and mediates 
both G1 and G2/M arrest. Both p53 and p21 prevent cells with DNA breaks from 
entering DNA synthesis, holding them back until they are repaired, or if repair is not 
possible, directing them to undergo apoptosis (Vousden and Lane 2007).  p53 has a 
central role in human malignancy, being mutated in at least 50% of all malignant 
tumours (Wijnhoven, Tilanus, & Dinjens 2000).  Mutations in TP53 have been 
reported in primary oesophageal adenocarcinomas and high grade Barrett's mucosa, 
in which both alleles are lost, one by point mutation (90%) and the second by LOH 
(Wijnhoven, Tilanus, & Dinjens 2000).  LOH refers to the loss of normal function of 
the other allele of a gene when the first allele is already inactivated. Point mutations 
of TP53 in oesophageal adenocarcinomas are often G:C to A:T transitions resulting 
from endogenous mechanisms such as exposure to oxygen and nitric oxide radicals. 
Mutations in TP53 frequently increase the half life of p53, leading to increased levels 
of protein expression which can be detected by immunohistochemistry as unusually 
intense nuclear staining. In contrast normal (wild type) p53 has a short half life and is 
not readily detectable at all or is detected at low levels only (Keswani, Noffsinger, 
Waxman et al. 2006).  Although p53 mutations are common in adenocarcinoma, they 
are relatively uncommon in non-dysplastic Barrett's oesophagus and low grade 
dysplasia. Patients with high grade dysplasia often overexpress p53, suggesting that 
TP53 mutation may play a role in the transition from low to high grade dysplasia 
(Ross, Kinney, Larghi et al. 2005;Younes, Lebovitz, Lechago et al. 1993).  Younes 
showed that p53 accumulation increased along the metaplasia-dysplasia-carcinoma 
sequence (0%, 9% and 87% for no dysplasia, LGD and HGD). On follow up studies, 
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only one of 21 patients with p53-negative biopsies developed dysplasia (Younes, 
Ertan, Lechago et al. 1997). 
Overexpression of p53 may therefore be a marker of progression in patients 
histologically indefinite for dysplasia or with LGD only.   Sikkema showed that p53 
overexpression and Ki67 were predictive of progression from metaplasia to cancer 
(Sikkema, Kerkhof, Steyerberg et al. 2009).  However, some TP53 mutations 
produce a truncated p53 protein undetectable by immunohistochemistry (Keswani, 
Noffsinger, Waxman, & Bissonnette 2006). Therefore, protein expression is neither 
as sensitive nor as specific as gene analysis. Coggi et al showed that in patients with 
p53 mutations, there was no detectable accumulation by immunohistochemistry in 
31% cases (Coggi, Bosari, Roncalli et al. 1997).  In addition, inflammation, DNA 
damage and other cellular stresses can upregulate p53. So, not all p53 mutations 
result in p53 protein accumulation, and not all protein accumulation is due to 
mutations (Keswani, Noffsinger, Waxman, & Bissonnette 2006).  In an attempt to 
overcome some of these difficulties, a study of 325 patients with Barrett's 
oesophagus investigated the prevalence of 17pLOH as a marker of dysplasia and risk 
of progression to cancer (Reid, Prevo, Galipeau et al. 2001).  The prevalence of 
17pLOH was 6% in non-dysplastic Barrett's mucosa, 57% in HGD, and it was an 
independent predictor of progression to adenocarcinoma. Of patients with baseline 
17p LOH, 37% developed cancer whereas only 3% without 17p LOH progressed to 
cancer.  These TP53 mutations seem to confer advantage to the mutant clone via 
three mechanisms: suppression of apoptosis, prevention of cell cycle arrest and 
senescence, permitting genetic instability (Maley 2007).  Despite some of the 
limitations associated with the p53 protein expression, p53 is a well studied potential 
marker of neoplastic progression in Barrett's epithelium and newer genotyping 
technology may overcome some of the current limitations surrounding p53. 
Alpha-methylacyl-CoA racemase 
Alpha-methylacyl-CoA racemase (AMACR) is a protein expressed in peroxisomes 
and mitochondria of normal liver and kidney cells, and plays a role in the beta-
oxidation of branched chain fatty acids (Maley, Galipeau, Finley et al. 2006).  
AMACR overexpression was initially reported in prostate cancer and high grade 
intraepithelial neoplasia but it is also expressed in dysplastic cases of Barrett’s 
oesophagus (Dorer and Odze 2006).  Immunohistochemistry suggests AMACR is not 
expressed in non-dysplastic Barrett’s epithelium, but is present in low grade 
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dysplasia (38%), high grade (81%) and adenocarcinoma (72%) (Maley, Galipeau, 
Finley, Wongsurawat, Li, Sanchez, Paulson, Blount, Risques, Rabinovitch, & Reid 
2006).  The exact role of AMACR in the oesophageal epithelium is unclear but its 
overexpression may be a useful adjunct in diagnosing dysplasia in difficult cases.  
Future studies are required to fully explore the role of AMACR and its prognostic 
significance. 
7.5.4 Invasion and Metastases 
Wnt signalling is a key pathway in normal human organogenesis, but aberrant 
activation is implicated in carcinogenesis. Key genes and proteins in this pathway 
include the adenomatous polyposis coli (APC) gene, -catenin and E cadherin and 
although much is known about these molecules, mechanisms by which they interact 
are still incompletely understood (Adams and Enders 2008). APC protein contains -
catenin degradation sites and E cadherin has -catenin binding sites. Disturbance of 
normal interactions between these molecules can lead to loss of growth inhibition or 
increased tumour invasiveness.   
Beta-catenin 
β-catenin mediates cell-cell adhesion via the transmembrane glycoprotein E-
cadherin. In carcinomas loss of the E-cadherin-catenin complex, which is involved in 
the maintenance of epithelial integrity, may confer increased invasiveness and 
metastatic ability on malignant cells (Washington, Chiappori, Hamilton et al. 1998).  
Beta-catenin is also an oncoprotein that can lead to carcinogenesis when APC--
catenin-TCF/LEF (T-cell factor/lymphoid enhancer factor) signalling is disrupted. 
This is the so-called canonical Wnt signalling pathway.  -catenin and its integral 
role within the Wnt signalling pathway shall be discussed in greater detail in the 
following chapter. 
E-cadherin 
E-cadherin is a transmembrane protein essential for maintenance of cells during 
development. The extracellular domain of E-cadherin mediates adhesion with 
cadherins on neighbouring cells, while the intracellular domain interacts with 
cytoplasmic proteins linked to actin via catenins. It plays a crucial role in cell-cell 
adhesion and reduced expression is an important molecular event concerned with 
invasion and metastases (Bailey, Biddlestone, Shepherd et al. 1998).  In conjunction 
with -catenin several studies have shown decreased E-cadherin expression is 
130 
 
associated with progression from Barrett's metaplasia to adenocarcinoma (Clement, 
Jablons, & Benhattar 2007;Kerkhof, Kusters, van Dekken, Kuipers, & Siersema 
2007).  Reduced E-cadherin expression promotes epithelial cell invasiveness and 
metastasis in various human cancers (Nair, Naidoo, & Chetty 2005).  Recent studies 
have shown that aberrant nuclear localisation of E-cadherin is present in some 
tumours (pancreatic endocrine tumours, oesophageal squamous and colorectal 
cancers) and associated with poor prognosis due to increased invasiveness of 
tumours (Chetty, Serra, & Asa 2008;Salahshor, Naidoo, Serra et al. 2008). Further 
research is required into the role of Wnt signalling in oesophageal adenocarcinoma. 
7.5.5 Ploidy 
Aneuploidy (abnormal cellular DNA content) is associated with increased risk of 
progression to dysplasia and adenocarcinoma. A large continuing phase 4 study by 
Reid et al has shown that patients with no dysplasia, indefinite or low grade dysplasia 
at baseline biopsy, and a diploid cell population (no aneuploidy) are at low risk of 
progression to adenocarcinoma (Reid, Levine, Longton et al. 2000).  Patients in 
whom baseline biopsies demonstrated aneuploidy, tetraploidy (4N DNA content) or 
high grade dysplasia had five year cancer incidences of 43%, 56% and 59%, 
motivating more intense surveillance. In some centres, like Seattle, flow cytometry to 
assess aneuploidy is routinely undertaken in the assessment of Barrett's biopsy 
samples. 
Despite good evidence in favour of ploidy as an early risk marker in Barrett's 
oesophagus, it is little used in clinical practice, probably because of its requirements 
in terms of costs and instrumentation and reimbursement issues. Flow cytometry has 
the disadvantage of divorcing DNA content measurements from morphology. Image 
cytometry of intact nuclei from thick sections partly addresses this issue by allowing 
histological control of the material submitted for analysis. Image cytometry on 
histological sections gives the best correlation of morphology and DNA content 
measurements but introduces its own problems with nuclear truncation and 
overlapping. Nevertheless, DNA content measurements are possible on sections 
around 7 microns thick, and further evaluation in this area would be desirable. 
Fleskens and colleagues showed that combining DNA content measurement with the 
cell cycle marker Ki67 facilitates detection of aneuploid cell populations in oral 
premalignant conditions, and demonstrated combined immunofluorescence and 
staining with a fluorescent DNA intercalating agent (DRAQ5) under stoichiometric 
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staining conditions (Fleskens, Takes, Otte-Holler et al. 2010).  Aneuploidy is a 
biomarker which carries significant potential as a clinical biomarker, although cost 
and technical issues need reviewed before its routine use is implemented in hospital 
laboratories. 
7.5.6 Inflammation 
The association between inflammation and cancer was first described by Virchow in 
1863 when he observed that leucocytes were present in cancerous tissues 
(Colleypriest, Palmer, Ward et al. 2009).  Since then the role of systemic and local 
inflammation has been documented in many malignancies (Roxburgh and McMillan 
2010).  Reflux oesophagitis is often associated with Barrett’s oesophagus and various 
cytokines (such as interleukins IL-1 and IL-8) are increased in Barrett’s metaplasia.  
Two key factors which appear to link Barrett’s oesophagus, inflammation and 
progression to dysplasia are nuclear factor κB (NFκB) and CDX genes (Colleypriest, 
Ward, & Tosh 2009).  Inflammatory profiling as a biomarker for Barrett’s 
oesophagus and risk of disease progression would be appealing, and an excellent 
target for therapeutic interventions.  The role of anti-inflammatory agents and 
Barrett’s oesophagus is currently being assessed by the AsPECT trial, the results of 
which are eagerly awaited (Jankowski & Barr 2006). 
Nuclear Factor Kappa-B 
Transcription factor NFB regulates pro-inflammatory genes, differentiation and 
growth. It exists in the cytoplasm of most cells in an inactive form complexed to the 
inhibitory molecule IB which prevents the migration of the heterodimer to the 
nucleus. Cytokines, oxygen free radicals and acid stimulate translocation of NFB to 
the nucleus, where it binds specific DNA sites and upregulates transcription of genes 
involved in inflammatory processes and immune responses (Yamamoto and Gaynor 
2001).  NFB has been linked to lung fibrosis, autoimmune arthritis and IBD 
(Rogler, Brand, Vogi et al. 1998). 
Over the years there has been much interest in the role of inflammation, either local 
or systemic, in the development of cancer. The NFB pathway is therefore of interest 
in Barrett's epithelium, where there is often an associated inflammation.  O'Riordan 
et al showed a stepwise increase in expression of NFB, IL-8 and IL- 1in patients 
with Barrett's mucosa adjacent to adenocarcinoma (O'Riordan, Abdel-Latif, Ravi et 
al. 2005).  They also showed that NFB was upregulated in 60% of patients with 
132 
 
Barrett's oesophagus (all grades). In those with metaplasia but no dysplasia, 50% had 
NFB overexpression; this rose to 63% in LGD and 100% in HGD. Adenocarcinoma 
patients with increased expression of NFB had elevated levels of cytokines IL-8 
and IL-1. Further studies are required to determine the role of these molecules in the 
metaplasia-carcinoma sequence. 
Cyclooxygenase-2 (COX-2), an Oncogene 
COX-1 and the oncogene COX-2 cyclooxygenases mediate synthesis of 
prostaglandins from arachidonic acid. COX-1 is generally expressed whereas COX-2 
is undetectable in most tissues. It is induced by cytokines, gastric acid and bile acids. 
Overexpression of COX-2 in vitro has effects from increasing cell proliferation, 
reducing apoptosis, promoting angiogenesis, decreasing E cadherin expression and 
increasing the invasive and malignant potential of cells (Maley, Galipeau, & Li 
2004;Shirvani, Ouatu-lascar, & Kaur 2000).  COX-2 is detectable in metaplastic 
Barrett's mucosa and is overexpressed in high grade dysplasia and adenocarcinoma. 
Its expression in LGD is similar to that of metaplasia in the absence of dysplasia 
(Morris, Armstron, Bigley et al. 2001).  Other studies have reported a progressive 
increase in COX-2 expression along the metaplasia-dysplasia sequence (Kuramochi, 
Vallbohmer, Uchida et al. 2004).  Different techniques have been used to evaluate 
COX-2 expression such as immunohistochemistry, western blotting and polymerase 
chain reaction, with inconsistent results. While COX-2 overexpression may play a 
role in Barrett's oesophagus, at present there is not enough data to support a useful 
role as a biomarker. 
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7.6 Conclusions 
Barrett's 'columnar lined' oesophagus is important as the precursor of oesophageal 
adenocarcinoma, which has the most rapidly rising incidence of any solid tumour in 
the western world, with Scotland having some of the highest rates in the world 
(Jankowski, Provenzale, & Moayyedi 2002).  Advances in disease management over 
the last decade have seen improvements in endoscopic therapies to treat high grade 
dysplasia, better imaging and biopsy detection systems, and several candidate 
molecular biomarkers. At present, dysplasia develops in around 5% of patients with 
Barrett's oesophagus, with 10-50% progressing to high grade dysplasia and cancer 
over 2-10 years. The remainder remain static. Despite the risk of malignant 
progression, only 2-3% of the Barrett's oesophagus patients will die from 
oesophageal adenocarcinoma, and overall life expectancy is not very different from 
those without the disease.  
The role of biomarkers in Barrett's oesophagus is potentially two fold. Firstly, to 
identify patients at risk of progression to high grade dysplasia and cancer, so they can 
be diagnosed and treated earlier with endoscopic therapies, minimising morbidity 
and avoiding the morbidity and mortality of oesophagectomy. Secondly, and almost 
equally useful, markers able to identify patients at little or no risk of progression 
would allow less frequent surveillance endoscopy and biopsy for low risk patients, 
minimising health care costs and patient anxiety. Being able to reassure a patient of a 
low progression risk is at least as important as to be able to assign a high risk, given 
limited evidence of effective risk management. 
Barrett's oesophagus is a complex disease process with significant genetic 
heterogeneity, and greater heterogeneity identified within a Barrett's segment is itself 
a predictor of disease progression (Maley, Galipeau, Finley, Wongsurawat, Li, 
Sanchez, Paulson, Blount, Risques, Rabinovitch, & Reid 2006).  Many individual 
mutations have been identified, but no one marker has yet been identified with ideal 
characteristics or the potential to fulfil clinical requirements on its own. It may be 
naïve to expect a single biomarker will fulfil all expectations in such a complex 
disease and many centres now think biomarker panels may be more likely to aid 
management. 
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Dysplasia, our 'gold' standard biomarker, and aneuploidy are at present the only 
markers routinely used in clinical practice. Many biomarkers have not passed 
through phase III or IV trials and much more work needs to be performed in this area 
before any of them is established on secure evidence as a basis for clinical practice. 
Multicentre trials will be required for assessment and integration of both clinical and 
molecular variables so comprehensive conclusions can be made. This will require a 
degree of cooperation rarely so far seen in the field, but without which greater 
understanding and appropriate management of Barrett's oesophagus will be further 
delayed. 
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Chapter 8  
The Wnt Signalling Pathway –A mouse model 
ancer cells are characterised by their ability to proliferate outwith normal 
control mechanisms.  Hanahan and Weinberg proposed seven hallmarks 
which are applicable to all cancer cells - (1) self-sufficiency in growth 
signals; (2) insensitivity to inhibitory growth signals; (3) evading apoptosis; (4) 
sustained angiogenesis; (5) limitless reproductive potential; (6) tissue invasion and 
metastasis and (7) inflammation (Hanahan & Weinberg 2011).  A series of mutations 
and epigenetic changes are required for cancerous change within cells.  Changes in 
the configuration, concentration or location of certain molecules involved in key 
signalling pathways can lead to malignant transformation (Doucas, Garcea, Neal et 
al. 2005).  One example of such important signalling pathways involved in human 
cancer is the Wnt canonical pathway.  Under normal conditions the Wnt pathway 
plays a key role in embryogenesis and organogenesis in humans, but when aberrantly 
activated is associated with carcinogenesis.  More than 90% of colorectal cancers 
have a mutation which aberrantly activates the Wnt pathway but little is known about 
the role of Wnt signalling in oesophageal adenocarcinoma and Barrett’s oesophagus 
(Giles, van Es, & Clevers 2003).  The aim of the following two chapters is to further 
understand the role of Wnt signalling in Barrett’s oesophagus and dysplasia in 
human tissue with a complementary mouse model. 
 
 
C 
136 
 
8.1 Introduction 
8.1.1 An Overview of Wnt Signalling Pathway 
Wnt signalling is an ancient signalling pathway crucial to development and 
morphogenesis in embryos.  In adults it is responsible for the maintenance of normal 
tissue and control of stem cell functions.  The role of Wnt in cancer became clear 
more than 20 years ago in viral carcinogenesis experiments in mice, where the 
presence of Wnt1 was associated with the development of breast tumours 
(Shackleford, MacArthur, Kwan et al. 1993).  In recent years, aberrant activation of 
the Wnt pathway is associated with many malignancies.  
The Wnt family of genes code for a group of glycoproteins which are responsible for 
physiological responses within their target cells as a result of interactions with cell 
surface receptors (Reya and Clevers 2005).    The canonical Wnt pathway describes 
the series of events that occur when extracellular Wnt ligands bind to their cell 
surface receptors (Frizzled proteins), causing activation of the intracellular 
Dishevelled proteins which ultimately results in changes in the amount of β-catenin 
which reaches the nucleus.  β-catenin is a key component on the Wnt pathway as its 
presence in the nucleus allows transcription of various target genes involved in 
proliferation. 
The canonical Wnt pathway shall be described in further detail as a clear 
understanding of this pathway is required to understand the role of β-catenin in 
carcinogenesis (Figure 8.1).  In the absence of a Wnt signal, two scaffolding proteins 
axin and adenomatous polyposis coli (APC) form a destruction complex, which 
binds with newly synthesised β-catenin.  Glycogen synthase kinase-3β (GSK3), a 
kinase also bound to the destruction complex then phosphorylates specific residues in 
the amino terminus of β-catenin.  The phosphorylated β-catenin complex binds to the 
β-TrCP protein, and is tagged by a small protein called ubiquitin, ready for 
proteasomal degradation (Figure 8.1A).  Wnt ligand receptor occupancy causes 
phosphorylation of the Dishevelled protein which leads to dissociation of the 
APC/axin/GSK complex.  This releases β-catenin which accumulates in the 
cytoplasm and is transferred to the nucleus, where it binds to T cell factors (TCF) 
and activates a number of proliferative target genes such as cyclin D1, c-myc and c-
jun (Figure 8.1B).   
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Figure 8.1 Overview of the canonical Wnt signalling pathway 
 
 
Reproduced with permission from (White, Chien, & Dawson 2012) 
(A) In the absence of a Wnt signal, cytoplasmic β-catenin is phosphorylated by a destruction complex 
(Axin, APC and GSK3).  It is targeted for ubiquitination and subsequent degradation.  This 
maintains low levels of cytoplasmic and nuclear β-catenin. 
(B) In the presence of a Wnt ligand, the Frizzled and Dishevelled proteins bind to axin, thus 
disrupting the destruction complex.  β-catenin remains unphosphorylated and is translocated to 
the nucleus which it bind with TCF/LEF transcription factors, displaces Groucho and allows 
activation of nuclear transcription genes (eg cyclin D, c-myc). 
 
8.1.2 Wnt and Cancer 
The canonical Wnt signalling pathway is frequently activated in human cancers, 
either by activating mutations in β-catenin or inactivating mutations in the tumour 
suppressor genes (APC or axin) (Adams & Enders 2008).  The most carefully studied 
model of Wnt signalling is found in colon cancer where mutations in APC and β-
catenin are not uncommon (Pinto and Clevers 2005).  Mutations of the APC gene 
occur early in colorectal cancer, leading to reduced β-catenin degradation and 
increased expression of transcription factors promoting carcinogenesis (Segditsas 
and Tomlinson 2006).  β-catenin mutations, particularly common in epithelial 
tumours, suppress APC dependent binding and degradation of β-catenin.  Tyrosine 
kinases such as epidermal growth factor, are commonly increased in cancer, resulting 
in hyperphosphorylation of tyrosine on β-catenin, making it unable to bind to 
cadherins.  This reduces cell to cell adhesion and may account for invasion and 
metastases (Hoschuetzky, Aberle, & Kemler 1994). 
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Wnt ligands 
Studies in human cell lines and animal models have shown that Wnt ligands play a 
role in carcinogenesis.  A number of head and neck cancer cell lines have increased 
levels of Wnt1 mRNA, and blocking Wnt1 signalling leads to reduced cell 
proliferation and increased apoptosis (Rhee, Sen, & Lu 2002).  The levels of β-
catenin and cyclin D1 were also reduced.  Wnt2 mRNA is detected in colon cancer 
but absent in normal colonic cells (Holcombe, Marsh, & Waterman 2002).  In most 
human cancers, Wnt proteins themselves are not linked to carcinogenesis, but 
mutations mimicking Wnt stimulation leads to activation of the pathway and its 
downstream effects.  The Wnt signalling pathway is now known to be involved in 
various tumours such as colon cancer, melanoma and leukaemia. 
βeta-catenin 
β-catenin is a protein involved in two independent processes - cell to cell adhesion 
and signal transduction.  β-catenin is the key mediator of the canonical Wnt 
signalling pathway.  In its unphosphorylated state, it migrates to the nucleus where it 
interacts with TCF and leads to the activation of tumour promoting genes such as c-
myc, cyclin D1 and MMP-7. 
β-catenin plays an important role in maintaining cell-cell adhesion by binding to the 
cytoplasmic domain of cadherins, particularly E-cadherin, and to α-catenin which 
links the cadherin-catenin complex to the actin cytoskeleton (Schuhmacher, Becker, 
& Oswald 1999).  Disruption of β-catenin binding to cadherin results in loss of cell-
cell adhesion and leads to loss of tissue architecture and invasion.  Reduced 
expression of β-catenin in tumour cells may lead to impairment of the cadherin-
catenin system and one study has shown a correlation between reduced expression of 
β-catenin and poor prognosis from oesophageal adenocarcinoma (Krishnadath, 
Tilanus, van Blankenstein et al. 1997).  Unlike colon cancer, mutations in APC, axin 
and β-catenin are rare in oesophageal adenocarcinoma, and Wnt signalling appears to 
be activated upstream of β-catenin.   
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8.1.3 Wnt and Oesophageal Development 
During embryonic development, the single endodermal tube is lined with a ciliated 
columnar epithelium before it differentiates into two separate tracts (the respiratory 
and upper gastrointestinal tracts) at 7 weeks gestation.  The embryonic oesophagus 
remains covered with a columnar epithelium until 17 weeks when the oesophagus is 
progressively replaced by a squamous epithelium.  The exact mechanisms underlying 
the mucosal transformation are unclear but it is thought that signalling pathways such 
as Hedgehog, Notch and Wnt may play a role.  In the normal gut, activated Wnt 
signalling is required for the development and maintenance of the midgut and 
hindgut (small and large intestine), whereas formation of the foregut (oesophagus 
and stomach) is thought to result, at least in part, from a lower level of Wnt 
signalling (Gregorieff, Grosschedt, & Clevers 2004).  Perhaps aberrant activation of 
Wnt signalling in adults may be involved in Barrett’s metaplasia, or disease 
progression. 
  
140 
 
8.2 Study rationale and aims 
Barrett’s mucosa is predisposed to genetic and epigenetic changes, leading to low 
and high grade dysplasia, with high grade dysplasia carrying the greatest risk of 
progression to oesophageal adenocarcinoma (Shaheen & Richter 2009).  Despite 
intensive research, the molecular mechanisms underlying Barrett’s metaplasia and 
disease progression remain unclear.  Previous chapters have shown molecular risk 
biomarkers have been sought with modest success and at present dysplasia remains 
the most reliable clinical marker of patients at risk of progression.  There is therefore 
a real need to be able to identify those at greatest risk of malignant transformation.  
Without an improved molecular understanding of Barrett’s metaplasia, clinically 
useful prognostic biomarkers will be delayed.  With this in mind, the Wnt signalling 
pathway and its role in Barrett’s oesophagus and dysplasia will be investigated in 
human tissue with a complementary mouse model. 
The aim of this pilot study was to determine whether aberrant activation of Wnt 
signalling lead to phenotypic changes of metaplasia or dysplasia in a mouse model. 
  
141 
 
8.3 Methods 
8.3.1 Mouse Model of Wnt Signalling 
The Ah-Cre-ER
+
 β-catenin ∆ex3/∆ex3 mouse model with tamoxifen and β-
napthoflavone-inducible gastrointestinal (GI) expression of activated β-catenin was 
used to upregulate Wnt signalling in the mouse oesophagus.  This mouse model was 
chosen due to its availability in the Beatson Institute and its previous successful use 
in the upregulation of the Wnt signalling pathway in colorectal cancer.  In this 
model, the Ah (aryl hydrocarbon) promoter directs expression of Cre-ER in the GI 
tract.  Treatment with tamoxifen and β-napthoflavone activates Cre recombinase 
activity which generates the constitutively activated form of β-catenin lacking exon 3 
and its associated inhibitory phosphorylation sites (Harada, Tamai, Ishikawa et al. 
1999;Kemp, Ireland, Clayton et al. 2004). 
Outbred mice segregating for the C57BL6J and S129 genomes were used from 6-10 
weeks of age.  The following alleles were used: Ah-Cre-ER and Catnb exon3fl.  To 
induce recombination using the Ah-Cre-ER construct, mice were given four 
intraperitoneal injections of beta-napthoflavone (Sigma, Dorset, UK) and tamoxifen 
(Sigma, Dorset, UK) in corn oil at 80mg/kg over two days.  At the appropriate time 
point, ie weight loss of 10%, or when showing signs of illness (hunched, pale feet), 
the mice were sacrificed and the oesophagus harvested, opened and fixed flat in 10% 
neutral buffered formaldehyde overnight.  The oesophagus was embedded in paraffin 
and stained with H&E for initial pathological evaluation. 
8.3.2 Tissue analysis 
H&E Assessment 
The H&E slides for each mouse were analysed with the assistance of Dr Catherine 
Lamm, a veterinary pathologist (University of Glasgow, Garscube Estate, Glasgow).  
Each slide was assessed for the type of mucosa present, any nuclear atypia, the 
presence of mitotic figures and any disorganisation within the tissue specimen.  Each 
slide was assessed blindly, i.e the pathologist was unaware of whether the tissue 
came from a wild type mouse, or one containing the activated β-catenin∆ex3 allele. 
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Immunohistochemistry 
Serial sections (4μm thick) were cut from the paraffin embedded blocks of mouse 
oesophagus, and immunohistochemistry using the EnVision kit (Dako, Glostrup, 
Denmark) on a Dako autostainer was performed.  The protocol used for 
immunohistochemistry was similar for most experiments, although the buffer and 
primary antibody varied.   
Sections were initially deparaffinised in xylene and rehydrated in serial alcohols.  
Heat induced epitope retrieval was performed on a Thermo Pre-treatment module (25 
minutes at 97
o
C) with an appropriate buffer for each antibody (either 10MM sodium 
citrate (pH6), or 1 mM EDTA (pH8)).  Endogenous peroxidase activity was blocked 
by incubation with hydrogen peroxidase (EnVision, Dako) for six minutes.  All 
primary antibodies (see Table 8.1 for further details) - Ki67, β-catenin, cyclin D1, c-
myc, Sox9, villin, CK8, CLDN3 were incubated at room temperature for 45 minutes, 
followed by the appropriate secondary antibody.  3,3-diaminobenzidine 
tetrahydrochloride was used as chromagen.  Sections were counterstained with 
haematoxylin, dehydrated in alcohol and mounted from xylene.  The special stain, 
Alcian blue-periodic acid Schiff (PAS), a marker for the presence of goblet cells was 
used to stain the mouse oesophagus.  
8.3.3 Ethical approval 
The study was carried out at the Beaton Institute for Cancer Research under the 
supervision of Peter Adams and his lab staff.  All mouse experiments were 
performed under the UK Home Office guidelines. 
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Table 8.1 Primary antibodies for immunohistochemistry on mouse oesophagus  
 
Antibody Clone Dilution Manufacturer Catalogue Number 
Anti-Sox9  1:700 Millipore, Livingstone, UK AB5535 
Cyclin D1 SP4 1:50 Dako, Glostrup, Denmark M3635 
Ki67 SP6 1:200 Thermo Fisher Scientific, Cheshire, UK RM-9106 
β catenin 14 1:1200 BD Transduction Laboratories, San Jose, CA 610154 
Villin   Abcam, Cambridge, UK ab52102 
MUC-5 CLH2  Leica, Milton Keynes, UK NCL-HGM-45M1 
CK8  1:250 University of Iowa, USA Troma-1 
CLDN-3  1:100 Thermo Fisher Scientific, Cheshire, UK Rb9251 
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8.4 Results 
Twelve Ah-Cre-ER β-catenin ∆ex3 mice were used in this initial study (wild type, 
n=3; heterozygous, n=4; homozygous, n=5).  There were 6 males and 6 females with 
a mean life expectancy of 15 days (range 4-25 days).  The life expectancy of the 
homozygous mice was significantly less than the heterozygous or wild type mice 
(p<0.001) (Figure 8.2).  The wild type mice were culled if they were showing signs 
of illness, or at the end of the experiment. 
Figure 8.2 Mean survival in Ah-Cre-ER β-catenin ∆ex3 mice 
 
The mean survival in homozygous Ah-Cre-ER β-catenin ∆ex3 mice was 6.2 days (range 4-11), in 
heterozygous mice 20.2 days (range 18-21) and wild type mice 22.3 days (range 20-25).  There was a 
significant reduction in survival in the homozygous Ah-Cre-ER β-catenin ∆ex3 mice (p<0.001). 
 
Histological assessment of mouse oesophagus 
The wild type mouse oesophagus (expressing Ah-Cre-ER only) showed a normal 
keratinised squamous epithelium with organised architecture and no nuclear atypia 
(Figure 8.3A).   After induction with tamoxifen, the homozygous Ah-Cre-ER
+
 β-
catenin 
∆ex3
 mice (harbouring two alleles of activated β-catenin ∆ex3) developed a very 
abnormal oesophageal mucosa (Figure 8.3C).  The epithelium displayed nuclear 
atypia with increased numbers of suprabasal mitotic figures.  The normal maturation 
pattern was disrupted with disorganisation of cells resulting in the formation of 
unusual intraepithelial clusters of cells.  Many of these features, namely disruption of 
0
5
10
15
20
25
HOM HET WT
M
e
an
 s
u
rv
iv
al
 (
d
ay
s)
 
Presence of mutated beta-catenin 
145 
 
maturation and increased proliferation, are classically associated with dysplasia but 
for the purposes of this study, these changes shall be labelled “quasi-dysplasia” as 
there is, as yet, little evidence to suggest these areas carry malignant potential.  Little 
effect was observed on activation a single β-catenin ∆ex3 allele in the heterozygous 
mice, besides a slightly thickened basal layer (Figure 8.3B).  Table 8.2 summarises 
the histological differences between the three groups of mice.  The term “dysplasia 
counts” relates to the number of abnormal nuclei visualised within the section.  There 
was no phenotypic change to a columnar type mucosa identified on H&E staining 
within this specific mouse model. 
 
Table 8.2 Histological description of Ah-Cre-ER β-cateninΔex3 mice 
 
 Wild type 
n=3 
Heterozygous 
n=4 
Homozygous 
n=5 
p value * 
Mitotic figures in basal layer 2 (1-3) 3.25  (2-6) 4 (3-8) 0.061 
Nuclear disorganisation Absent Absent Present 0.002 
Nuclei (basal layer to surface) 3 (2-3) 4.5 (3-5) 11.5 (5-20) 0.023 
Intraepithelial clusters Absent Absent Present 0.002 
Dysplasia counts 0 0 14 (2-50) 0.007 
 
Table describes the histological features identified on H&E staining of mouse oesophagus (n=12).   
* p value describes difference in histology between groups using Chi square test 
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Figure 8.3 Histological assessment of mouse oesophagus (H&E stain)  
   
A - Ah-Cre-ER β-catenin
∆ex3
 wild type demonstrating 
keratinised squamous mucosa of normal mouse 
oesophagus. 
B - Ah-Cre-ER β-catenin
∆ex3
 heterozygous mouse 
oesophagus with normal squamous mucosa similar to wild 
type.  Note few more cells in basal layer.  
C - Ah-Cre-ER β-catenin
∆ex3
 homozygous mouse oesophagus 
demonstrating a thickened squamous mucosa with areas of 
nuclear atypia. 
 
H&E staining of mouse oesophagus (magnification x20) * Cell with abnormal nucleus, ** Area of nuclear atypia forming cluster of disorganised cells 
(intraepithelial cluster) in keeping with abnormal maturation 
B A C 
* 
** 
100µm 
Basement membrane 
Mucosal surface 
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β-catenin expression in Ah-Cre-ER∆ex3 mouse oesophagus 
β-catenin expression in the oesophageal mucosa of the wild type mouse was 
membranous with no evidence of nuclear staining (Figure 8.4 Panel A).  After 
induction of activated β-catenin, the homozygous mouse mucosa showed a change in 
β-catenin expression with upregulation of nuclear β-catenin, particularly in the areas 
of “quasi-dysplasia”.  However, nuclear β-catenin was not distributed uniformly 
throughout the epithelium; instead, activation was more focal likely due to mosaic 
Cre-ER mediated activation of β-cateninΔex3 in cells throughout the epithelium 
(Figure 8.4 Panel B).  Interestingly the focal activation of β-catenin coincided with 
areas of nuclear atypia with membranous staining preserved in “non-dysplastic” 
cells.  There was no change in the expression of β-catenin in heterozygous mice. 
Wnt target gene expression in Ah-Cre-ER∆ex3 mouse oesophagus 
The Wnt target genes cyclin D1, and Sox9 were analysed by immunohistochemistry.  
In wild type mice (and heterozygous mice) cyclin D1 was expressed in the nuclei of 
basal cells and some cells lining the basement membrane, while Sox9 was absent 
(Figure 8.4 Panel A).  However in homozygous mice, upregulation of Wnt target 
genes, cyclin D1 and Sox9, in the oesophageal squamous mucosa coincided with the 
foci of nuclear β-catenin and apparent “quasi-dysplastic” areas (Figure 8.4 Panel B). 
Since Sox9 is a Wnt target gene that is normally expressed in the intestinal 
epithelium but not the oesophageal epithelium (Blache, van de Wetering, Duluc et al. 
2004), its expression in the epithelium of mice expressing activated -catenin, might 
be indicative of change from squamous oesophageal mucosa to an “intestinalised” 
metaplasia, at least at the molecular level. 
Markers of intestinal phenotype in Ah-Cre-ER∆ex3 mouse oesophagus 
To test more completely for molecular changes of metaplasia in the mouse 
oesophagus, a panel of biomarkers and gene products normally associated with a 
columnar epithelium and/or Barrett's oesophagus was assessed.  Alcian blue/PAS, a 
marker of goblet cells often associated with an intestinalised phenotype, did not 
reveal the presence of specific goblet cells within the mouse oesophagus.  With the 
help of Mr Hamish McEwan, a fellow clinical research fellow, further 
immunohistochemistry was performed using villin, MUC-5, CDX2, cytokeratin 8 
(CK8) and claudin-3 (CLDN-3).  However, consistent with the histological analysis, 
there was no increased expression of villin, MUC-5 or CDX2 within this mouse 
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model.  Interestingly there was increased expression of CK8 and CLDN-3 in the 
homozygous mouse, particularly in the areas of nuclear β-catenin expression.  CK8 is 
often expressed in columnar mucosa and CLDN-3 is a marker of intestinal 
differentiation, associated with gastric cancer (Moll, Franke, & Schiller 1982;Satake, 
Semba, Matsuda et al. 2008).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.4 legend (Figure overleaf) Activation of Wnt signalling induces 
“dysplasia-like” features and intestinal gene expression (magnification x20) 
Panel A Ah-Cre-ER
∆ex3 
wild type mouse oesophagus.  H&E stain demonstrating the keratinised 
squamous mucosa of normal oesophagus.  β-catenin staining is membranous and cytoplasmic, with 
cyclin D1 positive cells lining the basement membrane.  There is no evidence of Sox9 expression in 
the wild type mouse. 
Panel B Ah-Cre-ER
∆ex3 
homozygous mouse oesophagus.  H&E stain of homozygous mouse 
demonstrating a thickened squamous mucosa with areas of “dysplasia-like” features such as 
intraepithelial clusters nuclear atypia.  Nuclear β-catenin expression is associated with areas of nuclear 
atypia with positive expression of the Wnt target genes, cyclin D1 and Sox9. 
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Figure 8.4 Activation of Wnt signalling induces “quasi-dysplasia” features 
and intestinal gene expression 
Panel A Wild type mouse Panel B Homozygous Ah-Cre-ER β-catenin 
  
  
  
  
   
H&E H&E 
Sox9 Sox9 
Cyclin D1 Cyclin D1 
β-catenin β-catenin 
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8.5 Discussion 
This study has shown that upregulation of Wnt signalling by means of activated β-
catenin expression, is associated with the development of quasi-dysplasia in the 
mouse oesophagus.   
Wnt signalling is associated with the development of cancer, and increased 
expression levels of Wnt ligands and mutations within key genes are often found in 
colorectal cancer.  However the underlying processes involved in Barrett’s 
metaplasia and progression to dysplasia remain unclear.  The Ah-Cre-ER β-
catenin
∆ex3 
mouse model has shown activation of Wnt signalling is sufficient to 
disrupt the normal architecture of the oesophageal mucosa, generating dysplasia-like 
features within the epithelium.  At a molecular level, activation of Wnt signalling 
induced some features associated with an “intestinalised” mucosa, specifically by 
expression of Sox9, CK8 and CLDN3.  Sox9 is not expressed in the normal mouse 
squamous oesophageal epithelium, but is expressed in the immature quasi-dysplasia 
cells harbouring nuclear β-catenin. 
A recent paper by Kong and colleagues explored the role of Wnt signalling in human 
oesophageal keratinocytes, specifically focusing on the emergence of a Barrett’s 
epithelium from squamous keratinocytes (Kong, Crissey, Stairs et al. 2011).  They 
induced Wnt signalling by expression of CatCLef (a dominant Wnt effector) and 
showed that CatCLef-expressing cells were more proliferative, developed a thicker 
epithelium with cysts, filled with intestinal mucins (MUC5B and MUC17).   
Unfortunately this mouse model failed to show any histological features in keeping 
with columnar metaplasia, or any intestinal mucin staining.  One difficulty with the 
Ah-Cre-ER β-catenin∆ex3 mouse model is the reduced life expectancy of the mice.  
The homozygous mice had a mean survival of only 6 days.  It would appear the mice 
succumbed to other more serious diseases before the oesophageal mucosa had time 
to develop any further histological changes.  A further limitation of the model may 
be a dosage phenomenon in the heterozygous mice, and further work would be 
required to explore this possibility.  Nonetheless, it appears other factors besides Wnt 
signalling are required for the development of a columnar mucosa in the Ah-Cre-ER 
β-catenin∆ex3 mouse model metaplasia within the oesophagus.   
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Taken together, these results indicate that activated Wnt signalling induced only 
selected molecular indicators of metaplasia and did not induce detectable metaplasia 
at the histological level.  However, activation of canonical Wnt signalling did disrupt 
maturation of normal oesophageal squamous epithelium, creating an immature 
phenotype sharing quasi-dysplastic features.  Further studies are required within this 
in vivo field to improve our understanding of the initial transformation from a 
squamous to a columnar epithelium, and while Wnt signalling is not the key driver, it 
may have a role in the disease progression associated with Barrett’s oesophagus. 
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Chapter 9 
The Wnt Signalling Pathway - A study in human oesophageal tissue  
arrett’s oesophagus is a precursor of oesophageal adenocarcinoma with 
risk of cancer increasing substantially with dysplasia, particularly high 
grade.  Thus there is a clinical need to identify and treat patients with early 
stage disease (metaplasia and low grade dysplasia) that are at risk of progression.  
Activated Wnt signalling is critical for normal intestinal development and 
homeostasis, but less so for oesophageal development.  Therefore this study explored 
the interactions between increased Wnt signalling and the development of Barrett’s 
oesophagus and/or dysplasia.  Forty patients with Barrett’s metaplasia, dysplasia or 
adenocarcinoma underwent endoscopy and biopsy.  Immunohistochemistry of β-
catenin, Ki67 and a panel of Wnt target genes and markers of intestinal metaplasia 
was performed.  Expression of nuclear β-catenin was found in dysplasia, particularly 
high grade.  Upregulation of Ki67 and Wnt target genes was also mostly associated 
with high grade dysplasia.  Based on the results in human tissues and the mouse 
model, abnormal activation of Wnt signalling likely plays only a minor role in 
initiation of Barrett’s metaplasia but a more critical role in progression to dysplasia.   
 
Publication 
Moyes LH, McEwan H, Radulescu S, Pawlikowski J, Lamm CG, Nixon C, Sansom 
OJ, Going JJ, Fullarton GM, Adams PD.  Activation of Wnt signalling promotes 
development of dysplasia in Barrett’s Oesophagus.  Journal of Pathology 2012; 228 
(11): 99-112.  
B 
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9.1 Introduction 
The role of Wnt signalling in the development and maintenance of normal tissue, and 
in carcinogenesis has been reviewed in previous chapters.  In many clinical studies, 
β-catenin is the key molecule associated with Wnt signalling, with few studies 
considering other Wnt target genes.  There are a handful of studies assessing the role 
of β-catenin in the development of oesophageal adenocarcinoma, with conflicting 
results.  In some studies nuclear β-catenin was found in a limited subset of cancers, 
yet in other series there was positive staining in up to 80% of cases (Clement, 
Jablons, & Benhattar 2007).  In one study of patients with adenocarcinoma, increased 
nuclear β-catenin expression was surprisingly associated with improved one year 
survival (Osterheld, Bian, Bosman et al. 2002).  However there is paucity in the 
literature regarding the role of β-catenin in Barrett’s metaplasia and dysplasia. 
It is not known whether aberrant activation of Wnt signalling is causal in Barrett’s 
metaplasia and the associated dysplastic or neoplastic transformation, or a passive 
bystander.  Chapter 8 demonstrated aberrant activation of Wnt signalling in the Ah-
Cre-ER β-catenin ∆ex3 mouse model resulted in areas of nuclear atypia and abnormal 
maturation, but failed to show a histological transformation from a squamous to a 
columnar epithelium in the oesophagus.  It would appear that Wnt signalling is not a 
key player in the metaplastic transformation of the squamous oesophagus, but may 
be involved in the metaplasia-dysplasia-carcinoma sequence. 
9.2 Study aims 
On the background of the mouse model, the aim of this study was to assess whether 
increased Wnt signalling was associated with disease progression in patients with 
Barrett’s oesophagus using immunohistochemical analysis. 
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9.3 Methods 
9.3.1 Patients 
Oesophageal mucosal biopsies from patients with endoscopically and histologically 
confirmed Barrett’s oesophagus were collected at Glasgow Royal Infirmary from 
2009 to 2010.  For the purposes of this study, Barrett’s oesophagus was defined 
endoscopically as a columnar lined oesophageal mucosa, and histologically by the 
presence of goblet cells.  Patients were selected to obtain approximately twenty 
biopsies of each stage of the disease: 10 normal squamous mucosa, 26 Barrett’s 
mucosa without dysplasia, 20 low grade dysplasia, 22 high grade dysplasia and 21 
with Barrett’s associated adenocarcinoma.  Biopsy specimens were fixed in 10% 
neutral buffered formalin, embedded in paraffin wax, sectioned (4µm) and stained 
with haematoxylin and eosin (H&E) for histological assessment by an experienced 
gastrointestinal pathologist (Dr JJ Going).  
9.3.2 Immunohistochemistry 
Serial sections (4μm thick) were cut from formalin fixed paraffin embedded (FFPE) 
blocks of human oesophagus, and immunohistochemistry using the EnVision kit 
(Dako, Glostrup, Denmark) was performed using a Dako autostainer.  The protocol 
used for immunohistochemistry was similar for most experiments, although the 
buffer and primary antibody varied.   
Sections were initially deparaffinised in xylene and rehydrated in serial alcohols.  
Heat induced epitope retrieval was performed on a Thermo Pre-treatment module for 
25 minutes at 97
o
C with an appropriate buffer for each antibody (either 10MM 
sodium citrate (pH6), or 1 mM EDTA (pH8)).  Endogenous peroxidase activity was 
blocked by incubation with hydrogen peroxidase (EnVision, Dako) for six minutes.  
All primary antibodies (see Table 9.1 for further details), i.e. Ki67 (clone SP6, 1:200, 
Thermo Fisher Scientific, Cheshire, UK), p21 (clone M19, 1:800, Santa Cruz 
Biotechnology, Santa Cruz, CA), p53 (clone DO7, 1:1000, Dako, Glostrup, 
Denmark), p16 (clone 2D9A12, 1:2000, Abcam, Cambridge, UK), β-catenin (clone 
14, 1:1200, BD Transduction Laboratories, San Jose, CA), cyclin D1 (clone SP4, 
1:50, Dako, Glostrup, Denmark), Sox9 (1:700, Millipore, Livingstone, UK) and c-
myc (1:300, Abcam, Cambridge, UK) were incubated at room temperature for 45 
minutes, followed by the appropriate secondary antibody.  3,3-diaminobenzidine 
tetrahydrochloride was used as chromagen.  Sections were counterstained with 
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haematoxylin, dehydrated in alcohol and mounted from xylene.  The special stain, 
Alcian blue-periodic acid Schiff (PAS), a marker for the presence of goblet cells was 
also used to stain the biopsy tissues.  
9.3.3 Analysis of Immunohistochemistry 
Immunohistochemistry of human tissues was assessed using light microscopy by two 
independent observers (LHM and Dr JJG).  Weighted histoscores allowing semi-
quantitative evaluation of epithelial protein expression were assigned at 
magnification x20 (Kirkegaard, Edwards, Tovey et al. 2006).  Staining intensity was 
scored as negative (0), weak (1), moderate (2) or strong (3) before multiplication by 
the percentage of cells stained with that intensity.  On each slide, each scorer scored 
3 separate fields and the mean was calculated.  For each slide, the mean of 
histoscores of LHM and JJG was calculated.  The final histoscore ranges from 0 to 
300.  For some antibodies such as β-catenin, separate cellular locations 
(membranous, cytoplasmic and nuclear) were scored separately where appropriate.  
If there was any discrepancy between histoscores of >30, the slides were reviewed 
and a consensus reached.  Figure 9.1 illustrates a general overview of the scores 0, 1, 
2 and 3. 
9.3.4 Statistical analysis 
The mean histoscores obtained from combined LHM and JJG scoring were taken 
forward for analysis.  Categorical data (ordering of ranks between histological 
grades) were compared by Kruskal-Wallis test and individual groups compared by 
Mann-Whitney test.   A p-value of <0.05 was taken to be significant.  The analysis 
was performed using SPSS for Windows v18.0, SPSS Inc, Chicago, IL, USA. 
9.3.5 Ethical approval 
Ethical approval for the study was given by West of Scotland Research Ethics 
Committee.   
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Table 9.1 Table of primary antibodies for immunohistochemistry studies on human oesophageal tissue 
Antibody Clone Dilution Buffer Manufacturer Catalogue Number 
Anti-Sox9  1:700 Na Citrate pH6 Millipore, Dundee, UK AB5809 
CDX2  1:300 Na Citrate pH6 Abcam, Cambridge, UK ab88129 
c-myc 9E10 1:300 Na Citrate pH6 Abcam, Cambridge, UK ab32 
Cyclin D1 SP4 1:50 Tris-EDTA pH9 Dako, Glostrup, Denmark M3642 
Ki67 SP6 1:200 Na Citrate pH6 Thermo Fisher Scientific, Cheshire, UK RM-9106 
p16 2D9A12 1:2000 Na Citrate pH6 Abcam, Cambridge, UK ab54210 
p16 CINtec®  Na Citrate pH6 mtm laboratories, Westborough, USA 9517 
p21 M19 1:800 Na Citrate pH6 Santa Cruz Biotechnology, Santa Cruz, CA SC-397 
p53 CM5 1:200 EDTA pH8 Vector Laboratories, Peterborough, UK VP-P596 
p53 DO7 1:1000 EDTA pH8 Dako, Glostrup, Denmark M7001 
β catenin 14 1:1200 Na Citrate pH6 BD Transduction Laboratories, San Jose, CA 610154 
E cadherin 36/E cad 1:300 Na Citrate pH6 BD Transduction Laboratories, San Jose, CA 610182 
E cadherin 36B5 1:40 Na Citrate pH6 Vector Laboratories, Peterborough, UK VP-E601 
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Figure 9.1 Histoscores – a general guide  
  
  
Overview of slides for histoscores (magnification x10).  (A) no staining, (B) weak staining, (C) 
moderate staining and (D) strong staining.  
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9.4 Results 
Patient population 
Table 9.2 summarises the basic demographics of the patients with Barrett’s 
oesophagus in this study.  The majority were males, with a mean age at presentation 
of 67 years (range 50-81 years).  The length of Barrett’s segment increased with the 
degree of dysplasia (p<0.05). 
Table 9.2 Patient demographics according to histological grade 
Histology Sex (M:F) Age (years) Segment (cm) 
Metaplasia (n=10) 9:1 64 (54-77) 6.0 (4-10) 
LGD           (n=10) 8:2 68 (50-79) 6.4 (4-10) 
HGD           (n=10) 8:2 70 (49-81) 7.1 (5-12) 
Adenocarcinoma (n=10) 10:0 65 (54-78) 6.9 (3-10) 
 
Wnt markers in Barrett’s oesophagus 
An initial immunohistochemical analysis of a panel of markers associated the p53 
tumour suppressor pathway and Wnt signalling was used to initially assess the 
human oesophageal biopsy tissue.  The p53 pathway plays a role in the progression 
of Barrett’s oesophagus and therefore was a useful control pathway for future 
studies. 
9.4.1 H&E and special stains  
Ninety nine mucosal biopsies from 40 patients with Barrett’s oesophagus or Barrett’s 
associated adenocarcinoma were stained with H&E, complemented with Alcian blue-
PAS.  The normal oesophageal mucosa was composed of sheets of stratified 
squamous cells lying above a well-defined basement membrane (Figure 9.2A).  
Barrett’s metaplasia was identified by the presence of a columnar epithelium with 
glandular crypts and the presence of goblet cells.  The glands tended to be present in 
the middle zone of specimen, with columnar cells lined up regularly on the epithelial 
surface (Figure 9.2B&C).  The Alcian blue stain helped to identify the acid mucin 
within the goblet cells, recognised by their purple/blue colour and characteristic 
shape (Figure 9.2D). 
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Low grade dysplasia can be recognised by cellular atypia.  High grade dysplasia is 
associated with rounded nuclei with chromatin clearing and easily visible nucleoli.  
High grade dysplasia is associated with loss of normal tissue architecture and areas 
of necrosis.  In some cases it can be difficult to differentiate between invasive 
adenocarcinoma and high grade dysplasia and expert pathologists are required in the 
accurate diagnosis in these challenging cases. 
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Figure 9.2 Histology of Barrett’s oesophagus 
  
  
  
 
(A) The normal stratified squamous lining of the oesophagus. (B) Typical area of Barrett’s metaplasia 
displaying a glandular mucosa with goblet cells seen more clearly in (C) with magnification x20.  
Alcian blue/PAS stains mucins within goblet cells, aiding detection (D).  In the presence of dysplasia 
there is nuclear atypia and increased proliferation (E-F).  High grade dysplasia is represented by loss 
of normal tissue architecture and areas of necrosis (F). 
A 
C D 
E F 
B 
161 
 
9.4.2 The relationship between p53 and p21 
In normal oesophageal squamous epithelium, p53 staining was observed in the nuclei 
of scattered suprabasal cells (Figure 9.3A).  Metaplastic Barrett’s mucosa showed 
numerous weakly positive cells in the mid zone (Figure 9.3B).  A change in the 
staining pattern was associated with the transition from LGD to HGD, with weak to 
moderate intensity staining of clusters of cells in dysplastic glands in cases with LGD 
(Figure 9.3C), and more intense diffuse staining throughout HGD and carcinoma 
(Figure 9.3D-E).  Overall the extent and intensity of p53 staining increased 
significantly with progression from Barrett’s metaplasia to adenocarcinoma (Figure 
9.3F).   
p21 is a tumour suppressor gene closely linked with p53 in controlling the cell cycle.  
In the squamous epithelium, p21 expression was limited to suprabasal cells with no 
surface expression (Figure 9.4A).  In Barrett’s metaplasia, p21 expression was 
strongly associated with the mucosal surface, with extension of expression to the 
middle and deeper zones in dysplasia (Figure 9.4B-D).  There was a trend towards 
decreased surface p21 staining from metaplasia to cancer (Figure 9.4E-F).  It would 
appear that a reciprocal relationship exists between p53 and p21: p53 staining 
increases with disease progression, while p21 staining decreases.  Mutational 
inactivation of p53 is associated with its increased expression and failure to activate 
target genes, such as p21 (Goh, Coffill, & Lane 2011).  Therefore these results are 
consistent with previous published reports associating mutational inactivation of p53 
with progression of Barrett’s metaplasia to adenocarcinoma (Reid, Prevo, Galipeau, 
Sanchez, Longton, Levine, Blount, & Rabinovitch 2001;Woodward, Klingler, Genco 
et al. 1998).              
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Figure 9.3 p53 expression in squamous tissue and Barrett’s oesophagus 
 
 
Figure 9.2 p 
 
  
A 
C D 
E 
B 
Basement membrane 
Mucosal surface 
100µm 
Suprabasal 
keratinocytes 
Mid / proliferation zone 
(A) Minimal p53 expression in normal squamous tissue, besides occasional positive cells in suprabasal 
layer. (B) Barrett’s mucosa with occasional weakly positive cells in proliferative zones with no staining at 
the mucosal surface.  (C) LGD with focal p53 expression extending to mucosal surface.  (D) HGD 
displaying diffuse p53 expression in all areas and similar expression in cases with adenocarcinoma (E).  (F) 
Boxplot of p53 histoscore by disease stage showing significant difference in expression.  Magnification x20 
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Figure 9.4 p21 expression in squamous tissue, Barrett’s metaplasia, 
dysplasia and adenocarcinoma
(A) Normal squamous epithelium maximally expressed p21 in suprabasal layer.  (B) Barrett’s 
metaplasia expressing p21 at the mucosal surface.  (C) Low grade dysplasia with p21 expression at 
mucosal surface, migrating down to lower zones.  (D) High grade dysplasia with reduced p21 
expression at mucosal surface and in deeper glands.  (E) Adenocarcinoma with reduced p21 
expression at mucosal surface.  (F) Boxplot quantitating expression of p21 at mucosal surface by 
disease stage.   
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9.4.3 Expression of β-catenin in Barrett’s oesophagus 
On the basis of these findings, an attempt was made to identify other markers which 
were associated with Barrett’s metaplasia.  Previous studies have suggested a link 
between the presence of β-catenin and oesophageal adenocarcinoma, but few studies 
have assessed its role in patients with metaplasia and dysplasia, before the 
development of adenocarcinoma.  Therefore an evaluation of the pattern of 
expression of β-catenin in Barrett’s metaplasia and dysplasia was performed using 
immunohistochemistry. 
Across the series from normal squamous epithelium to adenocarcinoma, three 
patterns of β-catenin expression were observed.  In the normal squamous epithelium, 
β-catenin expression was predominantly membranous, with some cytoplasmic 
staining close to the basement membrane, and no definite nuclear accumulation 
(Figure 9.5A).  A similar pattern was also found in Barrett’s metaplasia (Figure 
9.5B).  However, increased cytoplasmic β-catenin was observed in LGD with some 
cells in focal dysplastic glands expressing nuclear β-catenin.  Nuclear expression was 
most abundant in dysplasia, being present in 44% of LGD cases and 93% of HGD 
cases.  Interestingly, nuclear β-catenin accumulation was most marked in HGD even 
compared with some cases of adenocarcinoma.  The median nuclear β-catenin 
histoscore for Barrett’s metaplasia was 2 (interquartile range [IQR] 0-5), compared 
with 36 (IQR 25-96) in LGD, 145 (IQR 60-180) in HGD and 55 (IQR 35-77) in 
adenocarcinoma.  Some cases of adenocarcinoma expressed high levels of nuclear β-
catenin, whereas others did not.  The increase in cytoplasmic and nuclear β-catenin 
was associated with a marked reduction in membranous expression from metaplasia 
to carcinoma (Figure 9.5B-F). 
β-catenin is a key player in the Wnt signalling pathway, and nuclear expression 
equates with activation of canonical Wnt signalling.  Therefore it appears that based 
on β-catenin localisation, Wnt signalling is markedly upregulated in dysplasia, 
particularly HGD, compared with earlier stages of disease and the normal squamous 
epithelium.   
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Figure 9.5 β-catenin expression and localisation in Barrett’s oesophagus 
  
A 
D 
C 
D 
E 
B 
(A) Normal squamous epithelium expressing membranous β-catenin with minimal cytoplasmic and nuclear 
staining.  (B) Barrett’s metaplasia expressing membranous β-catenin with no nuclear staining.  (C) LGD with 
focal areas of strong nuclear and cytoplasmic β-catenin staining.  (D) HGD with obvious nuclear β-catenin 
expression and a marked reduction in membranous expression.  (E) Oesophageal adenocarcinoma with focal 
areas of nuclear localisation and minimal membranous staining, while other areas show an overall reduction in 
β-catenin expression. (F) Boxplot quantitating nuclear β-catenin histoscore by disease stage. Magnification x20. 
D 
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9.4.4 Expression of Wnt target genes 
In order to understand the role of Wnt signalling in Barrett’s metaplasia and disease 
progression, the expression of a panel of Wnt target genes was analysed.  Since 
canonical Wnt signalling often promotes cell proliferation, Ki67 a marker of cell 
proliferation was initially stained. 
In the normal squamous oesophagus, Ki67 was maximally expressed in the nuclei of 
suprabasal keratinocytes (Figure 9.6A).  In Barrett’s metaplasia, Ki67 was maximally 
expressed in a restricted mid-zone of proliferating cells (Figure 9.6B).  In the 
presence of dysplasia, the proportion of Ki67-positive cells increased and the 
proliferative zone extended onto the mucosal surface (Figure 9.6C -D).  Overall, 
Ki67 expression increased with progression from metaplasia to HGD and cancer 
(Figure 9.6B-F) with the highest proliferation scores were seen in HGD.  The areas 
of increased nuclear β-catenin coincided with maximal areas of Ki67. 
Cyclin D1, a cell cycle proto-oncogene and Wnt target gene, was expressed in the 
suprabasal proliferative layer of the oesophageal squamous epithelium and in the 
proliferative zone in Barrett’s metaplasia (Figure 9.7A-B).  With increasing degrees 
of dysplasia, cyclin D1 expression moved away from the middle proliferative zone to 
the mucosal surface (Figure 9.7C-D, F).  The superficial cyclin D1 expression in 
LGD and HGD recalls the expression of Ki67, and was associated with areas of 
nuclear β-catenin. 
Sox9, an intestinal marker and target gene involved in the Wnt pathway, showed a 
similar pattern of staining to nuclear β-catenin, cyclin D1 and Ki67, with increased 
expression in HGD (Figure 9.8).  There was a similar movement towards mucosal 
surface expression in LGD and HGD.  Interestingly, Sox9 was also present in the 
normal squamous epithelium although it is most often seen in intestinal mucosae. 
There was weakly detectable c-myc expression in the basal and suprabasal nuclei of 
the oesophageal squamous epithelium (Figure 9.9A).  Barrett’s metaplasia and LGD 
displayed weak heterogenous nuclear staining in some glands whereas other cases 
had no identifiable staining (Figure 9.9B-C).  HGD was associated with scattered and 
mostly superficial areas of intense nuclear c-myc, with widespread staining found in 
adenocarcinoma (Figure 9.9D-E).  Overall, c-myc expression was higher in 
dysplastic Barrett’s epithelium than metaplasia (Figure 9.9F).   
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The expression of nuclear β-catenin and Wnt target genes increased with progressive 
dysplasia (particularly the transition from low grade to high grade dysplasia).  These 
are summarised in Table 9.3 and displayed in the boxplots in each figure. 
 
Table 9.3  p values for Wnt biomarkers in human oesophageal tissues 
 Metaplasia vs LGD LGD vs HGD HGD vs Cancer 
p53 <0.001 0.001 0.142 
p21 0.006 0.050 0.153 
Β catenin <0.001 0.001 <0.001 
Cyclin D1 0.786 <0.001 0.001 
Sox9 <0.001 <0.001 0.393 
c-myc 0.955 0.020 0.009 
Ki67 0.002 <0.001 0.135 
Difference in expression of biomarkers between metaplasia, LGD, HGD and adenocarcinoma.  p 
value <0.05 significant (Chi square test) 
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Figure 9.6 Ki67 expression in squamous tissue and Barrett’s oesophagus 
 
 
  
A B 
C D 
E 
(A) Normal squamous epithelium with Ki67 positive nuclei in the suprabasal layers.  (B) Barrett’s metaplasia 
showing Ki67 expression in cells in the lower and middle crypts, with minimal expression on the mucosal 
surface.  (C) LGD illustrating an increase in mucosal expression of Ki67.  The extension of Ki67 positive cells 
onto the mucosal surface is highly characteristic of LGD.  (D)  HGD showing Ki67 expression throughout the 
mucosal epithelium.  (E) Adenocarcinoma showing Ki67 expression throughout the tissue.  Some sections had 
little Ki67 expression, particularly when necrosis was present.  (F) Boxplot quantitation Ki67 expression by 
disease stage.  Magnification x20. 
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Figure 9.7 Cyclin D1 expression in squamous oesophagus and Barrett’s 
oesophagus 
  
(A) Normal squamous epithelium showing cyclin D1 positive cells in the proliferative suprabasal layer in a 
similar pattern as Ki67.  (B) Cyclin D1 expressed in the proliferative zone of Barrett’s metaplasia.  (C) 
Increased expression of cyclin D1 in cells of the mucosal surface in LGD.  (D) High levels of cyclin D1 in HGD 
including at the mucosal surface and in the deeper proliferation zone.  (E) Cyclin D1 expression remains 
elevated in adenocarcinoma.  (F) Boxplot quantitating cyclin D1 expression by disease stage.  Magnification 
x20. 
A B 
C D 
E 
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Figure 9.8 Sox9 expression in squamous and Barrett’s oesophagus 
  
A B 
C D 
E 
(A) Sox9 expression present in the suprabasal layer of the squamous epithelium.  (B)  In Barrett’s metaplasia 
Sox9 was most highly expressed in the proliferation zone, resembling Ki67 and cyclin D1 expression.  (C) In 
LGD, Sox9 was upregulated with increased expression on the mucosal surface.  (D) High levels of Sox9 
expression in HGD.  (E) High levels of Sox9 expression in adenocarcinoma.  (F) Boxplot quantitating Sox9 
expression by disease stage.  Magnification x20. 
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Figure 9.9 C-myc expression in squamous oesophagus and Barrett’s 
oesophagus 
 
 
  
A B 
C D 
E 
(A) Minimal c-myc expression in the basal layer of squamous oesophageal mucosa.  (B)  Occasional cells 
staining for c-myc in some glands, but no expression visible at the mucosal surface.  (C) In LGD, c-myc 
expression is present in some dysplastic cells on the surface epithelium.  (D) Focal areas of c-myc expression 
found in HGD.  (E) Widespread c-myc expression in oesophageal adenocarcinoma.  (F) Boxplot quantitating c-
myc expression by disease stage.  Magnification x20. 
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9.5 Discussion 
This study presents data supporting the hypothesis that upregulation of canonical 
Wnt signalling is associated with the neoplastic progression of Barrett’s oesophagus.  
Cell proliferation, as measured by Ki67 staining showed a similar pattern, consistent 
with the notion that activated Wnt signalling contributes, at least in part, to 
dysregulated cell proliferation and dysplasia. 
It is generally accepted that the progression of Barrett’s oesophagus to dysplasia and 
carcinoma is associated with increasing p53 expression, mainly due to the 
accumulation of mutant p53 (Moskaluk, Heitmiller, Zahurak et al. 1996;Prasad, 
Bansal, Sharma, & Wang 2010;Reid, Prevo, Galipeau, Sanchez, Longton, Levine, 
Blount, & Rabinovitch 2001;Woodward, Klingler, Genco, & Wolfe 1998).  The 
results of this study reflect this phenomenon, especially in HGD and OA.  It seems 
that p53 inactivation may be a later event in the metaplasia-dysplasia sequence, 
instead of being a key factor in the initial metaplastic transformation from a 
squamous to glandular mucosa.   
There was an interesting reciprocal relationship between p53 and p21 expression. 
With increasing dysplasia, p21 expression reduced and was associated in a shift from 
a mucosal expression in metaplasia to generalised expression in adenocarcinoma.  
This paper has shown activation of canonical Wnt signalling, reflected by increased 
cytoplasmic and nuclear -catenin and increased expression of Wnt target genes, is 
associated with progression from Barrett's metaplasia to dysplasia and oesophageal 
adenocarcinoma.  Previous reports have linked Wnt activation to progression of 
Barrett's metaplasia to adenocarcinoma (Clement, Jablons, & Benhattar 2007;Clevers 
2006)
, 
(Bian, Osterheld, Bosman et al. 2000).  However, these studies assessed β-
catenin in patients with established adenocarcinoma and associated dysplasia.  In 
contrast, this paper studied patients with Barrett’s metaplasia and dysplasia who have 
not progressed to adenocarcinoma.  Therefore, in terms of the ultimate goal of early 
prognostication and risk assessment, the most relevant patient population was 
analysed in this study.  By focusing on dysplasia associated with adenocarcinoma, 
previous studies might have selected an unrepresentative subset of samples.  
Moreover, the conclusions from this study are drawn from an analysis of both -
catenin localization and expression of a panel of Wnt target genes, whereas previous 
studies examined only -catenin localization.  This increases confidence in the 
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conclusions regarding the status of Wnt signalling activity in the tissues.  Finally, 
while Wnt activation has been previously broadly linked to progression of Barrett's 
metaplasia and adenocarcinoma (Bian, Osterheld, Bosman, Fontolliet, & Benhattar 
2000;Clement, Braunschweig, Pasquier et al. 2006), we specifically found that 
activation of Wnt signalling is most strongly associated with the transition to HGD. 
Wnt signalling may be activated by overexpression of Wnt ligands, downregulation 
of Wnt antagonists and/or mutation of key downstream signalling components, e.g. 
β-catenin, APC or axin. Unlike colon cancer, Barrett’s oesophagus and 
adenocarcinoma are not associated with frequent mutation of the APC, -catenin or 
axin genes (Choi, Heath, Heitmiller et al. 2000;Clement, Braunschweig, Pasquier, 
Bosman, & Benhattar 2006;Koppert, van der Velden, van der Wetering et al. 2004).  
However, Clement et al showed upregulation of ligand Wnt2 in dysplasia and 
adenocarcinoma (Clement, Braunschweig, Pasquier, Bosman, & Benhattar 2006). 
Also, Wnt antagonists, secreted frizzled receptor proteins (SFRPs) and Wnt 
inhibitory factor 1 (WIF-1) have been shown to be hypermethylated and silenced in 
cases of Barrett’s metaplasia (as well as adenocarcinoma) (Clement, Braunschweig, 
Pasquier, Bosman, & Benhattar 2006;Zou, Molina, Harrington et al. 2005).  
Together, these results suggest that activation of Wnt signalling in Barrett's-
associated dysplasia and adenocarcinoma is frequently achieved by upregulation and 
downregulation of Wnt ligands and antagonists (Clement, Guilleret, He et al. 2008). 
Although there was no marked activation of Wnt signalling in Barrett's metaplasia 
without dysplasia, epigenetic silencing of Wnt antagonists reported in some studies 
might yield low level activation of Wnt signalling and promote progression to 
dysplasia.  Given the association between acid and bile reflux and Barrett's (Shaheen 
& Richter 2009), altered Wnt signalling presumably initially stems, directly or 
indirectly, from this reflux.  
This study has shown that Wnt targets, Cyclin D1, c-myc and Sox9, are upregulated 
especially in HGD.  Bani-Hani et al previously found increased levels of cyclin D1 
expression in Barrett’s oesophagus and suggested this is associated with higher risk 
of progression to adenocarcinoma (Bani-Hani, Martin, Hardie, Mapstone, Briggs, 
Forman, & Wild 2000).  Consistent with this role in cell proliferation (Sherr 2000), 
there was good concordance between cyclin D1 expression and cell proliferation, 
indicated by Ki67, in Barrett’s metaplasia with and without dysplasia and 
adenocarcinoma.  In normal squamous epithelium, cyclin D1 and Ki67 were both 
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maximally expressed in cells lying in the proliferative transit-amplifying zone 
immediately above the basement membrane.  Both cyclin D1 and Ki67 increased in 
expression along the metaplasia-carcinoma sequence, with peak expression observed 
in HGD.  
C-myc is a pleiotropic proto-oncogene broadly implicated in a variety of cancers, 
including gastric, colon, breast and lung cancer (Pelengaris, Khan, & Evan 2002). 
Consistent with results presented here, increased c-myc expression has previously 
been shown in adenocarcinoma, compared with normal squamous epithelium 
(Schmidt, Meurer, Volkweis et al. 2007;Stairs, Nakagawa, Klein-Szanto et al. 2008). 
However, there is a paucity of data in the literature regarding expression of c-myc in 
Barrett’s oesophagus.  Here I have shown that, like other Wnt targets, c-myc protein 
expression is already upregulated in HGD.  
Recent work by Blache et al has shown that Sox9 is a downstream -catenin target 
gene, playing a role in the normal development of mouse intestine (Foster, 
Dominguez-Steglich, Guioli et al. 1994)
,
 (Blache, van de Wetering, Duluc, Domon, 
Berta, Freund, Clevers, & Jay 2004).  In human tissues, we found that Sox9 was 
upregulated with disease progression, but with a tendency to highest expression in 
HGD.  Underscoring the link between Sox9 and dysplasia, in the mouse model 
described in the previous chapter, Sox9 is not expressed in the normal mouse 
squamous oesophageal epithelium, but is expressed in the immature quasi-dysplastic 
cells harbouring nuclear β-catenin.  
A lower level of canonical Wnt signalling is one determinant of the anterior gut 
(oesophagus and stomach), compared to the posterior gut (small intestine and colon), 
where the importance of activated Wnt signalling is well-established (Gregorieff, 
Grosschedt, & Clevers 2004).  Thus, it has been reasonable to hypothesize that 
abnormal activation of Wnt signalling in the anterior gut contributes to Barrett's 
metaplasia (together with other factors, such as exposure to excess acid and bile).  
While Wnt-induced expression of Sox9, CK8 and CLDN3 in the mouse oesophagus 
supports this notion to some extent, on balance data indicate that activated Wnt is not 
a key driver of metaplasia in either human or mouse.  Instead, these results support a 
frequent and causative role for activation of Wnt signalling in oesophageal dysplasia.  
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9.6 Conclusion 
In conclusion, the results from this study link activated Wnt signalling to HGD, and 
to a lesser extent to LGD.  This raises the important possibility that the subset of 
patients with LGD and activated Wnt signalling carry a higher risk of progression to 
HGD and subsequent adenocarcinoma.  Based on these results, it will be important to 
test the predictive power of activated Wnt signalling in a cohort of patients with 
LGD.  
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Chapter 10 
Conclusions and Future Directions 
The West of Scotland has one of the highest incidences of Barrett’s oesophagus and 
adenocarcinoma in the world.  Barrett’s oesophagus is a common premalignant 
condition which has the potential to be diagnosed and treated at an early stage before 
invasive cancer develops.   
This thesis has highlighted the important clinical issues surrounding Barrett’s 
oesophagus and has focused on specific topics such as the clinical identification of 
dysplasia and risk of malignant progression, reinforcing the high risk nature of the 
Scottish Barrett’s population and furthering the knowledge of underlying molecular 
abnormalities, in particular the Wnt signalling pathway. 
The first hypothesis was proved to be true – patients with Barrett’s oesophagus in the 
West of Scotland have high rates of progression to high grade dysplasia and 
oesophageal adenocarcinoma.  The second hypothesis was disproved – the 
WavSTAT optical biopsy system was unable to correctly identify patients with 
Barrett’s oesophagus or indeed dysplasia.  Finally, I hypothesised the Wnt signalling 
pathway would be upregulated in patients with Barrett’s oesophagus, however this 
was only partly proved.  Wnt signalling is upregulated in patients with dysplasia, 
particularly high grade, but this thesis has failed to demonstrate upregulation of the 
Wnt pathway in metaplasia. 
10.1 Molecular mechanisms 
Despite being the focus of research for many years, the mechanisms underlying the 
initial metaplastic transformation of the oesophagus, from a squamous to a columnar 
mucosa remain unclear.  The Wnt signalling pathway is known to play a crucial role 
in embryogenesis and the normal development of the gastrointestinal tract but its role 
in the progression of Barrett’s metaplasia, dysplasia and adenocarcinoma has not 
been extensively investigated.  This thesis presents the first mouse model to assess 
the role of Wnt signalling in mouse oesophagus.  Although no phenotypic changes 
from a squamous to a columnar mucosa were noted, there was upregulation of 
expression of Wnt target genes in areas of dysplasia.  One of the limitations of the 
Ah-Cre-ER β-catenin∆ex3 mouse model related to the limited survival within 
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homozygous mice.  These mice succumbed to other diseases, possibly before any 
overt phenotypic changes were noted.  However, this mouse model has demonstrated 
that upregulated Wnt signalling contributes to abnormal maturation of cells within 
the epithelium and further mouse work should be carried out to further this work.   
The second phase of the Wnt study assessed the role of Wnt signalling in human 
oesophageal biopsy tissue.  Wnt signalling, as demonstrated by the presence of 
nuclear β catenin and downstream target genes, was upregulated in patients with 
dysplasia, particularly HGD but also noted in some cases of LGD.  This study 
suggests that although Wnt signalling did not seem to play a major role in the initial 
metaplastic transformation of the squamous oesophagus, Wnt signalling is involved 
in the malignant progression of Barrett’s oesophagus. 
These results are novel and exciting but in order to understand the role of Wnt 
signalling and assess its use as a clinical biomarker of disease progression, further 
studies are required.  Firstly, the results should be corroborated in a larger scale 
study.  Ideally this would be a prospective study, but in the first instance a 
retrospective cohort with follow up data may be the most appropriate means of 
assessing Wnt signalling as a marker for progression.  A tissue microarray of 
oesophageal tissue should be constructed providing more tissue for histological 
assessment.  Perhaps the most interesting group of patients are those with low grade 
dysplasia, as some patients progress to high grade dysplasia while others do not.  In 
an ideal world, a biomarker should be able to predict those with metaplasia at risk of 
progression, but in the meantime, if we were able to predict those with low grade 
dysplasia who are at risk of progression, these patients could be offered intensive 
surveillance, or endoscopic treatments such as RFA to eradicate the “at risk” 
epithelium.  The ideal biomarker for Barrett’s oesophagus will not appear overnight, 
but the Wnt pathway would be an interesting one to explore.  Therefore, a tissue 
microarray of all low grade patients with Barrett’s oesophagus in Glasgow is under 
construction to compare the expression of Wnt target genes in those who progress 
and those who do not progress to HGD or cancer.  
This study has largely been an observational study using immunohistochemistry as a 
means of assessing Wnt expression.  However there are various novel gene 
technologies available, and one method would be gene profiling of Barrett’s tissue 
using next generation sequencing technology.  This technology is in its infancy, but 
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would allow researchers to create a genetic profile in patients with Barrett’s 
oesophagus, comparing any differences in those with metaplasia alone, versus those 
who progress.    
The importance of understanding the molecular abnormalities associated with 
Barrett’s oesophagus cannot be overemphasised.  Effective and safe endoscopic 
therapies are now available, particularly for those with known dysplasia, and I would 
predict that in the future the key to the management of Barrett’s oesophagus, and the 
ultimate reduction in the incidence of dysplasia and adenocarcinoma lie in the 
accurate identification of patients at risk of progression, and offering them early 
treatment.  Furthermore, patients at no risk of progression could be reassured and 
discharged for surveillance.  
10.2 Scotland is an “at risk” population 
Within my cohort of patients with Barrett’s oesophagus in Glasgow, 1 in 10 patients 
died from Barrett’s associated oesophageal cancer.  This is much higher than 
reported rates in the literature.  Mortality from all-cause and cancer-specific deaths is 
higher in patients with Barrett’s oesophagus living in deprived areas, with patients 
four times more likely to die than those in affluent areas.  The annual risk of 
progression to HGD and adenocarcinoma were 0.2% and 0.4% respectively, rates 
which are similar to those quoted in recent European studies (0.2-0.4%) (de Jonge, 
van Blankenstein, Looman, Casparie, Meijer, & Kuipers 2010;Hvid-Jensen, 
Pedersen, Drewes, Sorensen, & Funch-Jensen 2011).  However, patients with LGD 
at baseline endoscopy have greater risk of progression to HGD and neoplasia, with 
40% patients progressing to HGD/adenocarcinoma within 10 years.  The West of 
Scotland is clearly an “at risk” population and deprivation may play a role in disease 
progression, along with other environmental and genetic factors.   
This study highlights the premalignant nature of Barrett’s oesophagus in our 
population with two particularly important risk factors for disease progression – low 
grade dysplasia and deprivation.  The presence of LGD is a clear risk factor to 
progression, and research to determine factors of progression, and improvement in 
the diagnosis and treatment of LGD is warranted.  Barrett’s oesophagus, and 
particularly dysplasia can be treated with endoscopic intervention (endoscopic 
resection and radiofrequency ablation) and specialist centres now have access to 
excellent endoscopic facilities allowing appropriate and timely intervention.  
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Therefore, we must not underestimate the premalignant nature of Barrett’s 
oesophagus in the West of Scotland.    
In order to tease out individual factors which may account for this high risk 
population and the role of deprivation, further work is required.  A prospective 
database of all patients diagnosed with Barrett’s oesophagus in the West of Scotland 
should be introduced.  This will require careful planning of personnel and resources 
including a dedicated IT support team, administrators to ensure accurate data 
collection and clinicians and pathologists capable of performing surveillance, and 
reporting the histological findings.  Prospective data collection of patient, 
endoscopic, histological and molecular factors would lead to an improved 
understanding of the disease.  The database would also be an excellent audit resource 
assessing the efficacy of endoscopic therapies and outcome measures, and resource 
planning. 
10.3 Improving the diagnosis of dysplasia 
Dysplasia remains the current gold standard marker of disease progression, yet it 
carries its own difficulties.  Improvements in high resolution endoscopes and image 
adjuncts such as NBI have improved the clinical assessment of Barrett’s mucosa and 
areas of dysplasia or intramucosal cancer but histology is still necessary for the 
definitive diagnosis of dysplasia.  The optical biopsy forceps (WavSTAT
®
 Optical 
Biopsy system) designed by SpectraScience is an exciting and novel technology.  
The preliminary results of the first algorithm reported in this thesis are disappointing 
with no correlation between the optical and physical biopsy result.  However a 
revised algorithm is underway by SpectraScience and the results are awaited with 
interest.  The technology has the potential to allow the clinician to diagnose the 
presence of dysplasia depending on the autofluorescence of the oesophageal mucosa 
and may allow targeted biopsies of the dysplastic area.   
One limitation of the current optical biopsy system is the small surface area which 
can be sampled in one reading, but this system could have a particular role in 
assessing the residual mucosa of patients post endoscopic therapies.  Any suspect 
areas could then be effectively targeted, reducing the overall time and discomfort of 
the procedure, and reducing the workload in the histopathology laboratory.  As a 
general surveillance tool, the optical biopsy system is limited and trimodal imaging 
modalities may be more successful. 
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Capsule sponge cytology is a newer technique in screening patients with Barrett’s 
oesophagus, eliminating the need for endoscopic assessment.  The attraction of this 
technique is that it can be performed in an outpatient setting, is associated with 
minimal patient discomfort, yet provides the pathologist with adequate tissue which 
can be analysed by cytology.  At present, a study assessing the efficacy of the 
capsule sponge in obtaining cytology from Barrett’s patients, and its ability in 
diagnosing the presence of dysplasia is underway in Glasgow.  If the results are 
promising, this technique has the potential to replace current surveillance 
endoscopies in patients with metaplasia. 
10.4 Conclusion 
Barrett’s oesophagus is a condition which continues to baffle clinicians, but further 
research must continue to ensure optimal treatment (or reassurance) for all patients in 
the West of Scotland.  This thesis has highlighted the importance of a comprehensive 
surveillance programme in our “high risk” population - an ideal niche for future 
chemopreventative and molecular studies.   
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